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Abstract 
 
The CCAAT enhancer binding protein beta (C/EBPβ) transcription factor regulates 
differentiation, proliferation, and functionality of many cell types, including various 
cells of the immune system. A detailed molecular understanding of how C/EBPβ 
directs alternative cell fates remains largely elusive. Ectopic expression of C/EBPβ 
has been previously shown to reprogram committed B cell progenitors into 
inflammatory macrophages. We took advantage of this reprogramming system in 
order to examine how C/EBPβ regulates (trans)differentiation. 
To determine which C/EBPβ protein modules are important for reprogramming, 
C/EBPβ wild type isoforms and mutants were ectopically expressed in primary 
mouse B cell progenitors. The data showed that the translationally regulated long 
isoforms LAP* and LAP, but not the N-terminally truncated isoform LIP can 
reprogram lymphoid cells into myeloid cells. Furthermore, we found that conserved 
regions 2,3 and 4 in the C/EBPβ protein transactivation domain are necessary and 
sufficient for B-to-myeloid cell conversion. Interestingly, the reprogrammed myeloid 
cells were found to represent a heterogeneous mixture of different myeloid cell types 
that express hallmarks of resident and inflammatory monocytes/macrophages, 
dendritic cells, and/or granulocytes. Detailed analyses of the reprogrammed CD11b+ 
cells, based on myeloid differentiation marker expression, cell morphology, and gene 
expression profiling, revealed that discrete conserved regions in C/EBPβ activated 
distinct pro- and anti-inflammatory genes and triggered divergent differentiation 
programs. Moreover, not only structural C/EBPβ mutants, but also post-translational 
modification (PTM) site mutations led to different reprogramming outcomes. These 
data suggest that C/EBPβ orchestrates myeloid diversification by integrating PTMs 
with structural plasticity as signal dependent adaptable modular properties to 
determine cell fate. 
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Zusammenfassung 
 
Der CCAAT enhancer binding protein beta (C/EBPβ) Transkriptionsfaktor reguliert 
die Differenzierung, Proliferation und Funktion vieler Zelltypen, einschließlich 
verschiedener Zellen des Immunsystems. Eine detaillierte molekulare Analyse des 
Mechanismus, wie C/EBPβ alternative Zellschicksale steuert, wurde jedoch bisher 
noch nicht unternommen. Es wurde gezeigt, dass die ektopische Expression von 
C/EBPβ in determinierten B- Vorläuferzellen diese zu inflammatorischen 
Makrophagen reprogrammieren kann. Wir haben dieses Reprogrammierungsystem 
verwendet, um die Strukturelemente in C/EBPβ, die für die Regulation der 
(Trans)Differenzierung durch C/EBPβ wichtig sind, zu untersuchen. 
Um die maßgeblichen C/EBPβ Proteinmodule für die Reprogrammierung zu 
bestimmen, wurden entweder C/EBPβ Wildtyp Isoformen oder Mutanten in primären 
murinen B-Vorläuferzellen ektopisch exprimiert. Die Analysen ergaben, dass die 
translational regulierten langen Isoformen LAP* and LAP, jedoch nicht die kurze 
Isoform LIP lymphoide Zellen zu myeloischen Zellen reprogrammieren können. Des 
weiteren haben wir gezeigt, dass die konservierten Regionen 2, 3 und 4 der C/EBPβ 
Transaktivierungsdomäne essentiell und ausreichend für die Konvertierung von B 
Zellen zu myeloischen Zellen sind. Die reprogrammierten myeloischen Zellen setzten 
sich aus einer heterogenen Population verschiedener myeloischer Zelltypen 
zusammen, die typische Erkennungszeichen von residenten und inflammatorischen 
Monozyten/Makrophagen, dendritischen Zellen, und/oder Granulozyten aufwiesen. 
Detaillierte Analysen von CD11b+ reprogrammierten Zellen, welche die Expression 
myeloischer Entwicklungsmarker und entsprechende Zellmorphologie aufwiesen, 
sowie für myeloische Genexpressionsmuster überprüft wurden, zeigten, dass 
diskrete konservierte Regionen von C/EBPβ verschiedene pro- und anti-
inflammatorische Gene und divergente Entwicklungsprogramme aktivierten. Des 
Weiteren führten nicht nur strukturelle C/EBPβ Mutanten sondern auch 
Puktmutationen an Stellen, die posttranslationalen Modifikationen (PTM) unterliegen, 
zu verschiedenen Reprogrammierungsergebnissen. Diese Daten zeigen, dass die 
C/EBPβ abhängige myeloische Diversifikation durch die Integration von strukturellen 
C/EBPβ Proteinmodulen und deren signalabhängigen PTMs erreicht wird. 
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List of abbreviations1 
 
°C degree Celsius 
A alanine 
AA amino acid 
ALP all-lymphoid progenitor 
APS ammonium persulphate 
BCR B cell receptor 
BLP B cell-biased lymphoid progenitor 
BM bone marrow 
bp base pairs 
BSA bovine serum albumin 
bZip basic leucine zipper 
CCL chemokine (C-C motif) ligand 
CD cluster of differentiation 
cDC conventional dendritic cell 
CDP common dendritic cell progenitors 
C/EBP CCAAT enhancer binding protein 
CFU colony-forming unit 
CLP common lymphoid progenitor 
CMP common myeloid progenitor 
CR conserved region 
CXCL chemokine (C-X-C motif) ligand 
DAPI 4',6-diamidino-2-phenylindole 
DNA deoxyribonucleic acid 
DC dendritic cell 
dpc days post coitum 
dwater distilled water 
EDTA ethylenediaminetetraacetate  
EPO erythropoietin 
ETP early T cell progenitor 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Gene symbols are not included in the list 
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FACS fluorescence activated cell sorting 
Fig. figure 
Flt-3 fms-like thyrosine kinase 3 receptor 
Flt-3L fms-like thyrosine kinase 3 ligand 
G-CSF granulocyte colony stimulating factor 
GFP green fluorescent protein 
GM-CSFR granulocyte-macrophage colony stimulating factor receptor 
GMP granulocyte-macrophage progenitor 
Gr granulocyte 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hiFCS heat inactivated fetal calf serum 
HSC hematopoietic stem cells 
IFN interferon  
Ig immunoglobulin 
IgH immunoglobulin heavy chain 
IL interleukin 
iPS induced pluripotent stem (cell) 
IRES internal ribosome entry site 
IRF interferon-regulatory factor 
L leucine 
LAP liver activating protein 
LCR low complexity regions 
Lin lineage 
LIP liver inhibitory protein 
LMPP lymphoid primed multipotent progenitor 
LPS lipopolysaccharide 
LZ leucine zipper 
MAPK mitogen-activated protein kinase 
M-CSFR macrophage colony stimulating factor receptor 
MDP macrophage and DC progenitor 
MEF mouse embryonic fibroblasts 
MEP megakaryocyte-erythrocyte progenitor 
miRNA microRNA 
MPh macrophages 
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MPP multipotent progenitor 
MSCV murine stem cell virus 
mRNA messenger RNA 
mTOR mammalian target of rapamycin 
NK natural killer 
pDC plasmacytoid dendritic cell 
pre-BCR pre-B cell receptor 
Q glutamine 
R arginine 
RNA ribonucleic acid 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PTM post-translational modification 
RD regulatory domain 
RT room temperature 
S serine 
SCF stem cell factor 
SEM standard error of the mean 
SUMO small ubiquitin-like modifier 
T threonine 
TAE Tris/ acetate/ EDTA buffer 
TAD transactivation domain 
TBST Tris-Buffered Saline / Tween 
Tris 2-amino-2-hydroxymethyl-propane-1,3-diol 
TH T helper cell 
Tip-DC TNF-α and iNOS-producing dendritic cell 
uORF upstream open reading frame 
URE upstream regulatory element 
WT wild type 
4Y 4 Yamanaka transcription factors 
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 1. Introduction 
 
The hematopoietic lineage specification depends on transcription factors that set 
lineage specific networks in different hematopoietic cells. Multiple transcription 
factors can act in sequential and synergetic manner or can antagonize each other to 
determine cell fate decisions (Fiedler and Brunner, 2012; Laiosa et al., 2006a; Laslo 
et al., 2008). Furthermore, the same transcription factor can be expressed in different 
cell types and may be involved in regulation of alternative cell fates (Dakic et al., 
2007). Despite recent advances and extensive efforts to understand hematopoietic 
cell fate choices, combinatorial interactions between transcription regulators and 
integration of extracellular signals remain challenging tasks in developmental biology 
and molecular genetics. When ectopically expressed, some key transcription factors 
can perturb the established gene expression profiles setting new ones, which might 
lead to reprogramming of one hematopoietic cell type into another (Graf, 2011; Graf 
and Enver, 2009). Importantly, this transcription factor induced trans-differentiation of 
one committed cell type into another one has been achieved through enforced 
expression of lineage-determining transcription factors which have a central function 
in the physiological differentiation of the resultant cell type, suggesting that cell 
lineage reprogramming could be used to explore cell fate decision mechanisms and 
their regulation. 
 
 1.1. Hematopoiesis and hematopoietic lineage diversification 
Hematopoiesis is the process of formation and differentiation of blood cells. 
Hematopoiesis is organized in a hierarchical manner, starting with the multipotent 
hematopoietic stem cells (HSCs) which reside in the bone marrow (BM) of the adult 
and give rise to lineage committed progenitors capable of terminal differentiation into 
mature cells. Within the HSC compartment there is a rare subpopulation of long-term 
HSCs which have the distinctive capability of life-long self-renewal and multilineage 
differentiation. They give rise to short-term HSCs, which keep the multilineage 
differentiation ability, however have a reduced self-renewal potential (Rosenbauer 
and Tenen, 2007). The classical model of hematopoiesis has suggested a 
mechanism of separate differentiation into two distinct lineage progenitors, namely 
common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs), 
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which are derived from a shared multipotent progenitor (MPP) completely lacking the 
self-renewal potential of the HSCs. CLPs can generate lymphoid lineage cells like 
natural killer (NK) cells, T cells, and B cells, while CMPs can further branch into two 
more restricted progenitors: megakaryocyte-erythrocyte progenitors (MEPs) and 
granulocyte (including neutrophils, eosinophils and basophils) -macrophage 
progenitors (GMPs) (Akashi et al., 2000; Kondo et al., 1997; Laiosa et al., 2006a). 
However, recent work has challenged this classical model due to the discovery of 
alternative differentiation pathways and additional intermediate progenitor steps 
(Graf, 2008; Murre, 2009) (Fig. 1.1). For example, Adolfsson et al. have shown that 
HSC can give rise of MEPs and lymphoid primed multipotent progenitors (LMPPs) 
which have lost erythroid and megakaryocytic developmental potential but retain 
myeloid and lymphoid potential, and this finding questions the concept of CMPs and 
the origin of MEPs and suggests that GMPs can be generated through alternative 
pathways (Adolfsson et al., 2005). Upon loss of myeloid potential LMPPs generate 
CLPs which are not a homogenous population and based on the expression of Ly-6D 
surface marker could be subdivided to Ly-6D– all-lymphoid progenitors (ALPs), which 
possess the full lymphoid potential and can differentiate into B, T, NK, and dendritic 
cells (DCs), and more restricted Ly-6D+ B cell-biased lymphoid progenitors (BLPs) 
which upregulate the B cell specific transcription factors Ebf1 and Pax5 and 
preferentially develop along the B cell differentiation pathway via the pre-pro and pro 
B cell stages (Inlay et al., 2009). The pro B cells undergo B-lineage commitment, 
rearrange their immunoglobulin heavy chain (IgH) locus and successful 
rearrangements result in expression of the pre-B cell receptor (pre-BCR) on the cell 
surface and transition from the pro B to the pre B cell stage (Medvedovic et al., 
2011). Productive immunoglobulin light chain gene rearrangements in pre B cells 
result in the development of immature surface IgM+ B cells which leave the BM and 
migrate to the peripheral lymphoid organs (Medvedovic et al., 2011). Moreover, 
studies have shown that pre-pro B cells possess not only B cell differentiation 
capacity but also residual T cell potential (Rumfelt et al., 2006). Moreover, the early T 
cell progenitors (ETPs) have combined T cell, B cell and myeloid potential, indicating 
the existence of alternative lineage commitment pathways (Bell and Bhandoola, 
2008; Luc et al., 2012). 
Earlier in vivo transplantation experiments have shown that CLPs, ETPs, pro T cells, 
as well as CMPs and GMPs can generate DCs, whereas pro B cells and MEPs do 
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Fig. 1.1 Current concepts of hematopoietic lineage diversification. 
The scheme represents a revised roadmap of the hematopoiesis, combining the classical model with 
recent advances in the hematopoietic cell development field, which have suggested the existence of 
alternative differentiation pathways and cell fate branching. For the sake of simplicity, only some but 
not all alternative paths are shown. See text for more details. HSC - hematopoietic stem cells; MMP - 
multipotent progenitors; LMPP - lymphoid primed multipotent progenitors; ALP - all-lymphoid 
progenitors; BLP - B cell-biased lymphoid progenitors; ETP - early T lineage progenitors; NK - natural 
killer cells; DC - dendritic cells; CMP - common myeloid progenitors; MDP - macrophages and DC 
progenitors; GMP - granulocyte-macrophage progenitors; MEP - megakaryocyte-erythrocyte 
progenitors. 
Figure is based on published data (Adolfsson et al., 2005; Fiedler and Brunner, 2012; Fogg et al., 
2006; Geissmann et al., 2010; Inlay et al., 2009; Ramirez et al., 2010; Rosenbauer and Tenen, 2007). 
 
not have DC differentiation capacity; furthermore, CLPs and CMPs have 
approximately equal DC developmental potential on a per cell basis (Manz et al., 
2001). Later, the existence of a common macrophage and DC progenitor (MDP) 
downstream of CMPs characterized as Lin– c-kit+ CX3CR1+ M-CSFR+ population was 
identified and this MDP can in vivo differentiate into monocytes, different tissue 
macrophage populations and resident splenic DC but not into granulocytes (Fogg et 
al., 2006). DC development further progresses to common DC progenitors (CDP), 
which ultimately give rise to conventional DCs (cDCs) and plasmacytoid DCs (pDCs) 
but not to monocytes (Liu et al., 2009). On the other hand, blood monocytes originate 
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in the BM from HSCs via several progenitor stages including CMP, GMP and MDP 
(Yona and Jung, 2010). Although it is currently accepted that monocytes do not 
reconstitute cDCs and pDCs in the steady state, under inflammatory conditions they 
can enter the tissues and give rise not only to macrophages but also to inflammatory 
DCs, like for example the TNF-α and iNOS (Nos2)-producing (Tip) DCs identified in 
spleens of mice infected with Listeria monocytogenes (Geissmann et al., 2010; 
Serbina et al., 2008; Serbina et al., 2003). However, the existence of HSC 
independent myeloid lineage, including liver Kupffer cells, epidermal Langerhans 
cells and brain microglia, has been shown. These cells may originate from embryonic 
yolk sac progenitors and are maintained through their local proliferation and BM-
independent renewal after birth (Belz and Nutt, 2012; Schulz et al., 2012). 
 
 1.2. Transcriptional regulators of B lymphoid and myeloid development  
In the hematopoietic system cell fate decisions are controlled by extrinsic and 
intrinsic factors. The extrinsic factors include cytokines, hormones and direct cell-cell 
interactions, however, they can have both permissive and instructive roles for 
hematopoietic cell differentiation (Laiosa et al., 2006a; Rieger et al., 2009). The 
hematopoietic lineage specification (induction of a lineage specific expression 
program) and commitment (cell fate determination through repression of alternative 
gene expression programs) crucially depend on intrinsic transcription factors that set 
lineage specific networks in the different hematopoietic cells (Laiosa et al., 2006a; 
Nutt and Kee, 2007). Every lineage is defined by dosage, combination and cross 
interaction of transcription factors which specifically synergize, antagonize and 
regulate each other, maintaining transcription factor networks and lineage specific 
gene expression profiles (Laiosa et al., 2006a). Furthermore, lineage-specific 
transcription factors determine and maintain the cell fate program through 
recruitment of proteins and protein complexes that mediate epigenetic gene 
expression regulation, including DNA methylation, post-translational modifications 
(PTMs) of histones and nucleosome restructuring (Broske et al., 2009; Gao et al., 
2009; Ramirez et al., 2010). The irrefutable evidence for the lineage instructive 
capacity of transcription factors is the demonstration that, when ectopically 
expressed, they reprogram a committed cell into another lineage through disruption 
of the established transcription factor network and creation of a new one (Cobaleda 
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and Busslinger, 2008). The overexpressed transcription factors activate their 
endogenous partners, set up autoregulatory loops and disrupt autoregulation of 
antagonistic factors (Laiosa et al., 2006a). Here, we will focus in more details only on 
the transcription regulation of the B cell- and the myeloid lineage without the 
megakaryocyte/erythrocyte branch. 
 
 1.2.1. B cell lineage transcription regulators 
Conventional B cell (B-2 cell) differentiation proceeds from HSCs through B cell 
progenitors till the production of surface IgM+ immature B cells via a series of distinct 
intermediate steps (Hardy et al., 2007; Medvedovic et al., 2011). Genetic ablation 
studies have demonstrated that the transcription factors PU.1, Ikaros, E2A, EBF1, 
and Pax5 play key roles in B cell lineage differentiation (Mandel and Grosschedl, 
2010; Nutt and Kee, 2007; Ramirez et al., 2010). The formation of more primitive 
lymphoid progenitors is dependent on the action of PU.1 and Ikaros and their 
deficiency severely impairs the early lymphoid lineage development (Nutt and Kee, 
2007). Prior to the differentiation of CLPs, Ikaros and PU.1 induce the expression of 
components of signaling pathways essential for B cell progenitors generation, 
including interleukin 7 receptor a chain (IL-7Ra) and fms-like tyrosine kinase 3 
receptor (Flt-3) (Laiosa et al., 2006a; Mandel and Grosschedl, 2010; Yoshida et al., 
2006). Beyond the CLP stage the key determinants of B lymphoid lineage are the 
transcription factors E2A, EBF1 and Pax5 which function in a hierarchical and 
combinatorial mode to activate and maintain the B cell-specific gene expression 
program. The E box-binding protein 2A (E2A) and the early B cell factor EBF1 are 
upstream of Pax5 in the genetic hierarchy of early B cell development and they are 
responsible for B cell lineage specification through activation of the expression of B 
lymphoid genes in pre-pro B cells (Lin et al., 2010; Treiber et al., 2010). Several lines 
of evidence suggest that E2A acts upstream of EBF1 and it has been shown that 
E2A deficient B lymphoid progenitors are blocked at the transition from ALP to BLP 
stage of B cell differentiation and fail to express EBF1 and Pax5, whereas Ebf1-/- pre-
pro B cells express E2A but lack Pax5 (Decker et al., 2009; Inlay et al., 2009; Nutt 
and Kee, 2007). E2A deficient B lymphoid progenitor cells fail to upregulate the early 
B cell genes Igll1 (λ5) and Cd79a and do not rearrange IgH locus beyond DH-JH 
rearrangements (Ikawa et al., 2004). However, EBF1 can also bind E2A gene and 
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conditional inactivation of Ebf1 leads to downregulation of E2A expression (Treiber et 
al., 2010). Moreover, E2A binding sites are present on more than two thirds of EBF1 
target genes, indicating that both proteins cross regulate each other and function 
cooperatively in B lymphocyte specification (Lin et al., 2010). 
Experiments comparing EBF1 gain- and loss- of function with genome wide analyses 
of EBF1 binding have identified that the direct EBF1 regulated genes are enriched in 
components of pre-BCR and B cell receptor (BCR) signaling pathway (Treiber et al., 
2010). Targeted inactivation of Ebf1 results in failure to express early B cell gene 
components of pre-BCR and BCR, including Cd79a, Cd79b, Igll1 (λ5), and Vpreb1, 
lack of VH-DJH IgH rearrangements and blockage of B cell development at B220+ 
CD19– uncommitted pre-pro B cell stage (Decker et al., 2009; Pongubala et al., 
2008). Down in the transcription factor hierarchy, EBF1 initiates chromatin 
remodeling at the Pax5 promoter and activates the expression of its direct target 
gene Pax5 at the onset of pro B cell stage (Decker et al., 2009; Treiber et al., 2010). 
Moreover, coordinated E2A and EBF1 binding to Pax5 gene regulatory elements has 
been shown (Lin et al., 2010). However, Pax5 is also able to activate Ebf1 
expression, as well as EBF1 binds its own promoter, suggesting that the 
transcriptional network controlling B cell specification and commitment is not a simple 
linear cascade but involves multiple combinatorial inputs and cross-regulatory loops 
(McManus et al., 2011; Nutt and Kee, 2007; Schebesta et al., 2007).  
The transcription factor paired box protein 5 (Pax5) is regarded as the master 
regulator of B cell commitment and a guardian of B cell identity and is expressed 
throughout B cells lineage from pro B to mature B cells and downregulated in plasma 
cells (Decker et al., 2009; Medvedovic et al., 2011). Pax5 expression is continuously 
required throughout B cell development, as supported by the observation that 
conditional Pax5 inactivation in mature B cells induces their conversion to functional 
T cells (Cobaleda et al., 2007a). Pax5 promotes B cell commitment at the transition 
to the pro B cell stage through repression of B lineage inappropriate genes like 
crucial receptors required for multipotency (Flt-3), macrophage (M-CSFR) and T cell 
(Notch1) differentiation, and activation of B cell specific genes (Delogu et al., 2006; 
Holmes et al., 2006; Nutt et al., 1999; Schebesta et al., 2007). Among Pax5 activated 
genes are multiple transcription factors (including Ebf1) and proteins involved in B 
cell signaling, adhesion, migration and immune function (e.g. the B cell co-receptor 
molecule CD19 whose expression marks all cells committed to the B cell lineage) 
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(McManus et al., 2011; Nutt and Kee, 2007; Schebesta et al., 2007). Pax5 directly 
binds to promoters and enhancers of its target genes and regulates their expression 
through induction of active chromatin at the activated genes and removal of active 
chromatin marks at repressed genes via recruitment of BAF chromatin-remodeling 
complexes, histone-modifiers and basal transcription factor TFIID complexes. 
Therefore, Pax5 orchestrates the epigenetic and transcriptional control of its target 
genes (McManus et al., 2011; Schebesta et al., 2007). EBF1 might also contribute to 
B cell commitment not only through activation of Pax5 expression but also through 
antagonizing the expression of myeloid determinants like C/EBPα and PU.1 in MPP 
and repression of T cell specific genes in B cell progenitors (Pongubala et al., 2008; 
Treiber et al., 2010). Interestingly, about 10% of EBF1 bound genome sites have also 
an additional Pax5 binding site and there is a remarkably high number of Pax5 
activated genes and to a lower extend Pax5 repressed genes which have EBF1 
binding sites, suggesting the cooperative function of the two factors (Treiber et al., 
2010). Additionally to gene expression regulation, Pax5 regulates VH-DJH 
recombination of the IgH locus by inducing its contraction by looping and its 
deficiency blocks B cell differentiation at the pro B cell stage shortly after completion 
of IgH DH-JH gene segments rearrangements (Medvedovic et al., 2011). Interestingly, 
related to the capacity of the three determinants of B lymphoid lineage E2A, EBF1 
and Pax5 to repress alternatively lineage choices, it has been shown that the 
deficiency of any of them permits multilineage differentiation potential (Ikawa et al., 
2004; Nutt et al., 1999; Pongubala et al., 2008). 
Although the majority of postnatal B lymphocytes are conventional B-2 B cells, an 
alternative B cell development pathway has been identified and these B-1 cells are 
preferentially generated during fetal hematopoiesis, while they represent only a minor 
fraction in adult mice (Barber et al., 2011; Hardy et al., 2007). Interestingly, compared 
to B-2 cells, the B-1 cells express lower levels of PU.1 and conditional ablation of 
PU.1 in CD19+ B cells in vivo, leads to de-differentiation of B-2 B cell into B-1 
resembling cells (Ye et al., 2005). 
 
 1.2.2. Transcription factor regulation of the myeloid cell differentiation 
The master regulators of the myeloid differentiation are PU.1 and C/EBPs and their 
interplay is critical for the cell fate decisions in the myeloid lineage (Rosenbauer and 
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Tenen, 2007). PU.1 is required for development of CMPs and CLPs but not MEPs 
from HSCs and deletion of PU.1 at the CMP or GMP stage blocks their maturation to 
granulocytes and monocytes (Iwasaki et al., 2005). PU.1 regulates numerous genes 
within the myeloid and lymphoid lineages, including those encoding the 
developmentally important cytokine receptors, macrophage colony stimulating factor 
receptor (M-CSFR), granulocyte-macrophage colony stimulating factor receptor (GM-
CSFR), IL-7Ra and Flt-3 (Carotta et al., 2010; Dakic et al., 2007). The fundamental 
role of PU.1 as a transcriptional master regulator of myeloid and lymphoid cell fates 
is highlighted by the presence of PU.1 binding motifs in the regulatory sequences of 
many macrophage and B cell specific genes and these sites are colocalized by 
C/EBPs or E2A and EBF1 in the respective lineage (Heinz et al., 2010). In peritoneal 
macrophages one third of the genome sites occupied by C/EBPα or C/EBPβ are 
located within 100bp of a PU.1 bound site, suggesting the collaborative function of 
these transcription factors for the establishment of macrophage gene expression 
program (Heinz et al., 2010). Furthermore, there are two auto-regulatory loops which 
activate the PU.1 locus in a cell type specific manner in macrophages and B cells. 
Although cis- upstream regulatory element (URE) at -14/-15 kb is essential for PU.1 
expression in all hematopoietic lineages, additional myeloid-specific cis-regulatory 
element at -12 kb is required to drive high PU.1 expression in macrophages, and 
binding of myeloid specific transcription factors like C/EBPα at URE initiates 
chromatin opening at -12 kb enhancer to drive cell type specific PU.1 expression 
(Leddin et al., 2011). 
The regulation of hematopoietic differentiation by PU.1 is however not a simple 
mechanism dependent on presence or absence of expression but it also dependents 
on the expression level (Mak et al., 2011). It has been shown that low dosage of 
PU.1 protein induces B cell development, whereas high expression level promotes 
macrophage differentiation (DeKoter and Singh, 2000). Ectopic expression of PU.1 in 
PU.1+/- fetal liver progenitors cultured on S17 feeder cells in the presence of IL-7 
blocks B cell development and induces macrophage differentiation (DeKoter and 
Singh, 2000). Moreover, in the B cell lineage higher expression of PU.1 is necessary 
for conventional B-2 cell differentiation, whereas B-1 cells express lower level of 
PU.1 (Ye et al., 2005). A similar dose effect exists in the myeloid lineages where 
C/EBPα and high PU.1 levels support monopoiesis, whereas combination of C/EBPα 
and low PU.1 levels supports granulopoiesis (Yeamans et al., 2007). 
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Although experiments have shown that PU.1 acts at an earlier stage of the 
hematopoietic lineage determination compared to C/EBPα (PU.1 is essential for CMP 
generation, whereas C/EBPα is important for GMP generation (Zhang et al., 2004)), it 
has been shown that C/EBPα binds and activates the PU.1 promoter and distal 
enhancer during myelopoiesis (Kummalue and Friedman, 2003; Yeamans et al., 
2007). C/EBPα induces monocytic differentiation when expressed in wild type (WT) 
murine BM myeloid progenitors but stimulates granulocytic development in PU.1kd/kd 
cells (lacking the PU.1 distal enhancer URE and expressing 20% of normal PU.1 
levels) and induces neither monocytic nor granulocytic differentiation in PU.1-/- cells 
(Yeamans et al., 2007). However, PU.1 and C/EBPs might antagonize each other 
during DC differentiation, as it has been shown that expression of PU.1 or a 
dominant negative C/EBP in human CD34+ cells enhances Langerhans cell 
differentiation, whereas C/EBPα and β promote preferentially granulocytic and to 
some extend monocyte/macrophage differentiation and disrupt DC differentiation 
induced by PU.1 (Iwama et al., 2002). Furthermore, it has been shown that moderate 
expression levels of PU.1 and co-expression of the basic leucine zipper (bZip) factor 
MafB favors macrophage fate, whereas high PU.1 levels induce DC differentiation 
and repress macrophage differentiation through inhibition of Mafb expression and 
transcriptional activity (Bakri et al., 2005). 
Conditional deletion of PU.1 in distinct hematopoietic progenitor populations leads to 
blockage of Flt-3 and GM-CSF induced DC differentiation and impairs generation of 
both cDCs and pDCs, suggesting a crucial role of PU.1 for the development of all DC 
types (Carotta et al., 2010). However, the differentiation of the variety of DC subsets 
requires a distinct combination of many different transcription regulators including 
IRF8, IRF4, BATF3, E2-2, RELB, STAT3, STAT5 and others (Belz and Nutt, 2012). 
In immature DCs PU.1 and its binding partner interferon-regulatory factor 8 (IRF8) 
are required for the expression of MHC Class II Transactivator (CIITA), a 
transcriptional co-activator which is a master regulator of MHC-II gene expression 
(Smith et al., 2011). Interestingly, IRF8 is expressed not only in DCs, but also in B 
cells and macrophages, however not in granulocytes and is considered as a 
determinant of monocyte/macrophage and DC over granulocytic differentiation 
(Becker et al., 2012; Rosenbauer and Tenen, 2007). Myeloid progenitor cells 
established from Irf8-/- mice differentiate into granulocytes in granulocyte colony 
stimulating factor (G-CSF) supplemented culture medium. However, retroviral 
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transduction of Irf8 results in their differentiation into mature phagocytic macrophages 
and blocks granulocytic differentiation upon G-CSF treatment (Tamura et al., 2000). 
In the B cell lineage Irf8 is directly regulated by Pax5, however on the other hand, 
IRF8 and PU.1 contribute to the maintenance of Pax5 expression during early and 
late B cell development (Decker et al., 2009; Ramirez et al., 2010). Furthermore, Irf8 
deficient mice have a significantly reduced number of pre-pro B cells and increased 
number of myeloid cells and Irf8-/- B cell progenitors show deregulated expression of 
IRF8 target genes PU.1 and Ebf1 (PU.1 is upregulated and Ebf1 is downregulated in 
Irf8 deficient compared to WT B cell progenitors) (Wang et al., 2008). 
C/EBPα deficient mice completely lack GMPs, neutrophil and eosinophil 
granulocytes, however C/EBPα is not strictly required for granulopoiesis (the 
formation of granulocytes within the BM) beyond the GMP stage, as its conditional 
deletion in GMPs does not disrupt normal granulopoiesis in vitro (Zhang et al., 1997; 
Zhang et al., 2004). It has been shown that other factors, like growth-factor 
independent 1 (GFI1) and C/EBPε are essential for terminal neutrophil granulocytic 
differentiation (Rosenbauer and Tenen, 2007). Interestingly, C/EBPε is expressed as 
four isoforms and each of them may display different roles during granulocytic 
differentiation. Transduction of human CD34+ progenitor cells with these isoforms 
has revealed that C/EBPε32/30 isoforms induce eosinophil differentiation; C/EBPε27 
and C/EBPε14 isoform strongly inhibit eosinophil differentiation and gene expression, 
while C/EBPε27 promotes neutrophil/macrophage differentiation and C/EBPε14 
repressor isoform promotes erythroid differentiation (Bedi et al., 2009). Interestingly, 
the order of expression of C/EBPα and GATA-2 can differentially control lineage 
commitment from GMPs to eosinophils, basophils, neutrophils and monocytes 
(Iwasaki et al., 2006). The last steps of neutrophil terminal differentiation are 
characterized by increased expression levels of PU.1 and the C/EBP protein family 
members C/EBPβ, C/EBPδ and C/EBPζ (Bjerregaard et al., 2003; Borregaard, 
2010). Furthermore, C/EBPβ can substitute for C/EBPα during emergency 
granulopoiesis or when expressed from its endogenous locus (Hirai et al., 2006; 
Jones et al., 2002). A detailed description of C/EBPβ functions during hematopoiesis 
will be given in the next subchapter. 
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 1.2.3. C/EBPβ structure, regulation and function in the hematopoietic system 
CCAAT enhancer binding protein (C/EBP) family consists of six members: C/EBPα, 
C/EBPβ, C/EBPδ, C/EBPε, C/EBPγ, and C/EBPζ. C/EBPs regulate cell proliferation, 
differentiation, metabolism, inflammation, apoptosis and tumorigenesis in a variety of 
cell types, including hepatocytes, adipocytes and hematopoietic cells (Akagi et al., 
2008; Cao et al., 1991; Chen et al., 1997; Johnson, 2005; Ramji and Foka, 2002; 
Smink and Leutz, 2012; Tanaka et al., 1995; Wethmar et al., 2010; Zahnow, 2009). 
C/EBPs orchestrate cell type specification in combination with other transcription 
factors. For example, C/EBPα and β require peroxisome proliferator-activated 
receptor gamma (PPARγ) for the induction of white adipogenic differentiation from 
fibroblasts (Rosen et al., 2002; Zuo et al., 2006), while co-expression of C/EBPβ and 
PRDM16 in fibroblasts or myoblastic precursors induces brown adipogenic 
differentiation (Kajimura et al., 2009). C/EBPβ cooperates with c-Myb in the activation 
of myeloid specific genes in heterologous cell types (Ness et al., 1993), and, in 
combination with PU.1, C/EBPα and β may evoke myeloid trans-differentiation of 
fibroblasts (Feng et al., 2008). 
As a member of C/EBP transcription factors family, C/EBPβ protein contains highly 
conserved C-terminal DNA binding and leucine zipper dimerization domain (bZip), 
central regulatory domain (RD) and N-terminal transactivation domain (TAD). The 
TAD and the RD consist of several conserved regions (CRs) with modular functions 
which are highly conserved between orthologous proteins and paralogous members 
of vertebrate C/EBPs (Kowenz-Leutz et al., 1994; Leutz et al., 2011). Individual CR 
modules are separated by low complexity regions (LCRs) which differ between family 
members and are polymorphic within the same family. Deletion and functional 
analyses suggest that LCRs may function as flexible hinges and recipients of signal 
dependent PTMs while CRs may serve scaffolding functions for regulated 
intramolecular interactions and docking of chromatin modulating complexes and the 
transcription machinery (Leutz et al., 2011). The N terminus of C/EBPβ is involved in 
the transcription activation and it is shown to interact with mediator complexes, basal 
transcriptional machinery (TBP/TFIIB) and with transcription co-factors, including 
chromatin-remodeling complexes (SWI/SNF), histone acetyltransferase (p300), 
methyltransferases (PRMT4 and G9a) and several other chromatin regulatory 
complex components (Kowenz-Leutz and Leutz, 1999; Kowenz-Leutz et al., 2010; 
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Lee et al., 2010a; Mink et al., 1997; Mo et al., 2004; Nerlov and Ziff, 1995; Pless et 
al., 2008; Steinberg et al., 2012). C/EBP proteins are active as dimers and via its 
leucine zipper dimerization domain C/EBPβ can form homo- or heterodimers with 
other C/EBPs or other bZip proteins. Additionally, C/EBPβ dimers may interact 
through the C-terminal bZip domain with other transcription factors, like c-Myb and 
PU.1 and this interaction mediates their cooperative target gene activation (Miller, 
2009; Tsukada et al., 2011). Furthermore, C/EBPβ binding sequences are found in 
the regulatory regions of many genes involved in the acute-phase response, 
inflammation, and hematopoietic differentiation including C reactive protein, α1-acid 
glycoprotein, α2-macroglobuin, hemopexin, haptoglobin; genes coding for the 
cytokines TNF-α, IL-1β, IL-6, IL-8, IL-12, G-CSF, CCL3 (also known as macrophage 
inflammatory protein-1α, MIP-1α), CCL4 (MIP-1β); and cytokine receptors G-CSFR, 
GM-CSFR and M-CSFR (Tsukada et al., 2011). 
C/EBPβ is expressed in three protein isoforms - long ones (LAP* and LAP, liver 
activating protein) with TAD and truncated form (LIP, liver inhibitory protein), which 
acts as a dominant inhibitory peptide lacking the N-terminal activation function 
(Descombes and Schibler, 1991). The three C/EBPβ isoforms are generated through 
a process of alternative translation initiation which is regulated by a highly conserved 
out of frame small upstream open reading frame (uORF) and the translation initiation 
is under the control of the mammalian target of rapamycin (mTOR). Regulation of the 
isoform ratio is crucial for the maintenance of the balance between cell proliferation 
and differentiation and its dysregulation is a prerequisite for a tumorigenesis 
(Calkhoven et al., 2000; Wethmar et al., 2010; Zahnow, 2009). However, the effect of 
C/EBPβ on the cell proliferation is cell type specific and in some cases C/EBPβ can 
have growth-promoting and in others growth-arresting activity (Berberich-Siebelt et 
al., 2006; Chen et al., 1997; Gutsch et al., 2011; Hirai et al., 2006; Sebastian et al., 
2005; Tang et al., 2003; Xie et al., 2004). Additionally, PTMs can modulate C/EBPβ 
transcriptional activity, DNA binding, protein interactions and subcellular localization 
(Nerlov, 2008; Tsukada et al., 2011; Zahnow, 2009). It has been shown that C/EBPβ 
functions are regulated by phosphorylation (Kowenz-Leutz et al., 1994; Lee et al., 
2010b; Lynch et al., 2011; Mo et al., 2004; Nerlov, 2008), methylation (Kowenz-Leutz 
et al., 2010; Leutz et al., 2011; Pless et al., 2008), acetylation (Cesena et al., 2007; 
Cesena et al., 2008) and SUMOylation (SUMO, small ubiquitin-like modifier) 
(Berberich-Siebelt et al., 2006; Eaton and Sealy, 2003; Leutz et al., 2011) (Fig. 1.2). 
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Mass spectrometry data have shown that many arginine (R) residues in TAD, RD 
and bZip of C/EBPβ are mono- or dimethylated and individual or combined mutation 
of these residues to alanine (A) results in increased reporter and endogenous gene 
activation potential, demonstrating that the PTM pattern regulates C/EBPβ 
functionality (Leutz et al., 2011). The complexity of C/EBPβ structure thus suggests 
highly modular, context specific N-terminal functions and a flexible adaptation to 
signaling and metabolic events (Leutz et al., 2011; Nerlov, 2008).  
 
   
 
Fig. 1.2 C/EBPβ is extensively post-translationally modified by methylation and acetylation. 
Localization of evolutionary conserved arginine (R) or lysine (K) residues in C/EBPβ LAP* in relation 
to the protein structure. Underneath: mass spectrometry analyses have identified mono-(me1), di-
(me2), tri-(me3) methylation, and acetylation (ac) on the respective residue in rat (R) and chicken (C) 
C/EBPb. TAD – transactivation domain, RD - regulatory domain, bZip - basic DNA binding and leucine 
zipper dimerization domain, CR - conserved region, H - human, M - mouse, PTM - post-translational 
modifications. Re-drawn from (Leutz et al., 2011). 
 
C/EBPβ deficient mice display defects in both lymphoid and myeloid lineages in the 
hematopoietic system. These mice have decreased number of BM B lymphocytes, 
which additionally display impaired expansion in long-term culture (Chen et al., 
1997). With aging, C/EBPβ deficient mice develop lymphoproliferative and 
myeloproliferative alterations (Screpanti et al., 1995). In the myeloid lineage, C/EBPβ 
is essential for macrophage bactericidal and tumor cytotoxicity role (Tanaka et al., 
1995) and is crucial for the survival of transformed macrophages through induction of 
the autocrine-acting pro-survival factor insulin-like growth factor I (IGF-I) (Wessells et 
al., 2004). C/EBPβ is important for the “emergency” granulopoiesis, as C/EBPβ 
deficient hematopoietic progenitor cells have impaired response to GM-CSF and G-
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CSF and C/EBPβ deficient neutrophils exhibit increased apoptosis (Akagi et al., 
2008; Hirai et al., 2006). Furthermore, C/EBPβ knock-in mice have been generated in 
order to examine the function of a single C/EBPβ isoform. In mice lacking C/EBPβ 
LAP isoform, the induction of C/EBPβ target genes in activated macrophages is 
abolished similarly to C/EBPβ deficiency, however no impairment of intracellular 
bacteria killing is observed, suggesting that the extended long isoform LAP* could 
compensate for some, but not for all functions of the LAP isoform (Uematsu et al., 
2007). Furthermore, after partial hepatectomy C/EBPβΔuORF hepatocytes (lacking only 
C/EBPβ LIP expression) demonstrate decreased proliferation, delayed cell cycle 
entry and constant repression of E2F regulated genes (Wethmar et al., 2010). 
Studies with C/EBPβ-/-, C/EBPβLIP and C/EBPβΔuORF mice have shown opposing 
roles of long and short C/EBPβ isoforms for the regulation of the osteoclast 
differentiation, demonstrating that lack of LIP leads to impairment of osteoclast 
differentiation, whereas C/EBPβ-/- and C/EBPβLIP genotypes (lacking the long 
C/EBPβ isoforms) exhibit strongly enhanced differentiation of the bone-resorbing 
cells (Smink et al., 2009; Wethmar et al., 2010). Furthermore, studies with mice 
carrying a targeted deletion of two CREB-binding sites in the C/EBPβ promoter 
(βΔCre mice) and incapable of upregulation of C/EBPβ upon inflammatory stimuli 
have shown that high C/EBPβ level is crucial for the induction of anti-inflammatory 
macrophage genes (Ruffell et al., 2009). 
 
 1.3. Cell plasticity and cell reprogramming 
Until recently cellular and developmental biology have postulated a dogma that 
lineage commitment, established through the collaborative action of transcription 
factors and epigenetic regulators, is irreversible (Carotta and Nutt, 2008). However, 
studies of the last two decades have provided evidence that committed cells do not 
lose their developmental potential and may retain lineage promiscuity. Lineage 
infidelity can be observed, for example, in classical Hodgkin lymphoma where the B 
cell specification transcription factor E2A is expressed, however due to an 
overexpression of two E2A antagonists (activated B cell factor 1 (ABF-1) and inhibitor 
of differentiation 2 (Id2)) the expression of B cell specific genes is lost, while B cell 
lineage inappropriate genes are expressed (Janz et al., 2006; Mathas et al., 2006). 
Furthermore, bi-phenotypic acute leukemia with expression of both, myeloid and 
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lymphoid cell surface markers have been described (Matutes et al., 1997), and 
lineage switching of B cell lymphoma, acute lymphoblastic leukemia or bi-phenotypic 
leukemia to acute myeloid leukemia (Muroi et al., 1995; Slany, 2009; Tsuboi et al., 
2002), as well as trans-differentiation of follicular lymphoma to histiocytic/DC 
sarcomas with clonal immunoglobulin rearrangements have been reported (Feldman 
et al., 2008), suggesting the potential role of cell reprogramming during 
leukemogenesis. However, lineage plasticity might be a characteristic not only of 
transformed cells but also of normal cells. For example, HSCs and progenitor cells 
express genes typical for different lineages and this process, known as lineage 
priming, might be the reason for the broad developmental plasticity of progenitor cells 
(Cobaleda and Busslinger, 2008; Laiosa et al., 2006a). Furthermore, mRNA for M-
CSFR and other macrophage specific genes are expressed in granulocytes and they 
can be trans-differentiated into macrophage-like cells upon M-CSF stimulation 
(Sasmono et al., 2007). The gene expression profile of preadipocytes is much closer 
to that of macrophages than to adipocytes and preadipocytes could efficiently be 
converted into Mac-1+ F4/80+ macrophages after in vivo transplantation into the 
mouse peritoneal cavity (Charriere et al., 2003).  
 
 1.3.1. Hematopoietic cell reprogramming 
Aside from the lineage infidelity seen in tumor cells and the physiological cellular 
plasticity described above, in the recent years experimental hematopoietic cell 
reprogramming has been achieved by stimulation through exogenously expressed 
cytokine receptors or targeted inactivation or enforced expression of specific 
transcription factors. For example, ectopical expression of M-CSFR in murine pre B 
cells reprograms them to phagocytic macrophages with rearranged immunoglobulin 
gene loci (Borzillo et al., 1990). Likewise, exogenous expression of IL-2Rβ and GM-
CSFR in CLP and pro T cells reveals their latent myeloid differentiation potential 
(Cobaleda and Busslinger, 2008; Hsu et al., 2006; Iwasaki-Arai et al., 2003; King et 
al., 2002; Kondo et al., 2000). At the molecular level, ectopical IL-2Rβ signaling leads 
to upregulation of the cytokine receptors GM-CSFR and M-CSFR as well as the key 
myeloid transcription factor C/EBPα (Hsu et al., 2006; Kondo et al., 2000). Enforced 
expression of Flt-3 in MEPs, which normally do not express Flt-3, results in the 
acquisition of pDC and cDC potential (Onai et al., 2006). 
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A particularly dramatic example of lineage plasticity resulting from inactivation of a 
transcription factor comes from studies of the deficiency of the B cell commitment 
factor Pax5. It has been shown that Pax5-/- pro B cells are no longer B cell lineage 
restricted but entail the capacity to de-differentiate into macrophages, osteoclasts, 
granulocytes, NK cells, DCs and T cells (Carotta and Nutt, 2008; Cobaleda et al., 
2007b; Nutt et al., 1999) (Fig. 1.3). At the molecular level, Pax5 deficiency allows 
promiscuous expression of myeloid, erythroid and T cell genes in Pax5-/- pro B cells, 
indicating the essential function of Pax5 to repress non B lymphoid genes (Delogu et 
al., 2006; Nutt et al., 1999). Furthermore, conditional inactivation of Pax5 in mature B 
cells results in their de-differentiation to a progenitor state with a multilineage 
potential, underlining the continuous requirement of Pax5 to maintain B cell lineage 
commitment (Cobaleda et al., 2007a). Interestingly, Cd19 locus insertion of the gene 
coding for osteoclastogenesis promoting chemokine Ccl3 (a gene repressed by 
Pax5) and its ectopic expression in B cells results in enhanced osteoclast formation 
and bone loss (Delogu et al., 2006). 
A similar capacity for multilineage differentiation has been reported for E2A deficient 
hematopoietic progenitor cells. These cells co-express genes associated with other 
hematopoietic lineages, such as Gata3 and Tcf7 for T cells, Gata1 and Epor for 
erythroid cells, as well as G-CSFR and M-CSFR for myeloid cells and can in vivo 
differentiate into T cells, NK cells, macrophages, granulocytes, erythrocytes and DCs 
but not to mature B cells (Ikawa et al., 2004). Likewise, it has been shown that Ebf1 
deficient B220+ CD19– B lymphoid progenitor cells have the potential to reconstitute 
several alternative hematopoietic lineages. These Ebf1-/- cells can in vivo generate 
Mac-1+ Gr-1+ myeloid cells, CD11c+ DCs, DX5+ NK cells, CD4+CD8+ double-positive 
and single-positive thymocytes, however have a neglectable erythroid potential 
(Pongubala et al., 2008).  
Furthermore, PU.1 excision in CD19+ B cells results in a B-2 to B-1 cell 
reprogramming (Ye et al., 2005). Knock-down of MTA3, a cell type specific 
component of Mi-2/NuRD co-repressor complex, impairs BCL-6-dependent 
repression of plasma cell differentiation program and activates this program in B 
lymphocytes. Conversely, ectopical co-expression of BCL-6 and MTA3 in plasma 
cells leads to their reprogramming to B lymphocytes through repression of plasma 
cell fate specific transcripts, including the master regulator of plasma cell identity 
Blimp-1, and reactivation of the B cell transcription pattern (Fujita et al., 2004). 
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Fig. 1.3 B lymphoid plasticity. 
In the absence of B cell lineage commitment factor Pax5, B cell development is blocked at the pro B 
cell stage. These cells are not committed to the B cell lineage but are able to differentiate into other 
hematopoietic cell types. It has been also shown that forced expression of C/EBPα or C/EBPβ in B 
cell progenitors or mature splenic B cells induces their trans-differentiation into macrophages. 
Furthermore, experiments have demonstrated that Oct4, Sox2, Klf4, and c-Myc (4 Yamanaka 
transcription factors, 4Y) induce iPS cell formation from pro B and pre B cells, however these factors 
are ineffective in mature B cells, which require additional C/EBPα overexpression or Pax5 knock 
down. DC - dendritic cells, Gr - granulocytes, NK - natural killers. Figure is adapted from (Carotta and 
Nutt, 2008; Graf and Busslinger, 2008; Laiosa et al., 2006a). 
 
As already mentioned, not only targeted gene inactivation but also ectopical 
expression of transcription factors that play a central role in the physiological cell 
differentiation can lead to disruption of the established cell fate. It has been shown 
that B lymphoid cells can be reprogrammed to macrophages by the ectopic 
expression of C/EBPα and β transcription factors (Bussmann et al., 2009; Xie et al., 
2004) (Fig. 1.3.), even though other groups have reported that this could be obtained 
only in Pax5-/- B cells, most probably due to accomplishment of low C/EBP 
expression or because of the lymphoid growth conditions (Heavey et al., 2003). This 
reprogramming process is direct and does not involve retro-differentiation into early 
hematopoietic progenitors or stem cells (Di Tullio et al., 2011). Further 
characterization of the B cell to macrophage conversion has demonstrated that it 
does not proceed with significant DNA methylation changes but is accompanied only 
by histone modification alterations on key lineage specific genes (Rodriguez-Ubreva 
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et al., 2012). Recently it has been also shown that cell division is not obligatory for 
C/EBPα-induced B-to-macrophage reprogramming (Di Tullio and Graf, 2012). Similar 
to B cells, MEPs and CLPs could also be de-differentiated to functional macrophages 
by enforced C/EBPα expression (Fukuchi et al., 2006; Hsu et al., 2006). The 
lymphoid to myeloid conversion by C/EBPs is dependent on both synergy with the 
endogenous PU.1 and repression of B lineage commitment factor Pax5 (Bussmann 
et al., 2009; Hsu et al., 2006; Xie et al., 2004). This repression of Pax5 functions is 
due to inhibition of the protein activity (Xie et al., 2004) and not due to direct binding 
of C/EBPβ to Pax5 promoter (Pal et al., 2009). On the other hand, enforced 
expression of EBF1 in CMPs or GMPs downregulates the expression of C/EBPα and 
PU.1 and induces reprogramming into CD19+ cells (Pongubala et al., 2008). 
Similarly, C/EBPα-induced B cell to macrophage reprogramming could be delayed by 
Pax5 coexpression, whereas EBF1 has weaker effect and E2A shows no influence 
(Bussmann et al., 2009). In the same set of experiments, lack of endogenous PU.1 
inhibits CD11b upregulation without affecting CD19 downregulation (Bussmann et al., 
2009; Xie et al., 2004). Even fibroblasts, not related to the hematopoietic lineage cell 
type, could be reprogrammed to macrophage-like cells by the myeloid determinant 
factors CEBPα and C/EBPβ in combination with PU.1 (Feng et al., 2008). The 
overexpression of another transcription factor Oct4 in combination with SCF and Flt-
3L cytokines supplemented media reprograms human fibroblasts directly without 
involvement of a pluripotent state into CD45+ multipotent hematopoietic progenitor 
cells which can be further differentiated into granulocytes, monocytes, erythrocytes 
and megakaryocytes after additional cytokine stimulation in vitro or after 
transplantation in vivo (Szabo et al., 2010). 
Unlike synergism during B cell or fibroblast to macrophage reprogramming, PU.1 and 
C/EBPs can also antagonize each other and determine alternative lineage choices. 
For example, PU.1 and C/EBPα / C/EBPβ have opposite effects on Langerhans cell 
differentiation (Iwama et al., 2002). Accordingly, C/EBPα and β reprogram committed 
T cell progenitors to inflammatory macrophages, whereas PU.1 reprograms them 
under the same culture conditions into myeloid DCs (Laiosa et al., 2006b). GATA-3, 
a transcription factor which is generally considered to be specific and essential for T 
cell differentiation, can convert T cell progenitors to mast cells (Taghon et al., 2007). 
However, Notch signaling can counteract the ability of C/EBPs, PU.1 and GATA-3 to 
reprogram the T cell progenitors (Laiosa et al., 2006b; Taghon et al., 2007).  
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Furthermore, similarly to enforced Flt-3 expression, its downstream targets STAT3 or 
PU.1 instruct MEPs to differentiate into pDC, cDCs and myelomonocytic cells while 
suppressing megakaryocyte/erythrocyte development (Onai et al., 2006). Expression 
of constitutively active β-catenin in lymphoid or myeloid hematopoietic progenitors 
converts them into cells which express lineage inappropriate genes and have 
multilineage differentiation potential (Baba et al., 2005). Forced expression of GATA-
1 in CLPs leads to megakaryocyte/ erythrocyte trans-differentiation and inhibition of 
the normal lymphoid development (Iwasaki et al., 2003). Interestingly, the 
reprogramming outcome might also be defined by the sequence of transcription 
factor ectopical expression. For example, when alternating the order of ectopical 
expression of C/EBPα and GATA-2, CLPs can be differentially reprogrammed to 
multiple myeloid cell subtypes including monocytes, neutrophils, eosinophils, 
basophils and mast cells (Iwasaki et al., 2006).  
 
 1.3.2. Cell plasticity of the non-hematopoietic lineages 
Numerous studies have shown that non-hematopoietic lineage cells can also be 
trans-differentiated into another cell type. For example, the exogenous expression of 
the skeletal myogenesis master regulatory transcription factor MyoD in fibroblasts or 
other cell types is sufficient to activate skeletal muscle differentiation program 
(Weintraub et al., 1989). The combination of three transcription factors involved in 
heart development, Gata4, Mef2c and Tbx5, directly reprograms cardiac or dermal 
fibroblasts into functional cardiomyocytes in vitro and in vivo (Ieda et al., 2010). The 
ectopical expression of the three key developmental regulators Ngn3, Pdx1 and Mafa 
converts mouse exocrine pancreatic cells into insulin-producing β-cells in vivo (Zhou 
et al., 2008), whereas Ngn3 is sufficient to trans-differentiate hepatic progenitors into 
β-cell islets (Yechoor et al., 2009). Transduction of Gata4, Hnf1a and Foxa3, and 
inactivation of p19Arf in mouse fibroblasts directly reprograms these cells into 
functional hepatocyte-like cells in vitro and in vivo (Huang et al., 2011). Forced 
expression of PR domain containing 16 (PRDM16) and C/EBPβ in mouse and 
human fibroblasts is sufficient to induce a functional brown fat differentiation program 
in vitro and in vivo after transplantation into mice (Kajimura et al., 2009). 
Furthermore, fibroblasts could also be directly reprogrammed into functional neurons 
by the combinatorial expression of defined neural specific transcription factors, even 
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in combination with microRNAs (miRNAs) (Ambasudhan et al., 2011; Vierbuchen et 
al., 2010). Moreover, a cocktail of the four reprogramming factors (Oct4, Sox2, Klf4, 
and c-Myc) and reprogramming medium supplemented with neural growth factors 
can efficiently trans-differentiate fibroblasts into expandable neural stem/progenitor 
cells that have the ability to give rise to functional mature neurons and glial cells (Kim 
et al., 2011), making direct reprogramming a very attractive method for derivation of 
expandable patient specific cells of interest. 
A groundbreaking discovery which has challenged all concepts about cell 
differentiation and plasticity is the finding that fibroblasts can be reprogrammed into 
the so-called iPS (induced pluripotent stem) cells through ectopic expression of the 
four transcription factors Oct4, Sox2, c-Myc and Klf4. These iPS cells can generate 
viable chimaeric animals with germline contribution and their similarities and 
differences from embryonic stem cells are subject to extensive research (Bar-Nur et 
al., 2011; Polo et al., 2010; Stadtfeld et al., 2010; Takahashi and Yamanaka, 2006; 
Wernig et al., 2007). On the other hand, Oct4 ectopic expression alone is enough to 
reprogram mouse and human neuronal stem cells to iPS cells (Kim et al., 2009a; Kim 
et al., 2009b). Interestingly, hematopoietic cells can also give rise to iPS cells by 
transduction with the four reprogramming factors, however, mature B cells require 
additional C/EBPα overexpression or Pax5 knock down (Eminli et al., 2009; Graf, 
2009; Hanna et al., 2008; Loh et al., 2009; Loh et al., 2010) (Fig. 3.1). 
 
 1.4. Monocyte and macrophage heterogeneity and plasticity 
Macrophages and their precursors peripheral blood monocytes are non-homogenous 
populations (Geissmann et al., 2003; Gordon and Taylor, 2005; Yona and Jung, 
2010). There are two main murine monocyte subsets in vivo – CD11b+ Ly-6C/Gr-1+ 
“inflammatory” monocytes, which are recruited to the sites of peripheral inflammation, 
and CD11b+ Ly-6C/Gr-1– “resident” monocytes, which home to non-inflamed tissue. 
These monocyte subsets share common monocyte characteristics, such as CD11b 
and M-CSF receptor expression, they are phagocytic and have a potential to 
differentiate into DCs, however they differ in the expression of adhesion molecules 
and chemokine receptors such as CD62L (L-selectin), CCR2, CX3CR1 which defines 
the distinct mechanisms of their tissue recruitment and biological functions (Arnold et 
al., 2007; Auffray et al., 2007; Geissmann et al., 2003; Nahrendorf et al., 2007; 
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Sunderkotter et al., 2004). Furthermore, there is a developmental relationship 
between the two subpopulations and it has been shown that Ly-6C/Gr-1 expression 
is downregulated in vitro and in vivo during monocyte maturation (Arnold et al., 2007; 
Drutman et al., 2012; Sunderkotter et al., 2004). 
Similarly to blood monocytes, tissue macrophages are heterogeneous and that 
reflects the variety of specific, even opposite functions they have in the different 
anatomical locations, e.g. pro-inflammatory or anti-inflammatory, digestion of old or 
damaged tissue or tissue healing, immunogenic or immune-tolerant functions (Arnold 
et al., 2007; Gordon and Taylor, 2005; Yona and Jung, 2010). Resembling T helper 
type 1 and type 2 polarization, macrophages could be polarized into classically 
activated (M1) and alternatively activated (M2) macrophage phenotypes, which have 
distinct biological functions and different gene expression profiles. Bacterial moieties 
(e.g. LPS) and IFNγ polarize macrophages toward inflammatory M1 phenotype, 
whereas M2 anti-inflammatory polarization is induced after stimulation with IL-4, IL-
13, immune complexes/TLR ligands, TGFβ or IL-10, and based on these polarizing 
stimuli M2 macrophages can be further subdivided into additional categories 
(Cassetta et al., 2011; Solinas et al., 2009). M1 macrophages provide a defense 
against infections and tumors, produce high levels of inflammatory cytokines, and 
activate immune response, whereas M2 polarized macrophages promote scavenging 
of cell debris, angiogenesis, remodeling and tissue repair, display immune-regulatory 
functions and might promote tumor progression. Classically activated M1 
macrophages are characterized by high production of TNF-α, IL-1β, IL-6, IL-12 and 
IL-23, high amounts of reactive nitrogen and oxygen intermediates and efficient 
antigen presenting capability. Hallmarks of M2 macrophages are high expression of 
IL-10, IL-1 receptor antagonist (IL-1RA) and IL-1 decoy receptor and low expression 
of IL-12, high expression of mannose, scavenger and galactose receptors, 
predominance of the arginase pathway and poor antigen presenting capability 
(Biswas and Mantovani, 2010, 2012; Mantovani, 2008; Mantovani et al., 2002; 
Solinas et al., 2009) (Fig. 1.4). Loss of equilibrium between M1 and M2 cells may 
lead to pathological outcomes: M1 macrophage predominance might lead to chronic 
inflammatory diseases, whereas M2 macrophage majority could result in severe 
immune suppression (Solinas et al., 2009). However, M1 and M2 polarized 
phenotypes are extremes of a spectrum of macrophage phenotypes and 
oversimplification of the whole range of intermediate functional states. Furthermore, 
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in response to environmental signals macrophages can display a considerable 
plasticity and alter their functional state (Biswas and Mantovani, 2010; Cassetta et 
al., 2011). Additionally, besides M1 and M2 macrophages, another macrophage 
polarization phenotype has been identified, namely regulatory macrophages, which 
might play a crucial role in diminishment of immune responses and restriction of 
inflammation. Similar to M2 macrophages, these macrophages produce high levels of 
IL-10, however, unlike M2 cells, they do not participate in the extracellular matrix 
production and in many cases might express high levels of co-stimulatory molecules 
(Cassetta et al., 2011; Mosser and Edwards, 2008). 
 
     
 
Fig. 1.4 Macrophage polarization. 
In the presence of LPS/IFNγ monocytes can be polarized into M1 classically activated macrophages, 
which produce high levels of IL-12, IL-1, IL-23 and TNF-α, attract TH1 cells, have high cytotoxic activity 
against microorganisms and neoplastic cells and have good antigen presenting capacity. On the other 
hand, stimulation with IL-4, IL-13, IL-10, or corticosteroids results in M2 alternatively macrophage 
polarization, which promotes angiogenesis, tissue remodeling and repair of damaged tissues and 
might suppress the inflammatory response by down-regulating M1-mediated functions and adaptive 
immunity. LPS - lipopolysaccharide, IFNγ  - interferon gamma, GM-CSF - granulocyte/macrophage - 
colony stimulating factor, M-CSF - macrophage - colony stimulating factor, IL - interleukin, IL-1RA - IL-
1 receptor antagonist, TNF-α - tumor necrosis factor-α, CXCL - chemokine (C-X-C motif) ligand, iNOS 
- inducible nitric oxide synthase, CCL - chemokine (C-C motif) ligand, MR - mannose receptor, SR - 
scavenging receptor, GR - galactose receptor, CHI3L3 - chitinase 3-like 3, Retnla- resistin like alpha, 
TH - T helper cells. Figure is adapted from (Biswas and Mantovani, 2010; Solinas et al., 2009). 
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Interestingly, C/EBPβ regulates various macrophage functions and macrophage-
associated genes. It has been shown that C/EBPβ is essential for macrophage 
bactericidal and tumor cytotoxicity role (Tanaka et al., 1995). C/EBPβ deficiency 
affects many macrophage genes, as these genes are deregulated in C/EBPβ-/- 
macrophages upon IFNγ and/or LPS stimulation: G-CSF, Clec4e, Il1b, Tnf, Il6, Nos2, 
Il12a, Ptges, Cxcl13 gene expression could not be upregulated upon inflammatory 
stimuli, whereas Il12b and Ccl4 (Mip1b) genes have higher expression in C/EBPβ-/- 
macrophages compared to WT (Gorgoni et al., 2002; Matsumoto et al., 1999; Tanaka 
et al., 1995; Uematsu et al., 2007). Deletion of CREB-binding sites in C/EBPβ 
promoter does not affect the induction of M1 pro-inflammatory genes upon 
macrophage activation, but impairs the upregulation of M2 anti-inflammatory genes, 
suggesting that C/EBPβ upregulation in macrophages is important for acquisition of 
anti-inflammatory gene expression profile (Ruffell et al., 2009). Furthermore, recently 
it has been shown that C/EBPβ is a crucial regulator of the tumor-induced tolerance 
and immune suppression and its deficiency results in abrogation of suppressive 
myeloid cells activity and reduced expression of crucial components of myeloid 
immuno-inhibitory machinery such as arginase 1 (Arg1) and inducible nitric oxide 
synthase (Nos2) (Marigo et al., 2010). Remarkably, tumor-associated macrophages 
and monocyte-type myeloid-derived suppressor cells in general have a M2 anti-
inflammatory phenotype and instead of countracting tumor progression they rather 
promote it (Biswas and Mantovani, 2010; Solinas et al., 2009). All these data suggest 
a pivotal role of C/EBPβ in the regulation of the inflammation and immune responses. 
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 1.5 Aims of the thesis 
C/EBPβ is a transcription factor which plays a crucial role in many cellular processes 
in a variety of cell types. Several lines of evidence have indicated that in the 
hematopoietic system C/EBPβ regulates the proliferation, functionality and 
development of B cells, monocytes/macrophages, granulocytes and DCs. But how 
does a single transcription factor fulfill all these tasks? Is the functional diversity 
orchestrated only by regulation of the isoform expression or is it also dependent on 
the acquisition of signaling dependent PTM pattern? Furthermore, whether and how 
the modular structure of C/EBPβ influence cell fate decisions is not known. 
Therefore, a refined molecular understanding of the mechanism of cell differentiation 
induced by C/EBPβ was a driving force for the current study. Based on the 
observation that ectopical C/EBPβ expression in B cell progenitors may reprogram 
them into myeloid cells, we addressed the following questions: 
 
I. Which C/EBPβ protein modules are important for its reprogramming function? 
To answer this question	  B cell progenitors were substituted with the WT isoforms and 
functional mutants of C/EBPβ, including conserved region (CR) deletion mutants and 
post-translational modification (PTM) site mutants. 
 
II. Does the C/EBPβ structure and signaling dependent PTMs navigate B cell 
reprogramming towards distinct differentiation outcomes? 
To gain insight whether structural alterations in C/EBPβ may orchestrate different 
myeloid lineage differentiation outcomes, I performed detailed analyses of 
characteristics associated with granulocytic, M1/M2 monocyte/macrophage and DC 
differentiation. 
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 2. Materials and Methods 
 
 2.1. Mouse work and isolation of primary B lineage cells and fetal liver 
cells 
 2.1.1 Mouse strains and genotyping 
Primary B cell progenitors were isolated from WT C57BL/6, as well as C/EBPβ-/- and 
Irf8-/- mice, which were described before (Holtschke et al., 1996; Sterneck et al., 
1997). All mice were bred and maintained in the animal facilities of Max Delbrück 
Center and Charité, Campus Virchow-Klinikum in accordance with guidelines from 
institutional Animal Care and Use Committee. 
For the mouse genotyping, tailtips were lysed overnight in 50 µl Proteinase K buffer 
(100 mM Tris pH 8.0, 0.2% SDS, 200 mM NaCl, 5 mM EDTA, 30 µg/ml Proteinase K 
(Sigma)) at 55°C in a horizontal shaker at 550 rpm. The digested tailcuts were 
incubated at 95°C for 10 min for Proteinase K inactivation and 150 µl distilled water 
(dwater) was added. For the genotyping PCR reactions, 1 µl of the liquid phase was 
used as DNA template. The same procedure was performed for the genotyping of the 
mouse embryos. 
PCR reactions were run on a Mastercycler epgradient S (Eppendorf) and product 
sizes were reveal by agarose gel electrophoresis and ethidium bromide staining. 
 
TAE buffer 
80 mM Tris base 
1 mM EDTA 
0.11% acetic acid 
in dwater 
 
C/EBPβ-/- mice genotyping primers 
Primer name Primer sequence 
Primer WT-Fw AGCCCCTACCTGGAGCCGCTCGCG 
Primer WT-Rev GCGCAGGGCGAACGGGAAACCG 
Primer KO-Fw GCTCCAGACTGCCTGGGAAAAG 
Primer KO-Rev GGCCCGGCTAGACAGTTACACG 
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C/EBPβ-/- mice genotyping PCR  
PCR reagents Stock concentration End concentration Amount per probe 
dwater   11.65 µl 
10x PCR buffer 
(Invitrogen) 
10x 1x 2 µl 
DMSO (Roth) 100% 10% 2 µl 
dNTP (Fermentas) 10 mM 0.25 mM 0.5 µl 
MgCl2 (Invitrogen) 50 mM 2 mM 0.8 µl 
Primer WT-Fw 50 µM 1.25 µM 0.5 µl 
Primer WT-Rev 50 µM 1.25 µM 0.5 µl 
Primer KO-Fw 50 µM 1.25 µM 0.5 µl 
Primer KO-Rev 50 µM 1.25 µM 0.5 µl 
Taq-polymerase 
(Invitrogen) 
5 U/µl 1.25 units 0.25 µl 
DNA template   1 µl 
 
Irf8-/- mice genotyping primers (Holtschke et al., 1996) 
Primer name Primer sequence 
A506 CATGGCACTGGTCCAGATGTCTTCC 
A540 CTTCCAGGGGATACGGAACATGGTC 
A541 CGAAGGAGCAAAGCTGCTATTGGCC 
 
Irf8-/- mice genotyping PCR  
PCR reagents Stock concentration End concentration Amount per probe 
dwater   11.4 µl 
10x PCR buffer 10x 1x 2.5 µl 
DMSO 100% 10% 2.5 µl 
dNTP 10 mM 0.2 mM 0.5 µl 
MgCl2 50 mM 1.25 mM 0.625 µl 
Primer A506 50 µM 0.5 µM 0.25 µl 
Primer A540 50 µM 0.5 µM 0.25 µl 
Primer A541 50 µM 0.5 µM 0.25 µl 
Taq-polymerase 5 U/µl 1.25 units 0.25 µl 
DNA template   1 µl 
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PCR program C/EBPβ-/- Irf8-/- 
95°C 90’’ 4’ 
95°C 30’’ 1’ 
annealing 30’’ (55°C) 1’ (64°C) 
72°C 1’ 1’ 
cycles 40 36 
72°C 5’ 10’ 
4°C HOLD HOLD 
   
PCR products:   
WT 283 bp 259 bp 
KO 351 bp 547 bp 
 
Agarose gel 
1.5% agarose (w/v) (Bio&SELL) in TAE buffer 
 
 2.1.2 Cell preparation and cell sorting 
To obtain primary B cell progenitors, BM cells from 3-6 months old C57BL/6, 
C/EBPβ-/- or Irf8-/- mice were flushed from hind leg bones. Cell suspension was 
subjected to erylyses with ACK buffer and cell aggregates were removed through 
filtering through 30 µm pre-separation filter (Miltenyi Biotec). Cells were washed twice 
in DPBS (Invitrogen), resuspended in MACS buffer and incubated with biotinilated 
antibodies against Gr-1 (RB6-8C5), CD11b (M1/70), CD4 (GK1.5), CD8 (53-6.7), 
TER-119 (TER-119), and CD49b (DX5) (all from Biolegend) (12.5 µl antibody / 108 
cells). The code given in parentheses designates the clone from which each antibody 
is derived. The lineage positive (Lin+) cells were depleted using Dynabeads sheep 
anti-Rat IgG (Invitrogen) and magnet stand DynaMag-15 (Invitrogen). The remaining 
Lin– cells were then stained with rat anti-mouse B220-PE Cy7 (RA3-6B2), CD19–
FITC (6D5), Gr-1-PE (RB6-8C5), SA-APC Cy7 (all purchased from Biolegend), IgM–
APC (II/41, BD), and 0.4 µM DAPI (Invitrogen, Molecular probes) to exclude dead 
cells. Lin– B220+ IgM– CD19+/- pre-pro/pro/pre B cells, Lin– B220+ IgM+ immature B 
cells and Lin+ cells were sorted by fluorescence activated cell sorting (FACS) on BD 
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FACS Area II (BD Biosciences, BCRT Flow Cytometry Lab) (Fig. 2.1A). The purity of 
all sorted populations was re-checked and confirmed after the sorting (Fig. 2.1B). 
 
           
 
Fig. 2.1 FACS sorting strategy. 
A. BM single cell suspension was prepared as described. Cells were stained with lineage cocktail 
biotinilated antibodies, B220-PE Cy7, CD19-FITC, IgM-APC, Gr-1-PE, SA-APC Cy7 and DAPI. Lin– 
B220+ IgM– CD19+/- pre-pro/pro/pre B cell progenitors were sorted for the reprogramming experiments. 
Lin+ cells were cultured for 7-10 days supplemented with M-CSF for obtaining BM derived 
macrophages for negative controls for IgH rearrangement PCR. Lin– B220+ IgM+ immature B cells and 
spleen B220+ B cells were sorted for positive rearrangement PCR controls.  
B. Reanalysis of the sorted pre-pro/pro/pre B cell progenitors population confirmed their purity. 
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For the spleen B cell preparation, splenic single cell suspensions were prepared 
using 100 µm cell strainer (BD). After erythrocyte lysis and blocking with rat anti-
mouse CD16/32 antibody (Cl. 2.4G2, BD Pharmingen), cells were stained with B220-
FITC (RA3-6B2) and 0.4 µM DAPI and B220+ DAPI– mature B cells were FACS 
sorted (Fig. 2.1A). 
 
Erythrocyte lysis buffer (ACK buffer) 
Content Concentration 
NH4Cl 0.15 M 
KHCO3 1 M 
EDTA 0.1 mM 
in dwater  
Adjust pH to 7.2-7.4  
 
MACS buffer 
Content Concentration 
BSA (Sigma) 2% 
EDTA 2 mM 
in PBS  
 
2.1.3 Isolation of Fetal Liver (FL) Cells 
Mouse embryos were generated from matings between C/EBPβ+/- male and female 
mice. Detection of the vaginal plug was designated as E0.5 dpc (days post coitum). 
Pregnant females were sacrificed at E14.5 dpc. Embryos were separated from 
maternal tissue and placed in a Petri dish containing PBS. The FL was removed and 
a single cell suspension was prepared by passing tissue through a 1 ml pipette tip. 
C/EBPβ genotyping PCR was performed as described in section 2.1.1. 
 
 2.2 Retroviral vectors and retrovirus production 
 2.2.1 Retroviral vectors 
The C/EBPβ expression plasmids are based on the chicken sequence (gene bank # 
EMBLZ 21646). The C/EBPβ LAP* start site was optimized to a Kozak consensus 
sequence by exchanging a glutamine at position 2 to glutamic acid. Construction of 
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CR-deletion mutants was published earlier (Kowenz-Leutz et al., 1994). CR1 covers 
AA 1-13; CR2 to AA 18-38; CR3 AA 42-63; CR4 to AA 99-113; CR 5 to AA 184-222; 
CR6 to AA 145-179; CR7 to AA 184-222 and CR8-9 (bZIP) to AA 243-317. 
C/EBPβ point mutations were done by site directed mutagenesis with the 
QuikChange site-directed mutagenesis kit (Stratagene). Mutations were confirmed by 
sequencing. All C/EBPβ expression plasmids were originally generated in the 
pcDNA3 plasmid backbone (Invitrogen) by 5’-end HindIII /EcoRI and 3’-end XbaI 
ligation. For introduction of the C/EBPβ constructs into the B cell progenitors, 
C/EBPβ WT isoforms and C/EBPβ deletion and point mutants were subcloned into 
MIEG3 (an improved murine stem cell virus (MSCV)-based bi-cistronic retroviral 
giving a very bright EGFP fluorescence (Williams et al., 2000)) by a 5’-end EcoRI 
ligation of vector and insert and the 3’-end using a fill-in reaction of the XhoI MIEG3 
vector site and 3’-end C/EBPβ insert XbaI site by Klenow followed by a blunt end 
ligation. Correct insertions of C/EBPβ variants were verified by sequencing and 
protein expression of the constructs was controlled by western blot. The rat C/EBPα 
p42 and p30 isoforms where cloned into the MIEG3 vector as described for C/EBPβ. 
 
 2.2.2 Bacteria transformation  
Chemically competent E. coli bacteria TOP10F’ (Invitrogen) were used to generate 
DNA plasmid. Bacteria were transformed with plasmid DNA using the heat-shock 
protocol. Competent bacteria were mixed and incubated with 100 ng plasmid DNA on 
ice for 30 min. Mixture was incubated for 90 sec at 42°C and quickly chilled on ice for 
2 minute. Then 1 ml LB medium without antibiotics was added and the suspension 
was incubated for 1 hour at 37°C under gentle shaking. After that bacteria were 
pelleted (3 min, 6000 rpm), supernatant was removed and bacteria were plated onto 
LB agar plates containing 200 µg/ml ampicillin (Roth). Plates were incubated 
overnight at 37°C. Colonies were picked and grown in LB medium with antibiotics 
under agitation (200 rpm, overnight, at 37°C). Transformed bacteria were maintained 
as glycerol stocks in 15% glycerol and stored at -80°C. 
 
2.2.3 Plasmid DNA isolation 
Plasmid DNA was extracted using NucleoBond Xtra Midi (Macherey-Nagel). LB 
medium was inoculated with either one colony from the LB agar plate or with 
bacterial pre-culture. The culture was incubated at 37° C overnight at 200 rpm on a 
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shaker. After peletting, bacteria were resuspended in 8 ml resuspension buffer RES 
containing RNase. Then 8ml lysis buffer LYS was added to the suspension and 
incubated for 5 min at room temperature (RT). Subsequently, lysis was stopped with 
8 ml neutralization buffer NEU and lysate was immediately loaded on equilibrated 
NucleoBond Xtra Column Filter. After loading, the filter and the column were washed 
twice and the filter was discarded. Plasmid DNA was eluted with 5 ml elution buffer 
ELU. The eluate was precipitated with isopropanol and centrifuged (30 min, 4°C, 
15000 x g). The plasmid DNA pellet was washed with 70% ethanol, airdried and 
finally resuspended in sterile dwater. 
 
2.2.4 Retrovirus production 
Viruses were produced by transfection of Plat-E cells (Morita et al., 2000), which 
before transfection were under constant selection with 1 µg/ml Puromycin (PAA) and 
10 µg/ml Blasticidin (PAA) for removing cells which had lost the gagpol and env 
transgenes. In the morning of the day of the transfection 3 x 106 cells Plat-E cells 
were plated in 10 cm dish in medium DMEM + Glutamax (Invitrogen), 10% hiFCS 
(FCS (Invitrogen) heat inactivated for 1h, 56°C), Penicillin-Streptomycin (PAA) and 
incubated at 37°C and 5% CO2 (Binder incubator). In the late afternoon the 
transfection mix was prepared in 1.5 ml tube as follows: 
 
Component  Amount per transfection 
retroviral vector pMSCV 5 µg 
pGagpol 10 µg 
pEnv 2 µg 
H2O up to 450 µl 
2.5M CaCl2 50 µl 
 
This DNA/CaCl2 mix was added to 500 µl 2xHEBS buffer in 15 ml tube drop wise 
while vortexing under the hood and incubated 20 min at RT. Meanwhile, the medium 
from the 10 cm dishes with the plated Plat-E cells was replaced with 9 ml fresh 
complete DMEM to which 25 µM chloroquine (Sigma-Aldrich) was added. The 
DNA/CaCl2/HEBS mix was carefully added to the cells while the plate was gently 
being swirled. The transfected cells were incubated overnight at 37°C and 5% CO2. 
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On the next morning the medium was removed and 8 ml complete DMEM without 
chloroquine was added. Plates were incubated at 32°C and 5% CO2 for the virus 
production and the virus supernatants were harvested every 48h after the 
transfection for one week, filtered through 0.45 µm filter and stored at -80°C.  
 
2xHEBS buffer 
Content Concentration 
HEPES 50 mM 
NaCl 280 mM 
Na2HPO4 1.5 mM 
in ddwater  
Adjust pH to 7.05 +/-0.05  
 
The transfection reagent stock solutions 2xHEBS buffer, 2.5 M CaCl2 and 25 mM 
chloroquine were sterile filtered through 0.22 µm filter and stored at -20°C. 
To test the quality of the produced virus, aliquots of the supernatants were used to 
infect 70Z/3 murine pre B cell line (gift from C. Scheidereit). 1 x 105 70Z/3 cells were 
plated in 500 µl medium RPMI 1640 (Invitrogen), 10% hiFCS (Invitrogen), Penicillin-
Streptomycin (PAA), 50 µM 2-mercaptoethanol (Invitrogen) and infected with equal 
volume retroviral supernatant to which 8 µg/ml polybrene (Sigma) was added. Cells 
were incubated for 3 - 5h at 37°C and 5% CO2, washed and analyzed 48h post-
infection by FACS for the percentage of GFP+ PI– / 7-AAD– (PI (Sigma) end 
concentration 1 µg/ml, 7-AAD (BD Pharmingen) end concentration 0.5 µg/ml) on 
Accuri C6 Cytometer, CFlow plus Analysis software (Accuri). Only supernatants that 
led to infection of more that 10% of 70Z/3 cells were used for the infection of the 
primary B cells. 
 
 2.3 Cell infection, cultivation and CFU assay 
 2.3.1 B cell progenitors infection and cell cultivation 
For the virus infection, purified B cell progenitors were resuspended at 1.5 - 2 x 105 
cells/ml in medium IMDM + Glutamax with 20% hiFCS, Penicillin-Streptomycin 
(PAA), 1 mM Sodium Pyruvate (PAA), 50 µM 2-mercaptoethanol (Invitrogen) as well 
as 10 ng/ml IL-7, SCF, Flt-3L (all purchased from Peprotech). Cells were deposited 
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into 24-well plates and infected twice with equal volume retroviral supernatant to 
which 8 µg/ml polybrene (Sigma) was added. Plates were centrifuges for 60-90 min 
at 2100 rpm at 32°C in an Eppendorf centrifuge 5810R followed by 3-5h incubation at 
32°C. Infected cells were transferred into polystyrene 0.4 µm pore membrane HTS 
Transwell-24 well (Corning) supplemented with 10 ng/ml IL-7, SCF, Flt-3L, IL-3 and 
M-CSF (Peprotech) (Xie et al., 2004) and co-cultured with S17 (gift from T. Graf) 
stromal cells (10 µg/ml mitomycin (Sigma) treated). Fresh medium was added every 
other day. 
 
 2.3.2 BM derived macrophages 
For obtaining BM derived macrophages, Lin+ cells were sorted during the sorting of B 
cell progenitors (Fig. 2.1A). Cells were cultured in IMDM medium, 20% hiFCS 
supplemented with 10 ng/ml recombinant murine M-CSF (Peprotech) for 6-9 days, 
medium was changes every 2-3 days. 
 
 2.3.3 CFU assays 
2 x 104 FL cells/well/1ml were plated in triplicates in methylcellulose MethoCult GF 
M3434 (Stem Cell Technologies), containing 50 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml 
IL-6, 3 U/mL EPO, or MethoCult M3234 (Stem Cell Technologies), containing a 
distinct cytokine: 10 ng/ml M-CSF, or 50 ng/ml G-CSF, or 20 ng/ml GM-CSF. Plates 
were incubated for 1 week at 37°C and total colony and differentiation counts for 
granulocyte-erythrocyte-macrophage-megakaryocyte (CFU-GEMM), granulocyte-
macrophage colonies (CFU-GM), macrophage colonies (CFU-M), granulocyte 
colonies (CFU-G) and burst forming unit erythroid colony formation (BFU-E) were 
performed.  
 
 2.4 FACS analyses 
 2.4.1 FACS analyses for characterization of lymphoid to myeloid lineage 
reprogramming 
Before the FACS analyses, 6 or 9 days in vitro reprogrammed cells were detached 
from the tissue culture plates using accutase (PAA), washed and resuspended in 
FACS buffer. After Fc blocking with rat anti-mouse CD16/32 antibody (Clone 2.4G2, 
BD Pharmingen) cells were stained with rat anti-mouse CD11b-PerCP Cy5.5 
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(M1/70), CD11b-APC Cy7 (M1/70), CD11b-PE (M1/70), CD19-APC (6D5), CD19-
biotin (6D5), CD19-PE Cy7 (6D5), CD45-PE Cy7 (30-F11), Gr-1-APC Cy7 (RB6-
8C5), Ly-6C-APC Cy7 (HK1.4), Ly-6G-APC (1A8), CD115-PE (M-CSFR, Cl. AFS98), 
CD115-APC (M-CSFR, Cl. AFS98), F4/80-Pacific blue (CI:A3-1), MHC-II (I-A/I-E-PE, 
Cl. M5/114.15.2), SA-PE (all from Biolegend), CD86-PE (B7-2), hamster anti-mouse 
CD11c-APC (HL3) and CD11c-V450 (HL3) (BD Pharmingen) and 7-AAD (BD 
Pharmingen) or DAPI (Invitrogen, Molecular probes) were added to discriminate cell 
viability. Samples were run on FACS Canto II machine (BD Biosciences, BD Diva 
Software) and analyzed with FlowJo software. 
 
FACS buffer 
Content Concentration 
hiFCS 2% 
EDTA 2 mM 
NaN3 0.1% 
in PBS  
 
2.4.2 Intracellular protein staining 
For the intracellular C/EBPβ protein staining, 6 days after the infection cells were 
incubated with Mouse BD Fc Block (Clone 2.4G2, BD Pharmingen) followed by 
CD11b-APC Cy7 (M1/70), CD19-APC (6D5), CD45-PE Cy7 (30-F11) (Biolegend) 
surface marker staining. Cells were washed and then fixed and permeabilized with 
BD Cytofix/Cytoperm Buffer for 20 min at 4°C. After blocking with 8% donkey serum 
(Jackson Immuno Research) for 30min at 4°C, cells were stained with rabbit anti 
C/EBPβ antibody (Santa Cruz, C-19) at 4°C for 1h at dark and then with anti - rabbit 
PE conjugated antibody (Jackson Immuno Research) at 4°C for 30 min at dark. Cells 
were washed and resuspended in FACS staining buffer prior to FACS analyses. All 
antibody dilutions, serum blocking and washing steps were performed in 1x Perm 
Wash Buffer (BD). The relative C/EBPβ expression in the virus infected cells was 
calculated as a delta (Mean) of C/EBPβ fluorescence of the probes incubated with or 
without the primary C/EBPβ antibody and after subtraction of the endogenous 
expression for each sample. 
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2.4.3 AnnexinV staining 
For AnnexinV staining, 6 days after the infection, cells were incubated with Mouse 
BD Fc Block (BD Pharmingen) and stained for surface marker expression. Cells were 
washed twice with PBS, up to 105 cells were resuspended in 100 µl 1x AnnexinV 
binding buffer (Biolegend) and stained with AnnexinV-APC (BD Pharmingen). After 
15 min incubation at RT at dark, 300 µl 1x AnnexinV binding buffer and DAPI at final 
concentration 0.4 µM were added to the stained cells prior to FACS analyses. Cells 
were defined as follows: live cells (AnnexinV– DAPI–), early apoptotic (AnnexinV+ 
DAPI–) and late apoptotic and/or necrotic cells (AnnexinV+ DAPI+). 
 
2.4.4 Phagocytosis assay 
For the phagocytosis assay, 10 days after the infection, cells were washed twice with 
PBS and equilibrated for 1h at 37°C in Opti-MEM (Invitrogen) without FCS in 24 well 
tissue culture plates supplemented with 10 ng/ml M-CSF. Cells were cooled to 4°C 
and pre-incubated with 1 µl 1.0 µm Blue (365/415) fluorescent carboxylate-modified 
microspheres (Molecular Probes). After washing cells were incubated for 1h at 37°C, 
detached with accutase (PAA) and incubated with Mouse BD Fc Block (BD 
Pharmingen) for 20 min at 4°C. Cells were then stained with CD45-PE Cy7 (30-F11), 
CD11b-PerCP Cy5.5 (M1/70), CD19-APC (6D5) (Biolegend), fixed with 1% 
paraformaldehyde in PBS for 20 min at 4°C, washed with FACS buffer and FACS 
analyzed. 
 
 2.5 Cytospins and Immunoglobulin Gene Rearrangements 
 2.5.1 Cytospins and May-Grunwald / Giemsa staining 
Cell morphology was assessed by spinning 10 days reprogrammed FACS sorted 
GFP+ CD11b+ and GFP+ CD19+ cells in a cytospin-centrifuge (Cytospin4, Thermo 
biosciences) at medium acceleration, 800 rpm for 5 min on a glass slide, followed by 
an air-drying step. Cells were fixed in Methanol for 5 min and subsequently subjected 
to May-Grunwald staining (Sigma-Aldrich) for 5 min. After a brief washing step in 
dwater, a second staining with Giemsa stain (Sigma-Aldrich) for 40 min was 
performed. Slides were washed thoroughly with dwater, dried, mounted with Entellan 
(Merck) and covered with a cover glass. Cells were photographed with an Axio 
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Scope.A1 microscope/camera system (Zeiss), AxioVision Rel. 4.7 software, 63x 
objective with immersion oil 518 N (Zeiss). 
 
 2.5.2 Immunoglobulin Gene Rearrangement PCR 
GFP+ CD11b+ and GFP+ CD19+ cells from the S17 co-cultures were sorted by FACS 
6 or 9 days after the retroviral infection. Genomic DNA was extracted using 
SDS/proteinase K method as described before for the tailtips. For DHJH 
rearrangements in IgH gene locus the primer pair DFS and JH4A was used together 
with DQ52 for the germline locus configuration (Ehlich et al., 1994). BM derived 
macrophages in vitro cultured in M-CSF supplemented medium (negative control) 
and splenic B cells (positive control) were used as controls. 
 
IgH Gene Rearrangement PCR primers (Ehlich et al., 1994) 
Primer name Primer sequence 
5’ DFS (Fw1) ACGTCGACTTTTGT(GC)AAGGGATCTACTACTGT 
5’ DQ52 (Fw2) ACGTCGACGCGGACGACCACAGTGCAACTG 
3’ JH4A (Rev) GGGTCTAGACTCTCAGCCGGCTCCCTCAGGG 
 
IgH Gene Rearrangement PCR 
PCR reagents Stock concentration End concentration Amount per probe 
Water   14.4 µl 
10x PCR buffer 10x 1x 2 µl 
dNTP 10 mM 0.2 mM 0.4 µl 
MgCl2 50 mM 1.5 mM 0.6 µl 
Primer Fw1 50 µM 1 µM 0.4 µl 
Primer Fw2 50 µM 1 µM 0.4 µl 
Primer Rev 50 µM 1 µM 0.4 µl 
Taq-polymerase 5 U/µl 2 units 0.4 µl 
DNA template   1 µl 
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PCR program  
95°C 5’ 
95°C 45’’ 
63°C 45’’ 
72°C 90’’ 
cycles 35 
72°C 8’ 
4°C HOLD 
  
PCR products:  
Germline configuration 2150 bp 
DHJH1 1460 bp 
DHJH2 1150 bp 
DHJH3 730 bp 
DHJH4 200 bp 
 
Agarose gel 
1.25% agarose (w/v) in TAE buffer 
 
 2.6 Protein and RNA analyses 
 2.6.1 Cell lysis and western blotting 
For the protein analyses, cells were lysed in RIPA buffer “upstate” supplemented with 
protease inhibitors and incubated for 1h on ice and every 10 min subjected to 
sonication (Bandelin). Cells were then centrifuged at 4°C for 30 min at 12.000 rpm in 
a microcentrifuge 5417R (Eppendorf) and the supernatant aspirated and placed in a 
fresh tube on ice, while pellet was discarded. Total protein concentration of individual 
samples was estimated using Bradford reagent (Sigma) and obtained from 
photometric analysis at 595 nm wavelength on NanoDropTM 1000 Spectrophotometer 
(Thermo Scientific) and calculated based on a standard Bovine serum albumin (BSA) 
curve. After that extracts were boiled for 5 min in 1x SDS-loading buffer, incubated 
for 5 min on ice and stored at -80°C or immediately used for electrophoresis.  
Proteins were separated on 10% SDS-polyacrylamide gels (run at 120 V until the 
bromophenol blue dye reached the end of the gel) in mini vertical gel electrophoresis 
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unit (Amersham Biosciences). In parallel to the probes, BenchMark Pre-Stained 
Protein Ladder (Invitrogen) was loaded and used for protein molecular weight 
estimation. Proteins were then electrotransferred onto nitrocellulose membranes 
(Millipore) in wet-blotting tank electrophoresis unit (Amersham Biosciences) for 1h at 
400 mA in Transfer buffer at constant stirring. Unspecific binding of immunoglobulin 
was reduced by incubating membranes in 1x Roti-Block (Roth) for 1h 30min at RT. 
Subsequently membranes were probed with polyclonal rabbit anti-	   C/EBPβ (Santa 
Cruz, C-19 or Leutz lab) or polyclonal rabbit anti-	  C/EBPα  (Santa Cruz, 14AA) and 
monoclonal mouse anti- α-tubulin antibody (Santa Cruz, TU-02) diluted in 1x Roti-
Block overnight at 4°C at constant shaking. After thoroughly washing with 1xTBST, 
blots were incubated for 2h at RT with IRDye™ 680 Goat anti-rabbit IgG and 
IRDye™ 800CW Goat anti-mouse IgG (LI-COR) diluted in 1x Roti-Block and scanned 
with Odyssey Infrared Imaging System (LI-COR).  
 
Ripa buffer “upstate” 
Content Concentration 
Tris-HCL, pH 7.4 50 mM 
NaCl 150 mM 
NP-40 1% 
Sodium Deoxycholat 0.25% 
SDS 0.1% 
EDTA 1 mM 
in dd water  
  
Proteinase inhibitors  
Na3VO4 1 mM 
phenanthroline 1 mM 
DTT 1 mM 
PMSF 1 mM 
pepstatin (AppliChem) 10 µg/ml 
aprotenin A (AppliChem) 10 µg/ml 
leupeptin (AppliChem) 10 µg/ml 
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SDS loading buffer (6x) 
Content Concentration 
DTT 600 mM  
Tris pH6.8 350 mM 
SDS 10% 
glycerol 10% 
bromphenol blue 0,1 mg/ml  
in dd water  
 
Polyacrylamid gels 
Content 10% separating gel (ml) stacking gel (ml) 
Acrylamid (30%)/Bisacrylamid (0.8%) 
(Roth) 
5 ml 0.65 ml 
4x Tris-HCl/ 0.4% SDS 3.75 ml (pH 8.8) 1.25 ml (pH 6.8) 
H2O 6.25 ml 3.05 ml 
10% APS (Bio-Rad) 0.060 ml 0.036 ml 
TEMED (Roth) 0.012 ml 0.006 ml 
 
Running buffer 
Content Concentration 
Tris base 25 mM 
glycine 200 mM 
SDS 0.1% 
in ddwater  
 
Transfer buffer 
Content Concentration 
Tris base 25 mM 
glycine 200 mM 
SDS 0.1% 
methanol 20% 
in ddwater  
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TBST buffer 
Content Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 150 mM 
Tween-20 0.1% 
in ddwater  
 
 2.6.2 RNA extraction and mRNA expression analyses by Nanostring 
technology 
Total RNA was extracted 6 days after infection of C/EBPβ-/- B cell progenitors with 
C/EBPβ constructs and from BM derived macrophages (after 6 days in vitro culturing) 
using RNeasy Micro Kit (QIAGEN) according to the manufacture’s recommendations. 
In brief, cells were lysed in RLT buffer, containing 150 mM 2-mercaptoethanol. After 
adding an equal volume of 70% ethanol, the sample was loaded on RNeasy MinElute 
spin column and briefly centrifuged. The flow through was discarded and the column 
was washed with Buffer RW1. DNA was digested with RNase free DNase set 
(QIAGEN) for 15 min at RT. After washing of the column with buffer RW1, buffer RPE 
and 80% ethanol, total RNA was eluted in RNase-free water. RNA concentration and 
purity was measured on NanoDropTM 1000 Spectrophotometer (Thermo Scientific) at 
260 nm (A260) and, additionally, RNA integrity was measured on Agilent 2100 
Bioanalyzer (Agilent Technologies). Only samples with A260/A280 = 1.9 - 2.1, RNA 
integrity number (RIN) >7 and RNA concentration >15 ng/µl were used for 
subsequent applications. 
Nanostring technology is described elsewhere (Fortina and Surrey, 2008). Briefly, the 
method involves mixing total RNA with pairs of capture and reporter probes custom-
synthesized for each mRNA of interest. After hybridization, excess reporters and 
capture probes were removed and probe-bound mRNAs was immobilized and color-
coded bar tags on the reporter probes were scanned and decoded. Synthesis of the 
oligonucleotide probes and Nanostring RNA expression analyses were performed by 
nCounter, Heidelberg. Table 2.1 represents the list of the targeted sequences in the 
analyzed genes. To determine mRNA expression levels, background was subtracted, 
all negative values were set to 1 for each gene of interest and the positive values 
were normalized to three house-keeping genes (Gapdh, Tbp and Ppia). 
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 2.7 Statistical analyses 
In all experiments, data are presented as mean ± SEM (standard error of the mean). 
Statistical analyses were done on Prism 4.0a (GraphPad Software) using unpaired 
two-tailed t test for the calculation of the P-value. The statistical significance of the P-
value was defines as: P>0.05 - not significant, P=0.01-0.05 - significant (*), P=0.001-
0.01 - very significant (**), P<0.001 - extremely significant (***). 
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Table 2.1 
Targeted sequences in the selected genes whose expression was analyzed in the reprogrammed cells 
and BM derived macrophages by NanoString technology; HKG - house keeping genes. 
 
 
Gene 
symbol Target ID 
Targeted 
Region Target Sequence 5’-3’ 
Tnf (Tnfa) NM_013693.1 
1135-
1235 
TTCCTGAGTTCTGCAAAGGGAGAGTGGTCA
GGTTGCCTCTGTCTCAGAATGAGGCTGGAT
AAGATCTCAGGCCTTCCTACCTTCAGACCTT
TCCAGACTC 
Il1b NM_008361.3 
1120-
1220 
GTTGATTCAAGGGGACATTAGGCAGCACTCT
CTAGAACAGAACCTAGCTGTCAACGTGTGG
GGGATGAATTGGTCATAGCCCGCACTGAGG
TCTTTCATT 
Il6 NM_031168.1 40-140 
CTCTCTGCAAGAGACTTCCATCCAGTTGCCT
TCTTGGGACTGATGCTGGTGACAACCACGG
CCTTCCCTACTTCACAAGTCCGGAGAGGAG
ACTTCACAG 
Il12b NM_008352.1 
1045-
1145 
TCGTAGAGAAGACATCTACCGAAGTCCAATG
CAAAGGCGGGAATGTCTGCGTGCAAGCTCA
GGATCGCTATTACAATTCCTCGTGCAGCAAG
TGGGCATG 
Il12rb1 NM_008353.2 
2765-
2865 
AAAGCAGGGCCTAGACATTCACGGGAAGTT
TATACGTCTGGACTCAGTTTCCCTATTAGAG
TATTGGGCACTTAATAAATGGGCCTTCCCAG
AGACTGAG 
Ccr7 NM_007719.2 755-855 
CCCAGATGGTTTTTGGGTTCCTAGTGCCTAT
GCTGGCTATGAGTTTCTGCTACCTCATTATC
ATCCGTACCTTGCTCCAGGCACGCAACTTTG
AGCGGAA 
Cxcl9 NM_008599.2 40-140 
TAGAACTCAGCTCTGCCATGAAGTCCGCTGT
TCTTTTCCTCTTGGGCATCATCTTCCTGGAG
CAGTGTGGAGTTCGAGGAACCCTAGTGATA
AGGAATGC 
Cxcl10 NM_021274.1 115-215 
AGGACGGTCCGCTGCAACTGCATCCATATC
GATGACGGGCCAGTGAGAATGAGGGCCATA
GGGAAGCTTGAAATCATCCCTGCGAGCCTA
TCCTGCCCAC 
Ccl2 
(Mcp-1) NM_011333.3 415-515 
TCTTCAGCACCTTTGAATGTGAAGTTGACCC
GTAAATCTGAAGCTAATGCATCCACTACCTT
TTCCACAACCACCTCAAGCACTTCTGTAGGA
GTGACCA 
Mmp8 NM_008611.4 
2285-
2385 
GGAGGGCTGTATCTATAAATCTATTTGCCAA
TAAGTTCCCAGGCAGAGGCAGGTAGGAGGG
GTTTAAAAAAAAGGACCATTCCTTTCTCAAG
CACATTCC 
Mmp9 NM_013599.2 
1570-
1670 
CCTCTACAGAGTCTTTGAGTCCGGCAGACAA
TCCTTGCAATGTGGATGTTTTTGATGCTATT
GCTGAGATCCAGGGCGCTCTGCATTTCTTCA
AGGACGG 
M
1 
ge
ne
s 
Nos2 NM_010927.3 
3715-
3815 
CCCCCCTCCTCCACCCTACCAAGTAGTATTG
TACTATTGTGGACTACTAAATCTCTCTCCTCT
CCTCCCTCCCCTCTCTCCCTTTCCTCCCTTC
TTCTCC 	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Il10 NM_010548.1 985-1085 
GGGCCCTTTGCTATGGTGTCCTTTCAATTGC
TCTCATCCCTGAGTTCAGAGCTCCTAAGAGA
GTTGTGAAGAAACTCATGGGTCTTGGGAAG
AGAAACCA 
Arg1 NM_007482.3 626-726 
GTACATTGGCTTGCGAGACGTAGACCCTGG
GGAACACTATATAATAAAAACTCTGGGAATT
AAGTATTTCTCCATGACTGAAGTAGACAAGC
TGGGGATT 
Il13ra1 NM_133990.4 845-945 
CTCAAACCGACCGACATAATATTTTAGAGGT
TGAAGAGGACAAATGCCAGAATTCCGAATCT
GATAGAAACATGGAGGGTACAAGTTGTTTCC
AACTCCC 
Msr1 NM_031195.2 555-655 
GATTTCGTCAGTCCAGGAACATGGGAATTCA
CTGGATGCAATCTCCAAGTCCTTGCAGAGTC
TGAATATGACACTGCTTGATGTTCAACTCCA
TACAGAA 
Tgfb1 NM_011577.1 
1470-
1570 
GGAGTTGTACGGCAGTGGCTGAACCAAGGA
GACGGAATACAGGGCTTTCGATTCAGCGCT
CACTGCTCTTGTGACAGCAAAGATAACAAAC
TCCACGTGG 
Il4ra NM_001008700.3 670-770 
TGGAATAACCTGTACCCATCGAACAACTTAC
TGTACAAAGACCTCATCTCCATGGTCAACAT
CTCCAGAGAGGACAACCCTGCAGAATTCATA
GTCTATA 
Alox15 NM_009660.3 815-915 
CAGCTGGATGAGGAGCTCAAGAAAGGCACT
CTGTTTGAAGCGGATTTCTTCCTTCTGGATG
GGATCAAGGCCAATGTCATCCTTTGTAGTCA
GCAGTACC 
Mmp12 NM_008605.3 
2725-
2825 
AGGAAAGGGCTCCTTTGCTCCATGTGTCAG
ATGTGAGTATTAACCTTCGACATCAACTTCAT
GAGATCCAGAGTCATGTAAGAGACATGTGA
GCACTACT 
Pparg NM_011146.1 
1060-
1160 
ACCAAGTGACTCTGCTCAAGTATGGTGTCCA
TGAGATCATCTACACGATGCTGGCCTCCCTG
ATGAATAAAGATGGAGTCCTCATCTCAGAGG
GCCAAGG 
Ccl22 NM_009137.2 
1096-
1196 
CCAAGAATCAACTTCCACCCCTCTTCAACCA
CATGCTAGGGTCTTTTACTTTCTCTGCCCCA
CACCTTTGACTCCTTGCCTGTGTAGCTGATA
GTCGAAG 
Kdm6b 
(Jmjd3) NM_001017426.1 
4915-
5015 
GGTGAAGAACGTCAAGTCCATTGTGCCCAT
GATTCATGTGTCCTGGAACGTCGCTCGAAC
GGTCAAGATCAGCGATCCTGACTTGTTCAAG
ATGATCAAG 
Chi3l3 
(Ym1) NM_009892.1 
1196-
1296 
AGAGGAGCTTTACACAATGATTTGTCCTTGA
AACTCTCAGAATAAGATCAAGTTCAACGGTT
TTTCCACAGCGCATTCTGCATCATGCTTCCA
TGGAGAA 
M
2 
ge
ne
s 
Fcgr3 NM_010188.5 
1175-
1275 
TCTGACCTCCACCATCCACCATGGCAGGTG
CACACAATAAATTAAAATGTCATGTATATTTT
TAAACAAGAGACAGGGGCAGGCTAAGGGTT
GATGGCAT 	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Mafb NM_010658.2 
2658-
2758 
TTGAGCCAAACAGCCATTCTTAGAATGTACT
AGAAACCCACACATTGGCAACTAACGCTGCA
ACTCTCAAGTGTGTCCTTTAGACCAGTGCAT
TATATGT 
Maf (c-
maf) NM_001025577.2 43-143 
CTGGCAATGAACAATTCCGACCTGCCCACC
AGTCCCCTGGCCATGGAATATGTTAATGACT
TCGATCTGATGAAGTTTGAAGTGAAAAAGGA
ACCGGTGG 
Myd88 NM_010851.2 
1595-
1695 
GCTGCAGGCTCAGCTGTTTTCTCCCCAGCA
GCGAGGTTTGCATCTTCTTATTCCTTTCACG
TTCTCTACCATAGAGGCAATGTCATGGTCCC
TCTCAGGG 
Kdm4a 
(Jmjd2a) NM_172382.2 
1675-
1775 
CTGTAGGAGGACGCCTCGTCTTCTCGGGTT
CCAAAAAGAAATCATCTTCCAGCCTGGGCTC
CACTTCATCTCAGGATTCAGTTTCTTCAGATT
CTGAAAC 
O
th
er
s 
Ddr2 NM_022563.2 595-695 
TGCTTGATGGAAACAGTAACCCTTATGATGT
ATTCCTGAAGGACTTGGAGCCACCCATCGT
CGCCAGATTTGTTCGCCTTATCCCAGTCACT
GACCACTC 
Gapdh 
NM_008084.1 755-855 
ATGTGTCCGTCGTGGATCTGACGTGCCGCC
TGGAGAAACCTGCCAAGTATGATGACATCAA
GAAGGTGGTGAAGCAGGCATCTGAGGGCCC
ACTGAAGGG 
Tbp 
NM_013684.3 70-170 
GTGGCGGGTATCTGCTGGCGGTTTGGCTAG
GTTTCTGCGGTCGCGTCATTTTCTCCGCAGT
GCCCAGCATCACTATTTCATGGTGTGTGAAG
ATAACCCA 
H
K
G
 
Ppia 
NM_008907.1 390-490 
CCAAGACTGAATGGCTGGATGGCAAGCATG
TGGTCTTTGGGAAGGTGAAAGAAGGCATGA
ACATTGTGGAAGCCATGGAGCGTTTTGGGT
CCAGGAATGG 
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 3. Results 
 
 3.1 B cell to myeloid reprogramming potential resides in the TAD of 
C/EBPβ 
Seven short peptide CRs in the TAD (CR1-4) and the RD (CR5-7), which are 
interrupted by LCRs, have been identified in the N-terminus of the transcription factor 
C/EBPβ (Kowenz-Leutz et al., 1994). An extensive set of approximately thirty 
different C/EBPβ constructs, including the three WT isoforms, as well as C/EBPβ CR 
deletion and PTM site mutants (Fig. 3.1, left panel, 3.3, left panel and data not 
shown) was used to identify the structures in C/EBPβ required for lympho-myeloid 
trans-differentiation.  
A retroviral approach was used to express the set of WT isoforms of C/EBPβ and its 
mutants in primary B cell progenitors. An early B cell progenitor compartment from 
murine BM, containing pre-pro, pro and pre B cells, was isolated by FACS sorting as 
Lin– B220+ IgM– CD19+/- cell population (Fig. 2.1). Infected cells were co-cultured with 
S17 BM stromal cells under conditions that support both B cell and myeloid cell 
development (Xie et al., 2004) and analyzed by FACS at 6 and 9 days post-infection. 
The percentage of infected GFP+ cells was in most of the experiments between 20 
and 50% (data not shown) and all analyses were performed only on these infected 
cells. No significant change in the B cell phenotype was observed in cells infected 
with the LIP C/EBPβ isoform, similarly to cells infected with MSCV vector or 
uninfected controls (Fig. 3.1 and 3.2). In contrast, both the LAP and LAP* C/EBPβ 
isoforms upregulated the myeloid surface marker CD11b and downregulated the B 
cell marker CD19, giving rise to double positive CD19+ CD11b+, as well as CD19– 
CD11b+ cells on day 6 post-infection and almost exclusively CD19– CD11b+ cells 9 
days after infection, indicating completion of the myeloid trans-differentiation process 
and loss of the B cell phenotype. 
The importance of each CR as an essential unit in C/EBPβ reprogramming was 
examined by deletion analysis (Fig. 3.1). Comparison between the FACS analyses 
for CD11b myeloid marker upregulation and CD19 lymphoid marker downregulation 
by the different C/EBPβ deletion constructs revealed that the RD (CR5,6,7) or an 
exchange of the leucine zipper dimerization domain, as in the mutant CREB LZ, are 
dispensable for reprogramming and these mutants had reprogramming properties 
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undistinguishable from WT C/EBPβ LAP*. Removal of CR5 or CR7 or the entire RD 
(ΔCR5,6,7) was previously found to enhance the transactivation function of C/EBPβ 
in various cell types (Kowenz-Leutz et al., 1994; Williams et al., 1995). Moreover, 
ΔCR6, which represents a dominant negative mutant in fibroblasts (Kowenz-Leutz et 
al., 1994), displayed trans-differentiation activity similar to the extended WT LAP* 
C/EBPβ isoform. This suggests that regulation of C/EBPβ activity in B cells differs 
from regulation in fibroblasts and in erythroid cells (Kowenz-Leutz et al., 1994). 
Furthermore, the mutant with replaced leucine zipper dimerization domain (CREB 
LZ) was indistinguishable from WT LAP*, suggesting that the bZip structure plays a 
minor role during trans-differentiation. 
 
   
 
Fig. 3.1 Structural requirements for B cell to myeloid reprogramming potential of C/EBPβ.  
Schematic representation of the different C/EBPβ constructs (left) indicating the conserved regions 
(CRs) in the transactivation domain (TAD; CR1,2,3,4; green), regulatory domain (RD; CR5,6,7; red), 
bZip domain (yellow), and the low complexity regions (LCRs, grey). Expression of lineage specific 
markers: B cell CD19 (red), myeloid CD11b (blue), or double positive (magenta) at 6 (middle panel) or 
9 days (right panel) after the infection. Bar graph shows percentage of GFP+ gated (virus infected) cell 
population; B cells - control uninfected GFP– B cell progenitors. Results represent mean ± SEM from 
at least two experiments. 
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Fig. 3.2 Reprogramming of B cell progenitors by C/EBPβ WT isoforms and deletion mutants. 
Representative FACS profiles of the infected B cell progenitors at 6 and 9 days after the infection. 
FACS plots represent GFP+ gated cell population, B cells - control uninfected GFP– B cell progenitors. 
Similar outcomes were obtained from at least two repeat experiments. 
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The data showed that C/EBPβ reprogramming function resides in its N-terminal TAD. 
While distinct deletions in the TAD kept, though decreased, reprogramming 
functions, certain others completely abrogated reprogramming (Fig. 3.1). For 
example, the deletion mutant	   ΔCR3 showed comparable to C/EBPβ LAP* 
reprogramming capacity. Other mutants, like Δ CR1,2 and Δ CR4, demonstrated 
strongly compromised reprogramming function and compared to LAP* induced a 
significantly lower percentage of CD11b+ cells after both 6 and 9 days 
reprogramming (ΔCR1,2 (N=5): day 6 - P<0.0001, day 9 - P<0.0001; ΔCR4 (N=4): 
day 6 - P<0.0001, day 9 - P=0.0002). On the other hand, the percentage of CD11b+ 
cells induced by LAP and CR2,3,4 (both proteins lack CR1) was significantly lower 
than LAP* (N=14) only after 6 days reprogramming but not after 9 days 
reprogramming (LAP (N=6): day 6 - P=0.020, day 9 - P=0.948; CR2,3,4 (N=6): day 6 
- P=0.004, day 9 - P=0.708). Interestingly, although C/EBPβ mutants with deletion in 
either CR3 or CR4 reprogrammed the primary B cells into myeloid cells (though 
ΔCR4 did it partially), the double deletion mutant ΔCR3,4 induced neither CD11b 
expression nor CD19 downregulation. This reveals the essential and redundant role 
of TAD CR3 and CR4 during B cell reprogramming and indicates that an important 
protein module in the TAD must be missing when CR3 and CR4 are simultaneously 
deleted. Surprisingly, the rescue experiments showed that CR2,3,4 but not CR3,4 (in 
combination with bZip) is the region that is sufficient and necessary to reprogram B 
cell progenitors into myeloid cells. In conclusion, our experiments with protein 
deletion mutants revealed that the capacity of C/EBPβ to reprogram B cells to 
myeloid cells resides in the TAD CR2,3,4 and, interestingly, both functions, 
downregulation of CD19 and upregulation of CD11b, depend on these TAD modules 
of C/EBPβ. 
Comprehensive mass spectrometry data have shown that C/EBPβ is extensively 
post-translationally modified through threonine (T) and serine (S) phosphorylation, 
lysine (K) acetylation, mono- and dimethylation of arginine (R) residues and mono-, 
di- and trimethylation of K residues (Leutz et al., 2011) (Fig. 1.2). Therefore, a set of 
C/EBPβ mutants with substitutions in amino acid (AA) residues subjected to PTMs, 
where mutations were introduced in the TAD, RD or bZip region of WT C/EBPβ 
LAP*, was additionally tested. R residues in LAP* were mutated to alanine (A) (to 
eliminate potential methylation site while maintaining secondary structure), to leucine 
(L) (to mimic methylation) or to glutamine (Q) (to mimic citrulination). Additionally, our 
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mutant-set comprised K substitution mutants abrogating G9a K methylation sites 
(e.g. K39/K168A ((Pless et al., 2008) and our unpublished data)), and constructs with 
mutated SUMO attachment site or the binding site of the SUMO-conjugating enzyme 
UBC9 (Kowenz-Leutz and Leutz, unpublished data), both disrupting SUMOylation 
(e.g. K156A, K156A/E158A, K156R). CD11b induction was detected for all tested AA 
substitution mutants suggesting that these mutated residues, which are potential 
target sites of PTMs, are not sufficient to abrogate C/EBPβ reprogramming function 
(Fig. 3.3). This is not surprising, if one considers that deletion of CR1, 2, 5, 6, and 7, 
and even CR3 and 4 (when they were individually deleted) did not abolish 
reprogramming. 
 
 
 
Fig. 3.3 Reprogramming of B cell progenitors by C/EBPβ PTM site mutants. 
Schematic representation of the C/EBPβ AA substitution constructs (left panel) and percentage of 
cells infected with C/EBPβ LAP* and AA substitution mutants expressing the B cell marker CD19, the 
myeloid cell marker CD11b, or both markers simultaneously (CD19+ CD11+ cells) 6 days (middle 
panel) or 9 days (right panel) after the infection. Graphs represent mean ± SEM from GFP+ (virus 
infected) gated cell population.  
 
The expression and proper size of the C/EBPβ constructs was validated by western 
blot analysis of the packaging cell line (Fig. 3.4A). Additionally to IRES-GFP 
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fluorescence read-out, intracellular protein staining confirmed the expression of WT 
or mutant C/EBPβ proteins in the primary retrovirally infected B cells (Fig. 3.4B). All 
C/EBPβ reprogrammed CD11b+ cells had comparable C/EBPβ ectopic expression 
levels, which were much higher than endogenous C/EBPβ expression in B cells (as 
determined in MSCV-infected cells), and even higher than the endogenous levels in 
WT BM derived macrophages. 
 
	  
 
Fig. 3.4 C/EBPβ is overexpressed and IgH gene loci rearranged in the C/EBPβ reprogrammed 
myeloid cells. 
A. Protein expression of the C/EBPβ WT and deletion constructs in the virus-packaging cell line Plat-
E. The size of the proteins is according to the size of the deletions. B. Intracellular C/EBPβ protein 
staining in the reprogrammed cells. The relative C/EBPβ expression in the virus-infected cells was 
calculated as described in Materials and Methods. The endogenous C/EBPβ expression level in WT 
BM derived macrophages (MPh) was also assessed. The relative C/EBPβ expression values varied 
between the different experiments, however the tendencies were highly reproducible. C. PCR for D-J 
rearrangements in IgH locus. CD11b+ reprogrammed myeloid cells and CD19+ MSCV-, LIP- and 
ΔCR3,4-infected B cells were sorted 9 days after the infection and PCR for D-J rearrangements in the 
IgH locus was performed. Controls: WT BM derived macrophages (MPh) and splenic B cells. Data 
shown are representative of multiple experiments. 
 
During B cell development rearrangements in the immunoglobulin (Ig) genes occur 
and this unique process allows B cell origin of the reprogrammed cells to be proven 
by Ig rearrangement PCR for D-J recombinations in the IgH locus (Ehlich et al., 1994; 
Xie et al., 2004). In control BM derived macrophages the IgH locus remained in 
germline configuration, whereas reprogrammed CD11b+ cells showed the same 
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rearrangements as the splenic B cell control and the MSCV infected CD19+ control 
cells, ruling out contamination with myeloid cell precursors (Fig. 3.4C). 
 
 3.2 C/EBPβ-mediated B cell reprogramming does not depend on the 
endogenous C/EBPβ 
C/EBPβ deficient B cell progenitors were further tested to exclude the possibility that 
B cell to myeloid conversion occurred through an auto-regulatory loop by initial 
activation of endogenous C/EBPβ (Mink et al., 1999; Niehof et al., 2001). These data 
showed that, similarly to WT B cell progenitors, C/EBPβ-/- primary B cells could be 
reprogrammed to CD11b+ myeloid cells by the ectopic expression of C/EBPβ, 
although the kinetics of reprogramming was somewhat accelerated in C/EBPβ-/- cells 
(Fig. 3.5A compared to Fig. 3.1). Hence, B cell to myeloid reprogramming by C/EBPβ 
does not depend on upregulation of the endogenous C/EBPβ gene. Interestingly, 
certain differences became apparent between the efficiency of LAP and LAP* to 
down-regulate CD19 in C/EBPβ-/- B cells (Fig. 3.5A, C). Both LAP and LAP* 
upregulated CD11b expression very effectively, however the extended isoform LAP* 
(which recruits the SWI/SNF complex) down-regulated CD19 expression more 
efficiently (similar differences between LAP and LAP* were also seen in some of the 
experiments with WT B cells, however they were not consistent). Furthermore, in 
C/EBPβ-/- B cell progenitors, the truncated isoform LIP showed some residual 
reprogramming capacity, which was not seen in WT cells. These discrepancies might 
be attributed to the lack of the endogenous C/EBPβ which may to some extend 
“buffer” the isoform specific effects. 
It has been shown that during the reprogramming of B cells to macrophages by 
C/EBPα, the expression of the endogenous C/EBPα is not affected, whereas the 
endogenous C/EBPβ is upregulated (Bussmann et al., 2009). To test whether the 
lack of endogenous C/EBPβ might alter C/EBPα-mediated B cell reprogramming, 
primary B cell progenitors derived from WT or C/EBPβ-/- mice were compared. No 
difference in the reprogramming capacity of C/EBPα p42 long isoform was detected 
in WT and C/EBPβ deficient B cells (Fig. 3.5B). This suggests that, like C/EBPβ, 
C/EBPα-induced B cell reprogramming does not require endogenous C/EBPβ. 
Moreover, the observation that the truncated C/EBPα p30 isoform which lacks the 
C/EBPα TAD corresponding to C/EBPβ CR2,3,4, failed to reprogram B cells (Fig. 
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3.5B) further suggests that the major reprogramming functions of C/EBPs reside 
within their TADs. 
 
       
 
Fig. 3.5 C/EBPβ B cell reprogramming capacity does not depend on the presence of 
endogenous C/EBPβ. 
A. Percentage of C/EBPβ-/- B cell progenitors infected with C/EBPβ WT and mutants expressing the B 
cell marker CD19 or the myeloid marker CD11b 6 days after the infection. Intermediates (CD19+ 
CD11+ cells) are also included. Graphs represent GFP+ (virus infected) gated cell population. Values 
represent mean ± SEM from two and more repeat experiments. B. Percentage of WT and C/EBPβ-/- B 
cell progenitors infected with WT C/EBPβ LAP* and WT C/EBPα p42 and p30 expressing the B cell 
marker CD19 or the myeloid marker CD11b 6 days after the infection. Intermediates (CD19+ CD11+ 
cells) are also included. Graphs represent GFP+ (virus infected) gated cell population. Values for 
C/EBPβ-/- B cell progenitors represent mean ± SEM from three repeat experiments. C. Representative 
FACS profiles of MSCV, LAP* and LAP infected C/EBPβ-/- B cell progenitors after 6 days 
reprogramming. FACS plots represent GFP+ (virus infected) gated cell population. Similar outcomes 
were obtained in three repeat experiments. 
 
 3.3 C/EBPβ B cell reprogramming and proliferation stimulating functions 
could be uncoupled 
Previously, it has been shown that in contrast to C/EBPα, the percentage of cells 
infected with C/EBPβ markedly increases over time during B cell reprogramming (Xie 
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et al., 2004). As shown in Figure 3.6, the population of control vector MSCV infected 
cells remained fairly constant between day 6 and 9, whereas the long isoforms LAP*, 
LAP and mutants that supported reprogramming also increased cell numbers. 
Surprisingly, the percentage of the cells infected with the short isoform LIP 
decreased over time. Interestingly, the C/EBPβ mutants ΔCR3,4 and CR3,4 which 
failed to reprogram still induced proliferation (although P value was not statistically 
significant for CR3,4). This suggests that, unlike LIP, ΔCR3,4 and CR3,4 still retain 
capacity to induce cell proliferation. On the other hand, the PTM site mutants R60A 
(P=0.805) and R43/48A (P=0.652) did not induce higher proliferation of the 
reprogrammed cells compared to the B cells, proposing involvement of CR3 and the 
adjacent LCR between CR2 and CR3 in the proliferation control by C/EBPβ (Fig. 3.6 
and data not shown). This suggests that C/EBPβ B cell reprogramming and 
proliferation-stimulating functions could be uncoupled. The uncoupling could be 
achieved either through deletions that abrogate the reprogramming, while keeping 
the proliferation-stimulatory function, or through PTM site mutations (in that case 
abrogating potential methylation sites) which preserve the reprogramming function, 
however abolish the stimulation of cell proliferation. However, proliferation ceased 
after 2 weeks in vitro culturing (data not shown) which might reflect the dual role of 
C/EBPβ in the regulation of hematopoietic cell proliferation, stimulation of the 
proliferation of B lymphoid progenitors and inhibition of myelomonocytic cell 
proliferation (Chen et al., 1997; Gutsch et al., 2011), or reaching the Hayflick limit 
(Shay and Wright, 2000). 
 
 
 
 
 
Fig. 3.6 Effect of C/EBPβ WT and mutants on cell 
proliferation. 
Relative number of infected GFP+ cells 9 days after 
the infection, calculated as a ratio between the 
percentage of GFP+ cells on day 9 to the percentage 
of GFP+ cells on day 6, where the percentage of 
GFP+ cells on day 6 was taken as value “1”. Values 
represent mean and SEM from different number of 
independent experiments. P values are all calculated 
versus MSCV. Number of repetitions: MSCV N=11, 
LIP - 4, R60A - 2, LAP* - 11, ΔCR4 - 4, CR3,4 - 2, 
LAP - 6, ΔCR1,2 - 5, ΔCR5,6,7 - 3, CR2,3,4 - 6, 
ΔCR3,4 - 5, ΔCR3 - 4, ΔCR6 - 4. 
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 3.4 WT C/EBPβ and its mutants differentially activate the expression of 
key macrophage pro-inflammatory and anti-inflammatory genes  
It has been shown that C/EBPα and β reprogrammed B cell progenitors display 
inflammatory macrophage phenotype (Xie et al., 2004). To analyze and compare 
how different C/EBPβ constructs contribute to the reprogrammed phenotype, we 
monitored the expression of several pro-inflammatory M1 and anti-inflammatory M2 
macrophage genes, as well as key regulators of macrophage differentiation by 
NanoString technology (Table S1). We chose this technique because it is a highly 
reproducible method with low error rate (Fortina and Surrey, 2008; Geiss et al., 2008) 
and applicable to low amount of sample material, with which we had to deal due to 
the restricted numbers of reprogrammed primary cells. Additionally to C/EBPβ-
reprogrammed cells, WT and C/EBPβ-/- BM derived macrophages were included, as 
it has been suggested that anti-inflammatory M2 properties rely on C/EBPβ and that 
M-CSF stimulated macrophages have similar gene expression patterns as M2 
macrophages (Martinez et al., 2006; Ruffell et al., 2009). 
Figure 3.7 and Table S2 show that many M1 (Il1b, Il12b, Il12rb1, Nos2, Cxcl10) and 
M2 genes (Arg1, Msr1, Il13ra, Pparg, Chi3l3) were upregulated during trans-
differentiation and in macrophages from WT or C/EBPβ-/- animals as compared to B 
cell progenitors. Some genes like Tnf, Il1b, Ccl2, Mmp9, Myd88, Il13ra, Msr1, Tgfb1, 
Mmp12, Pparg, Kdm6b, Chi3l3 and Fcgr3 were expressed at similar levels in WT and 
C/EBPβ deficient macrophages, whereas, others, including Il12b, Il12rb and Nos2 (all 
M1 genes) were upregulated in trans-differentiated cells but were neither expressed 
in WT nor in C/EBPβ-/- macrophages. However, differential gene expression between 
both genotypes was also identified, as Mmp8, Mafb, Maf and Il4ra demonstrated 
higher expression in WT as compared to C/EBPβ-/- macrophages. Interestingly, Il10 
was expressed in WT but not in C/EBPβ-/- macrophages, nor in the reprogrammed 
cells. On the other hand, Arg1, Ccl22, and Cxcl9 (which was also not expressed in 
the C/EBPβ reprogrammed cells) were expressed only in C/EBPβ-/- but not in WT 
macrophages. These three genes, among which two code for chemokines, might be 
C/EBPβ repressed targets. Furthermore, in comparison to the C/EBPβ 
reprogrammed CD11b+ myeloid cells, BM derived macrophages expressed higher 
levels of M2 genes (e.g. Msr1, Pparg and Il10) and did not upregulate some M1 
genes (e.g. Il12b, Il12rb and Nos2) which is in agreement with the finding that M-
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CSF-derived macrophages and IL-4 stimulated macrophages, which undergo M2 
polarization, are similar (Martinez et al., 2006). For example, Pparg upregulation in 
monocytes/macrophages has been associated with anti-inflammatory properties, 
suggesting the predominant anti-inflammatory nature of the BM M-CSF-derived 
macrophages (Arnold et al., 2007; Bouhlel et al., 2007). In our study, the relatively 
small differences in macrophage polarization specific gene expression between WT 
and C/EBPβ-/- BM derived macrophages might be due to the culture conditions 
(supplemented only with M-CSF), as major differences in the activation of many 
macrophage genes require stimulation with LPS/IFNγ (Gorgoni et al., 2002; Ruffell et 
al., 2009; Tanaka et al., 1995; Uematsu et al., 2007). 
For the majority of macrophage polarization genes, WT C/EBPβ isoforms LAP* 
and/or LAP were the strongest gene activators, whereas Δ CR1,2 reprogrammed 
cells showed lower or lacked gene activation capacity for certain M1 genes (Il12b, 
Nos2, Cxcl10 and Mmp9), M2 genes (Arg1, Pparg, Mmp12 and Chi3l3) and the 
transcription factor Maf. The fact that ΔCR1,2 construct only weakly activated both 
M1 and M2 genes is consistent with the observation that it is also partially impaired in 
reprogramming. Comparison between LAP*, LAP and Δ CR1,2 activated genes 
revealed certain genes whose expression was dependent on CR1 and CR2. 
Macrophage polarization genes that were similarly deregulated by LAP and ΔCR1,2 
compared to LAP* included Mmp8, Mmp9, Mmp12, Kdm6b, Pparg and Chi3l3, 
suggesting that recruitment of SWI/SNF chromatin remodeling complex might be a 
prerequisite for their activation (Kowenz-Leutz and Leutz, 1999; Kowenz-Leutz et al., 
2010). Other genes (Cxcl10, Arg1, Il4ra, Maf) were upregulated by LAP but not by 
ΔCR1,2 suggesting that they require the presence of intact CR2. Furthermore, some 
genes (Il1b, Cxcl10, Ccl2, Arg1, Il4ra and Maf) were more highly activated by LAP 
than LAP*, which is in agreement with previous reports showing that LAP might be 
the stronger activator on certain genes (Eaton and Sealy, 2003; Lee et al., 1996). 
The complexity of variegated C/EBPβ CR functions in macrophage gene activation 
was further highlighted by the finding that the LAP* and C/EBPβ deletion mutants but 
not LAP activated Mafb, whereas LAP was the strongest activator of the Maf (c-Maf) 
gene probably due to a compensatory effect of the lack of Mafb expression in these 
cells (Aziz et al., 2006). Furthermore, in agreement with the reprogramming 
impairment, ΔCR4 failed to activate many macrophage genes (Il12b, Nos2, Pparg 
and Arg1) or induced their expression to a lower extend (Cxcl10), whereas ΔCR3 
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and ΔCR6 trans-differentiated cells showed gene expression pattern similar to LAP* 
(Fig. 3.7 and Table S2). Interestingly, the ΔCR6 protein which was previously shown 
to be constitutively repressed (Kowenz-Leutz et al., 1994) activated both M1 and M2 
macrophage genes in the reprogrammed cells, supporting the idea that the RD is not 
a repressive structure in B cells. 
 
 
 
Fig. 3.7 Key macrophage genes are 
differentially expressed by reprogrammed 
C/EBPβ-/- B cell progenitors, WT and 
C/EBPβ-/- macrophages, as determined by 
Nanostring technology. 
A. mRNA expression of pro-inflammatory M1 
macrophage genes. 
B. mRNA expression of anti-inflammatory M2 
macrophage genes. 
C. mRNA expression of the 
monocyte/macrophage transcription factors 
Mafb and Maf. 
All graphs are presented as a logarithmic scale 
log10. Graphs represent mRNA counts after 
the background subtraction and normalization 
to three house-keeping genes (See Materials 
and Methods). Expression below the 
background level was set to value “1”. MPh 
WT - WT BM derived macrophages; MPh KO - 
C/EBPβ-/- BM derived macrophages. Results 
represent expression profiles from three 
independent experiments. 
 
Irrespective of these significant differences, the different C/EBPβ constructs 
simultaneously induced M1 and M2 genes in the trans-differentiated cells and did not 
show M1 or M2 bias. Some of these M1 genes (Tnf, Nos2, Il1b and Il12b) were 
already shown to be deregulated in C/EBPβ deficient macrophages upon LPS/IFNγ 
stimulation (Tnf, Nos2, Il1b are downregulated; Il12b is upregulated) (Gorgoni et al., 
2002). Similarly, certain M2 genes (Msr1, Il10, Il13ra, Arg1) are dependent on CREB 
mediated C/EBPβ upregulation upon inflammatory stimuli (Ruffell et al., 2009). 
Therefore, the expression profile of the reprogrammed cells might resembles 
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LPS/IFNγ stimulated macrophages (Ruffell et al., 2009) with distinct pro- and anti-
inflammatory genes showing C/EBPβ CR-dependent activation. The gene expression 
results also raised the possibility of the existence of heterogeneous trans-
differentiated cell populations. 
 
 3.5 The C/EBPβ structure determines the trans-differentiation outcomes  
It has been shown that high phagocytic activity is a hallmark on 
monocytes/macrophages, whereas DCs and granulocytes are characterized by a 
lower capacity of phagocytosis (Bakri et al., 2005; Drutman et al., 2012; Sunderkotter 
et al., 2004). Therefore, we decided to examine the potential functional heterogeneity 
in the cultures by performing an in vitro phagocytosis assay. Interestingly, this assay 
performed with C/EBPβ reprogrammed CD11b+ cells revealed the presence of cells 
with high and low phagocytic activity (Fig. 3.8), suggesting heterogeneity among the 
reprogrammed cells. On the other hand, the MSCV control virus infected CD19+ cells 
exhibited neglectable phagocytic activity, whereas WT BM derived macrophages 
showed homogenous phagocytic capacity. 
 
 
 
Fig. 3.8 Phagocytosis assay confirms the heterogeneity among C/EBPβ reprogrammed myeloid 
cells. 
Assay was performed after 10 days in vitro reprogramming. Red line represents cells incubated with 
fluorescent latex beads and the black line represents the auto-fluorescence of the untreated samples. 
For MSCV-infected cells histograms represent GFP+ CD19+ gated population, whereas C/EBPβ-
infected reprogrammed cells were gated on GFP+ CD11b+ cells. As positive controls for phagocytic 
capacity, BM derived macrophages were used. Similar outcomes were obtained in two repeat 
experiments. 
 
Full length C/EBPβ and C/EBPα reprogram B cell progenitors to CD11b+ F4/80+ Gr-
1+ CD62L+ inflammatory macrophages (Xie et al., 2004). To unravel heterogeneity of 
trans-differentiation outcomes by distinct C/EBPβ constructs, CD11b+ cells were 
examined by flow cytometry for the expression of Gr-1/Ly-6C to distinguish between 
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inflammatory type monocytes/macrophages (CD11b+ Gr-1/Ly-6C+) and resident type 
monocytes/macrophages (CD11b+ Gr-1/Ly-6C–) (Arnold et al., 2007; Auffray et al., 
2007; Geissmann et al., 2003; Nahrendorf et al., 2007). As shown in Table 3.1, 
C/EBPβ long WT isoforms and mutants reprogrammed B cell progenitors into two 
CD11b+ subpopulations, in most cases resulting in high percentage of CD11b+ Ly-
6C+ cells 6 days after the infection. However, 9 days after the infection, there was a 
significant decrease in the percentage of Ly-6C+ myeloid cells and an increase in 
CD11b+ Ly-6C– cells. The reduction of the percentage of Gr-1/Ly-6C+ cells was not 
due to selective apoptosis, as no differences in the apoptotic cell frequency between 
CD11b+ Gr-1– and CD11b+ Gr-1+ cells could be detected (Fig. 3.9). Accordingly, shift 
of CD11b+ Ly-6C+ to CD11b+ Ly-6C– cell subset might be due to simultaneously 
occurring cell reprogramming and cell maturation processes (Drutman et al., 2012; 
Sunderkotter et al., 2004). Interestingly, constructs that did not downregulate Ly-6C 
by day 9 (e.g. ΔCR6) and such that did not considerably upregulate Ly-6C (e.g. LAP 
and CR2,3,4) or resulted in a small number of Ly-6C+ cells by day 9 (e.g. ΔCR1,2) 
were also distinguished, suggesting that the activity of the individual protein modules 
in C/EBPβ might direct differentiation preferably towards inflammatory or resident 
monocyte/macrophage phenotypes. The reason for the relatively high percentage of 
 
 LAP* LAP ΔCR1,2 ΔCR3 ΔCR4 CR2,3,4 ΔCR6 
6 dpi a) 77 ± 1.7 39 ± 8.1 53 ± 6.9 78 ± 1.5 69 ± 1.8 18 ± 1.8 85 ± 1.5 
9 dpi a) 51 ± 3.2 13 ± 2.4 19 ± 3.4 47 ± 1.1 39 ± 0.56 5.7 ± 2.0 71 ± 5.5 
N b) 7 4 2 2 2 5 4 
P value c) <0.0001 0.021 0.047 0.003 0.004 0.002 0.046 
Signifi- 
cance d) 
Yes (***) Yes (*) Yes (*) Yes (**) Yes (**) Yes (**) Yes (*) 
 
Table 3.1. Differential Ly-6C expression on the CD11b+ cells reprogrammed by WT and mutant	  
C/EBPβ. 
a) Percentage of cells infected with WT and mutant C/EBPβ retroviral constructs expressing Ly-6C 
surface antigen 6 or 9 days after the infection. The total percentage of GFP+ CD11b+ cells was set to 
100%. Values represent mean ± SEM; b) N - number of experiments; c) P values were calculated by 
unpaired t test 6 versus 9 days reprogramming; d) Significance was defines as P>0.05 - not significant, 
P=0.01-0.05 - significant (*), P=0.001-0.01 - very significant (**), P<0.001 - extremely significant (***). 
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Ly-6C+ cells induced by ΔCR1,2 after 6 days reprogramming was probably due to the 
low percentage of CD11b+ reprogrammed cells after this reprogramming period (Fig. 
3.1) which perhaps led to an overestimation of CD11b+ Ly-6C+ cell outcome by this 
mutant on day 6, whereas, with the increase of the reprogramming efficiency on day 
9, ΔCR1,2 gave similar outcome as LAP and CR2,3,4. Interestingly, all constructs 
that showed reduced Ly-6C+ myeloid cell trans-differentiation outcome lacked CR1, 
suggesting its involvement in appointment of the resultant macrophage phenotype. 
 
                    
 
Fig. 3.9 Lack of significant difference in the frequency of the apoptotic cells between the 
subpopulations of cells ectopically expressing C/EBPβ. 
Apoptosis assay based on AnnexinV staining and evaluated by FACS. Dead cells were excluded by 
DAPI staining and the apoptosis assessment was done after gating on the different GFP+ cell 
populations (CD19+, CD11b+ Gr-1– and CD11b+ Gr-1+). na - no available cells with these surface 
characteristics. The graph represents data from four independent experiments. 
 
CD11b is a marker of different types of myeloid cells, including 
monocytes/macrophages, granulocytes and DCs; furthermore Ly-6C is expressed 
not only on inflammatory monocytes/macrophages but also on granulocytes. 
Accordingly, additional surface markers were examined in order to distinguish in 
more detail between reprogrammed CD11b+ myeloid cell phenotypes and to unravel 
potential trans-differentiation heterogeneity. It is known that granulocytes differ from 
monocytes/macrophages by the expression of M-CSFR on the latter and among M-
CSFR+ monocytes/macrophages Ly-6C/Gr-1 expression discriminates between 
inflammatory and resident monocytes/macrophages (Geissmann et al., 2003; 
Sunderkotter et al., 2004). As shown in Figure 3.10, CD11b+ cells reprogrammed by 
full length and several C/EBPβ deletion constructs, simultaneously expressed Ly-6C 
(and Gr-1, data not shown) and M-CSFR surface markers, indicating an inflammatory 
monocyte/macrophage phenotype in accordance with published results (Xie et al., 
Results 
69 
2004), however, we also identified Ly-6C– M-CSFR+ resident type 
monocytes/macrophages and cells with granulocyte characteristics, namely Ly-6C+ 
M-CSFR– cells (Geissmann et al., 2003; Sunderkotter et al., 2004), as well as 
CD11b+ cells that did not upregulate either of these two markers (Ly-6C– M-CSFR– 
cells). The percentage of Ly-6C+ M-CSFR+ cells decreased between 6 and 9 days of 
reprogramming, whereas the percentage of Ly-6C– M-CSFR+ cells increased (Fig. 
3.10). This is most likely due to differentiation of inflammatory 
monocytes/macrophages into resident monocytes/macrophages, as shown before 
(Drutman et al., 2012; Sunderkotter et al., 2004). The remaining M-CSFR– Ly-6C+ 
cells in the cultures expressed also Ly-6G, suggesting that this population 
corresponded to granulocytic differentiation (Fig. 3.11A) (Daley et al., 2008; 
Sasmono et al., 2007). However, no granulocytic differentiation was induced by LAP, 
CR2,3,4 and ΔCR1,2 and only a few inflammatory monocytes/macrophages were 
generated by LAP and CR2,3,4 (Fig. 3.10). In contrast, deletion of CR6 led to an 
increase of the Ly-6C+ Ly-6G+ M-CSFR– granulocytic population at the expense of 
the other populations (Fig. 3.11A). 
 
 
 
Fig. 3.10 Myeloid cell surface marker expression on the B cell progenitors reprogrammed by 
C/EBPβ WT isoforms and mutants after 6 and 9 days reprogramming. 
Expression of Ly-6C and M-CSFR myeloid cell markers on the reprogrammed cells 6 days and 9 days 
after the infection. FACS plots represent GFP+ (virus infected) CD11b+ gated cell population. For 
MSCV-infected cells FACS plots represent virus infected GFP+ CD19+ cells. The myeloid cell marker 
staining was repeated in at least two independent experiments and similar results were obtained. 
 
As the Ly-6C+ M-CSFR+ population represented inflammatory 
monocytes/macrophages, Ly-6C– M-CSFR+ population - resident 
monocytes/macrophages, and Ly-6C+ M-CSFR– cells granulocytic differentiation, we 
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were wondering about the rest of CD11b+ cells that were Ly-6C– M-CSFR–. CD11b is 
also a marker of cDCs, which are additionally characterized by high expression of 
CD11c, MHC-II and co-stimulatory molecules and are negative for M-CSFR 
expression (Geissmann et al., 2010). Further FACS analyses of the expression of  
 
                     
 
Fig. 3.11 Distinct myeloid cell surface marker expression on the B cell progenitors 
reprogrammed by C/EBPβ WT isoforms and deletion mutants. 
A. Expression of Ly-6C, M-CSFR and Ly-6G myeloid cell markers on the reprogrammed cells 9 days 
after the infection. FACS plots and histograms represent GFP+ (virus infected) CD11b+ gated cell 
population. For MSCV-infected cells FACS plots and histograms represent virus infected GFP+ CD19+ 
cells. On the histogram for Ly-6G expression, lines are colour coded as the populations on the Ly-
6C/M-CSFR FACS plot. B. Expression of the DC markers CD11c, MHC-II and CD86 on the 
reprogrammed Ly-6C– M-CSFR– cells 9 days after the infection. FACS plots and histograms represent 
GFP+ (virus infected) CD11b+ Ly-6C– M-CSFR– gated cell population (colour coded as the 
corresponding population on the Ly-6C/M-CSFR FACS plot in A). For MSCV-infected cells FACS plots 
and histograms represent virus infected GFP+ CD19+ cells. “++”, “+”, “med” and “-“ represent the 
expression levels of MHC-II and CD86 antigens. The cell marker staining was repeated in at least two 
independent experiments giving similar results.  
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CD11c, MHC-II and the co-stimulatory molecule CD86 showed that the 
reprogrammed CD11b+ Ly-6C– M-CSFR– cells were also characterized as CD11c+ 
MHC-II+/++ CD86+/med, phenotypic features of cDC (Fig. 3.11B and data not shown). 
We excluded pDCs as a trans- differentiation outcome, as their phenotype is defined 
as CD11b– B220+ CD19– Ly6C+ Ly6G– CD115– CD11cmed MHC-IIlo (Geissmann et 
al., 2010). The deletion mutant ΔCR6 not only induced lower DC outcome at expense 
of increased granulocytic trans-differentiation but these DCs had more immature 
phenotype suggested by their lower MHC-II and CD86 expression (Chow et al., 
2002). Interestingly, Ly-6C+ M-CSFR+ inflammatory monocytes/macrophage 
population expressed low levels of DC markers or was negative for them, whereas 
the majority of Ly-6C– M-CSFR+ resident monocyte/macrophage cells were CD11c+ 
MHC-II+/med CD86med (Fig. 3.12 and data not shown). This intermediate phenotype 
between DCs and monocytes/macrophages might be associated with partial 
acquisition of DC markers from activated monocytes or initial differentiation step 
towards monocyte-derived DCs from the resident monocyte/macrophage population 
(Belz and Nutt, 2012; Drutman et al., 2012). Furthermore, the reprogrammed DCs 
 
    
 
Fig. 3.12 DC markers are expressed also on the monocyte/macrophage populations. 
Expression of the DC markers CD11c, MHC-II and CD86 on the reprogrammed cells 9 days after the 
infection. FACS plots and histograms represent GFP+ (virus infected) CD11b+ gated cell population 
and are colour coded as the corresponding populations on the Ly-6C/M-CSFR FACS plot. For MSCV-
infected cells FACS plots and histograms represent virus infected GFP+ CD19+ cells. 
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and both monocyte/macrophage populations expressed F4/80 surface marker (data 
not shown), a marker of macrophages and subsets of DCs, also expressed on DCs 
derived through reprogramming of T cells by PU.1 (Laiosa et al., 2006b). In 
summary, structural alterations in C/EBPβ modified the reprogramming outcomes 
and based on the expression of surface molecules, CD11b+ cells were 
reprogrammed to a heterogeneous population of cells with surface marker 
characteristics of inflammatory and resident monocytes/macrophages, granulocytes 
and cDCs. 
Next, we determined the cell morphology of the reprogrammed cells by histological 
staining on cytospins of sorted GFP+ virus infected cells 9 days after the infection. 
The control virus MSCV infected CD19+ cells showed typical B cells morphology, 
whereas the morphological outcome of CD11b+ cells reprogrammed by the WT or 
mutant C/EBPβ was very different depending on the construct (Fig. 3.13 and data not 
shown). Constructs that induced similar surface marker expression also induced 
morphologically similar trans-differentiated cells. For example, LAP*-, ΔCR3- and 
ΔCR5,6,7-reprogrammed cells, which based on the FACS analyses could be 
subdivided into Ly-6C+ M-CSFR–, Ly-6C+ M-CSFR+, Ly-6C– M-CSFR+ and Ly-6C– M-
CSFR- populations (Fig. 3.10), displayed morphologic characteristic of 
polymorphonuclear neutrophils, monocytes/DCs and macrophages, suggesting that 
deletion of CR3 and CR5,6,7 does not significantly affect the differentiation outcome. 
Other constructs, like CR2,3,4 and LAP, which generated Ly-6C– M-CSFR– and Ly- 
 
                 
 
Fig. 3.13 Distinct cell morphology of C/EBPβ reprogrammed cells 
Cytospins of the control virus MSCV infected CD19+ cells and CD11b+ cells reprogrammed by WT 
C/EBPβ and its deletion mutants sorted 9 days after the infection and stained with May-Grunwald-
Giemsa. B - B cells, M - macrophages, G - neutrophil granulocytes, * - monocytes/DCs. 
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6C– M-CSFR+ cells and a minor fraction of Ly-6C+ M-CSFR+ cells, led to 
monocyte/DC and macrophage differentiation, however no granulocytic differentiation 
could be detected, suggesting the requirement of CR1 for the granulocytic trans-
differentiation outcome. Similarly, ΔCR1,2 failed to generate granulocytes but only 
less differentiated monocytes/DCs. Furthermore, in accordance to the FACS 
analyses, ΔCR6 reprogrammed cells had predominantly neutrophil granulocytic 
morphology. Hence, the surface marker expression reflected differences in the cell 
morphology of the reprogrammed cells, and depending on the function of discrete 
CRs in C/EBPβ abrogated or enhanced differentiation into distinct myeloid cell types. 
Except for the isoforms, deletions do not naturally occur in C/EBPβ, yet modular 
gene and chromatin regulatory functions of CRs have been noted before and found 
to be regulated by signaling dependent PTMs (Kowenz-Leutz et al., 2010; Leutz et 
al., 2011; Nerlov, 2008; Zahnow, 2009). The fact that recombination of C/EBPβ CRs 
affected myeloid trans-differentiation capacity therefore suggested regulation by 
PTMs. Accordingly, we used multiparameter flow cytometry to inspect more closely 
the myeloid reprogramming outcome by two C/EBPβ PTM site mutants which did not 
abrogate the reprogramming capacity of C/EBPβ (Fig. 3.3). As shown in Figure 
3.14A, the AA substitution mutant K39/168A led to enhancement of the granulocytic  
 
                  
 
Fig. 3.14 C/EBPβ PTMs also affect the cell differentiation outcome from C/EBPβ-mediated B 
cell reprogramming. 
A. Expression of Ly-6C and M-CSFR myeloid cell markers on the reprogrammed cells 9 days after the 
infection. FACS plots represent GFP+ (virus infected) CD11b+ gated cell population. For MSCV-
infected cells FACS plots represent virus infected GFP+ CD19+ cells. B. Cytospins of the cells infected 
with WT C/EBPβ and its PTM site mutants sorted 9 days after the infection and stained with May-
Grunwald-Giemsa. Experiments were repeated two to three times and similar results were obtained. B 
- B cells, M - macrophages, G - neutrophil granulocytes, * - monocytes/DCs. 
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differentiation, as compared to C/EBPβ WT LAP*. FACS data of cells reprogrammed 
by C/EBPβ K39/168A were confirmed by histological staining (Fig. 3.14B). Similarly, 
the majority of CD11b+ cells reprogrammed by the UBC9 binding and SUMOylation 
defective C/EBPβ mutant K156A/E158A were with granulocytic surface marker 
characteristics and morphology (Fig. 3.14A,B). Of note, residues K156, E158 and 
K168 are all located in CR6 or in the adjacent LCR and deletion of CR6 resulted in a 
dramatic increase in the granulocytic differentiation outcome (Fig. 3.11 and 3.13). In 
conclusion, PTMs on C/EBPβ, similarly to CR deletions, altered the reprogramming 
outcome, suggesting that C/EBPβ functions to direct distinct cell fates are adapted by 
signaling and PTMs. It is possible that some still unidentified PTMs might abrogate 
the granulocytic differentiation (one potential candidate is R3L (Kowenz-Leutz et al., 
2010)), while others might distort DC or monocyte/macrophage differentiation. 
 
 3.6 Irf8 deficiency affects neither C/EBPβ reprogramming efficiency nor 
the macrophage reprogramming outcome 
It has been shown that IRF8 directs myeloid hematopoietic progenitor differentiation 
into macrophages at expense of granulocytes (Tamura et al., 2000). Irf8-/- B cells 
were used for the reprogramming experiments to answer the questions whether (i) 
Irf8 deficient B cells could be reprogrammed, (ii) Irf8 is essential for C/EBPβ-induced 
macrophage reprogramming outcome (iii) increased trans-differentiation into 
granulocytes occurs in absence of Irf8. Our data, based on downregulation of CD19 
and upregulation of CD11b showed that after both 6 and 9 days reprogramming, Irf8 
deficient B cell progenitors were indistinguishable from their WT counterparts (Fig. 
3.15). Detailed analyses of the myeloid cell differentiation spectrum showed that in 
the Irf8 deficient genetic background after 6 days reprogramming, there was a 
dramatically impaired trans-differentiation into M-CSFR+ cells, including both Ly-6C+ 
and Ly-6C– cells. However, after 9 days reprogramming this impairment was no more 
detectable and macrophage differentiation could be confirmed by both FACS 
analyses and cytospins (Fig. 3.15A,B). A two fold increase in the granulocytic 
outcome was seen in the Irf8-/- cells reprogrammed by LAP*, however this increase 
was not observed when CR2,3,4 mutant was used in accordance to our data from 
WT B cells (Fig. 3.11, 3.13 and 3.15). In summary, these data indicate that Irf8 
deficient B cells could be reprogrammed to myeloid cells by C/EBPβ similarly to WT 
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B cells and IRF8 presence is not essential for the macrophage reprogramming 
outcome, however, in the absence of IRF8 there is an increase in the granulocytic 
outcome. 
 
             
 
Fig. 3.15 C/EBPβ induced reprogramming and its outcomes are IRF8-independent processes. 
A. FACS profiles of MSCV, LAP* and CR2,3,4 infected WT and Irf8-/- B cell progenitors after 6 and 9 
days reprogramming. FACS plots represent GFP+ (virus infected) gated cell population. B. Cytospins 
of the WT and Irf8-/- reprogrammed cells infected with MSCV, LAP* and CR2,3,4, sorted 9 days after 
the infection and stained with May-Grunwald-Giemsa. B - B cells, M - macrophages, G - neutrophil 
granulocytes, * - monocytes/DCs. 
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 3.7 C/EBPβ has a developmentally conserved essential function in G-
CSF and GM-CSF signaling 
It has been already shown that C/EBPβ deficiency in BM progenitors leads to 
impairment of G-CSF, GM-CSF and IL-3 cytokine-stimulated granulopoiesis (Akagi et 
al., 2008; Hirai et al., 2006). Furthermore, in our reprogramming system C/EBPβ 
induced granulocytic differentiation in the absence of G-CSF, suggested that C/EBPβ 
might be a key signaling molecule in cytokine signaling leading to granulocytic 
differentiation. We were wondering whether this is also true in another system like 
fetal liver (FL) hematopoietic progenitor cells. Although fetal and adult definitive 
hematopoiesis share many similarities, there are also substantial differences 
between them (He et al., 2011; Kikuchi and Kondo, 2006; Lessard et al., 2004; 
Mikkola and Orkin, 2006). 
 
 
 
Fig. 3.16 G-CSF and GM-CSF responses are impaired in C/EBPβ-/- FL hematopoietic cells 
Whole FL cells were isolated from C/EBPβ+/+, +/- and -/- embryos at E14.5 dpc (N=3 for each 
genotype). 2x104 FL cells/well/1ml were cultured in methylcellulose supplemented with 50ng/ml SCF, 
10ng/ml IL-3, 10ng/ml IL-6, 3 U/mL EPO, or with a single cytokine: 10ng/ml M-CSF, or 50ng/ml G-
CSF, or 20ng/ml GM-CSF. Colonies were scored at day 7. Results represent the mean plus or minus 
SEM from three technical replicates for each of the three embryos per genotype. 
 
To answer the question about the role of C/EBPβ in the context of fetal hematopoietic 
progenitors and stem cells specific transcription factor networks, whole FL cells were 
used as a source highly enriched in cycling HSCs and progenitors (Lessard et al., 
2004; Mikkola and Orkin, 2006). C/EBPβ+/+, +/- and -/- FL cells were analyzed by 
colony-forming unit (CFU) assay in methylcellulose supplemented with a distinct 
cytokine or a cytokine cocktail. The colony assay revealed that C/EBPβ deficiency 
did not significantly reduce the number of myeloid clonogenic cells when the FL cells 
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were cultured simultaneously with IL-3, IL-6, EPO, and SCF, or only with M-CSF (Fig. 
3.16). Furthermore, in the mixed myeloid lineage cytokine cocktail no significant 
differences between the number of CFU-GEMM, CFU-GM, CFU-M, CFU-G or BFU-E 
were seen (data not shown). On the other hand, the number of colonies generated in 
the presence of either GM-CSF or G-CSF was significantly diminished in C/EBPβ 
deficient FL cells compared to WT cells. The heterozygous genotype was haplo-
sufficient to rescue the WT phenotype and produced a significantly higher number of 
colonies in G-CSF and GM-CSF compared to C/EBPβ-/-, whereas no significant 
differences between C/EBPβ+/- and C/EBPβ+/+ were obtained for these cytokines. 
Hence, similarly to C/EBPβ-/- adult BM hematopoietic cells, FL cells displayed an 
impaired G-CSF and GM-CSF responses, suggesting a conserved key role of 
C/EBPβ in the signaling through these cytokines during FL and adult BM definitive 
hematopoiesis. 
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 4. Discussion 
 
Direct hematopoietic cell reprogramming or trans-differentiation of committed cells 
into another cell type can be achieved by stimulation through exogenously expressed 
cytokine receptors or targeted inactivation or enforced expression of lineage-
determining transcription factors which play essential roles in the physiological cell 
differentiation (Borzillo et al., 1990; Bussmann et al., 2009; Cobaleda and Busslinger, 
2008; Laiosa et al., 2006b; Nutt et al., 1999; Xie et al., 2004). Hence, a better 
understanding of how transcription factors determine lineage decisions will be 
instrumental in the elucidation of normal and aberrant differentiation processes and 
targeted regenerative therapies. Previously, we have shown that distinct functional 
modules of C/EBPβ are involved in interactions with the epigenetic machinery 
(Kowenz-Leutz and Leutz, 1999; Kowenz-Leutz et al., 2010; Mo et al., 2004; Pless et 
al., 2008). Using an experimental system where ectopical C/EBPβ expression 
reprograms primary B cell progenitors into myeloid cells, we show here that not only 
the long WT isoforms but also a variety of C/EBPβ deletion and PTM site mutants 
were capable to extinguish B cell commitment and activate a myeloid program 
(Fig.3.1, 3.2 and 3.3). The B cell origin of reprogrammed cells was confirmed by 
monitoring rearrangements in the IgH gene locus (Fig. 3.4C), which excluded the 
possibility that the emerging CD11b+ cells were a result of outgrowth of myeloid cells 
due to contamination during the sorting procedure. Furthermore, lack of myeloid 
differentiation from the control vector MSCV-infected cells, or uninfected controls also 
confirmed the specificity of observed phenotypic changes (Fig. 3.1 and 3.2). 
 
 4.1 C/EBPβ isoforms and reprogramming 
The long C/EBPβ isoforms LAP and LAP* differ from each other due to the usage of 
an alternative translation initiation site to generate a N-terminal 22 AA long region 
(CR1) which is present only in LAP* (Calkhoven et al., 2000). CR1 aids to 
differentially recruit SWI/SNF chromatin remodeling complexes and the LAP* specific 
CR1 functions are regulated by receptor tyrosine kinase/ mitogen-activated protein 
kinase (MAPK) mediated RD phosphorylation and methylation of R3 (Kowenz-Leutz 
and Leutz, 1999; Kowenz-Leutz et al., 2010). Accordingly, LAP and LAP* C/EBPβ 
long isoforms are reported to have some distinct functions in gene regulation. 
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Although LAP is the predominantly expressed C/EBPβ isoform and LAP and LAP* 
are equally efficient in plasmid reporter activation, subsets of chromosome-
embedded genes in myeloid cells and in adipocytes are differentially regulated by 
LAP* and LAP (Kowenz-Leutz and Leutz, 1999; Kowenz-Leutz et al., 2010). In mice 
that lack the C/EBPβ LAP isoform but express the LAP* isoform, no impairment of 
intracellular bacteria killing is observed, whereas the induction of some C/EBPβ 
target genes in activated macrophages is altered (Uematsu et al., 2007), suggesting 
the existence of cellular functions that LAP* could not fulfill when LAP expression is 
missing. LAP and LAP* might also be subjected to distinct regulation by 
SUMOylation, which occurs only on LAP* and is involved in differential regulation of 
the cyclin D1 promoter (Eaton and Sealy, 2003). Our data showed that both LAP* 
and LAP were competent of B cell to myeloid trans-differentiation, meaning that both 
long isoforms possess the modules important for reprogramming (Fig. 3.1 and 3.2). 
However LAP* displayed faster kinetics, reflecting the fact that recruitment of 
chromatin-remodeling complexes might facilitate reprogramming, although they are 
not absolutely necessary for the process (Singhal et al., 2010). Similarly to LAP, 
C/EBPβ deletion mutants lacking CR1 (CR2,3,4 and ΔCR1,2) retained 
reprogramming competence, which was however significantly reduced compared to 
LAP*, supporting the idea that accomplishment of euchromatin state contributes to 
reprogramming efficiency. 
 
 4.2 C/EBPβ activation and minimal reprogramming region 
C/EBPβ activity is auto-repressed and receptor tyrosine kinase - ras/MAPK signaling 
abrogates the auto-repression through phosphorylation, arginine and lysine (de-
)methylation and protein conformational changes (Kowenz-Leutz et al., 1994; Lee et 
al., 2010a; Lee et al., 2010b; Mo et al., 2004; Williams et al., 1995). Distinct 
mutations in the regulatory sequence result in a fully de-repressed protein which 
could not be further activated by Ras/MAPK signaling (Kowenz-Leutz et al., 1994; 
Lee et al., 2010a). Deletion of CR5, CR7, or the whole RD (ΔCR5,6,7) of C/EBPβ 
results in enhanced transactivation potential compared to LAP*, whereas the deletion 
of CR6 results in a constitutively repressed protein with dominant negative function 
(Kowenz-Leutz et al., 1994; Williams et al., 1995). CR6 contains a highly conserved 
SUMOylation site which has been suggested to be involved in the regulation of 
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C/EBPβ repression/activation or protein subnuclear localization (Berberich-Siebelt et 
al., 2006; Eaton and Sealy, 2003; Kim et al., 2002; Leutz et al., 2011). SUMO family 
members are conjugated to C/EBPβ K173 in the human protein (K156 in the chicken 
protein) (Eaton and Sealy, 2003; Kim et al., 2002). Despite the fact that the 
SUMOylation site is present in CR6 in both long isoforms of the transcription factor, 
SUMO2/3 target only LAP* and mutation of SUMO-targeted K residue to A relieves 
the repression of the cyclin D1 promoter by LAP* without altering the protein 
subnuclear localization (Eaton and Sealy, 2003). In murine T cells, SUMOylation of 
C/EBPβ and its redistribution to a more pericentric heterochromatin interferes with 
the repression of c-Myc expression but has no effect on the activation of the Il4 gene 
expression mediated by C/EBPβ (Berberich-Siebelt et al., 2006). Our reprogramming 
experiments showed that Δ CR5,6,7, ΔC R6 and the SUMO-site mutants K156A, 
K156A/E158A and K156R have similar to WT C/EBPβ LAP* capacity to reprogram B 
cell progenitors in terms of CD11b activation and downregulation of CD19 (Fig.3.1 
and 3.3), suggesting that regulation of the transactivation potential of C/EBPβ in B 
cells is different from what has been observed in other cell types (Kowenz-Leutz et 
al., 1994). Furthermore, ΔCR6 activated both pro-inflammatory and anti-inflammatory 
macrophage genes in the reprogrammed cells (Fig. 3.7 and Table S2), supporting 
the idea that the RD does not serve as a repressive structure in B cells and during 
their reprogramming. That might be due to a lack of co-repressor in B cells and 
proposes a cell specific regulation of C/EBPβ functions. It should be noted that 
besides SUMOylation, methylation has been found to modify the SUMO attachment 
lysine residue (Leutz et al., 2011). It will be necessary to determine the exact 
modification patterns of the RD in different hematopoietic cells before one could set 
out to determine the modification dependent interactome, which will help to deepen 
our understanding of cell type specific C/EBPβ regulation. 
Our group has already shown that the exchange of C/EBPβ DNA-binding and 
dimerization domain does not affect the functions of C/EBPβ TAD and RD (Kowenz-
Leutz et al., 1994). Furthermore, exchanging the bZip domains between C/EBPα and 
C/EBPβ has pointed out that the TAD but not differential DNA-binding is responsible 
for certain preferential promoter activation by C/EBPα and C/EBPβ (Mink et al., 
1999). In this context the mutant with exchanged leucine zipper CREB LZ is still 
effective in reprogramming B cells to myeloid cells (Fig. 3.1), meaning that C/EBPβ 
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reprogramming functions are not dependent on the native DNA-binding and 
dimerization C-terminal domain but on the N-terminus. 
Mass spectrometry analyses have demonstrated that C/EBPβ is extensively post-
translationally modified through R and K methylation (Leutz et al., 2011). Our 
previous data have shown that methylation has an inhibitory effect on C/EBPβ gene 
activation potential (Kowenz-Leutz et al., 2010; Leutz et al., 2011; Pless et al., 2008). 
In the current study we observed CD11b induction for all mutated R residues which 
we tested, suggesting that these single AA substitutions or their multiple 
combinations are not sufficient to disrupt C/EBPβ reprogramming function. That 
might not be unexpected as no abrogation of the cell reprogramming was 
accomplished after deleting CR1, 2, 5, 6 and 7, and even after individual deletion of 
CR3 or CR4 (Fig. 3.1 and 3.3). 
Residue K39 in C/EBPβ serves as a target for either methylation by histone lysine 
methyltransferase G9a or acetylation by histone acetyltransferases p300 and P/CAF 
and these modifications regulate C/EBPβ transcriptional activity (Cesena et al., 2007; 
Cesena et al., 2008; Pless et al., 2008). It has been shown that acetylation of murine 
C/EBPβ LAP in K39 residue enhances the transactivation activity of C/EBPβ and 
exchanging this residue to A leads to a reduced transactivation on C/EBP responsive 
promoters (Cesena et al., 2007; Cesena et al., 2008). However, in contrast to these 
data, it has been demonstrated that the chicken C/EBPβ LAP* mutant K39A is 
resistant to methylation and thus repression by the G9a and has a hyperactive gene 
activation function (Pless et al., 2008). Here we showed that the mutant K39/K168A, 
bearing the mutation in the methylation/acetylation site K39A in combination with 
mutation in a second G9a targeted residue K168A in CR6 (our unpublished data), 
achieved myeloid reprogramming, meaning that reprogramming is independent of 
methylation/acetylation state of these residues. 
Among the deletion mutants we tested, the mutant ΔCR3,4 was the one which, 
similarly to the short WT isoform LIP, lost C/EBPβ reprogramming function (Fig. 3.1 
and 3.2). Interestingly, the important protein modules CR3 and CR4 showed 
redundancy, as the presence of any of them rescued C/EBPβ induced 
reprogramming. The observed redundant functions of C/EBPβ CR3 and CR4 during 
B cell reprogramming might be due to interaction with a protein partner which has 
binding sites to both regions, or differential interaction with two (or more) 
collaborating proteins. Moreover, CR3,4 in combination with the bZip was not 
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sufficient but depended on CR2 for B cell to myeloid cell reprogramming. (Fig.3.1), a 
discrepancy which might be due to improper protein conformation of C/EBPβ CR3,4. 
Similarly, dependence of the functionality of the repressive RD on the presence of 
CR6 has suggested the importance of CR6 for the maintenance of proper protein 
conformation (Kowenz-Leutz et al., 1994). Notably, CR3,4 exhibited severely 
impaired transactivating function (our unpublished data). Therefore, TAD CR2,3,4 
emerged to be the structural module of C/EBPβ responsible for its reprogramming 
function. 
CR2,3,4 represents the major TAD of C/EBPβ and entail several phosphorylation, 
methylation, and acetylation sites which are involved in multiple co-factor 
interactions. For example, C/EBPβ and p300 interact with each other through the N-
terminus of C/EBPβ and p300 acts as C/EBPβ co-activator (Lee et al., 2010a; Mink 
et al., 1997). C/EBPα is shown to interact with TBP and TFIIB via a bipartite 
functional domain in the N-terminus and sequence homology to CR3 and CR4 in 
C/EBPβ are evident (Nerlov, 2008; Nerlov and Ziff, 1995). The histone lysine 
methyltransferase G9a methylates C/EBPβ and abrogates its transactivation 
potential and the interaction between C/EBPβ and G9a has been shown to occur 
through CR4 (Pless et al., 2008). C/EBPβ interacts through CR3 and CR4 with 
protein arginine methyltransferase 4 (PRMT4) which dimethylates R3 in CR1 leading 
to abrogation of the interaction with SWI/SNF and Mediator complexes (Kowenz-
Leutz et al., 2010; Leutz et al., 2011). As discussed in the case of the RD, it will be 
necessary to unravel CR2,3,4 cell type specific PTMs and modification dependent 
interactome to mechanistically address the sequence of events involved in C/EBPβ 
mediated reprogramming. 
C/EBPβ is naturally expressed in lymphoid cells and C/EBPβ deficient B cells display 
proliferation defects (Chen et al., 1997). This suggests silencing of C/EBPβ 
reprogramming function in normal lymphoid cells through cell type specific repressor 
complexes or their subunits that are specifically expressed in B lymphoid lineage but 
not in myeloid cells. For example, MTA3, a cell specific subunit of the co-repressor 
complex Mi-2/NuRD, has been implicated in cell-type specific gene repression and 
differentiation regulation (Fujita et al., 2004; Fujita et al., 2003). Furthermore, another 
component of this complex, Mi-2, could function independently of NuRD and has 
been found as a component of other alternative chromatin remodelers (Kunert and 
Brehm, 2009), suggesting that one protein subunit could be involved in different 
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complexes and hence different cellular functions. The mammalian SWI/SNF complex 
has different cell type specific subunit composition (Reisman et al., 2009; Wang et 
al., 1996). Interestingly, intrinsically repressed or activated C/EBPβ protein 
differentially interacts with either transcriptionally repressive or active Mediator 
complexes composed of alternative subunits and that depends on the methylation 
status of C/EBPβ R3 residue (Kowenz-Leutz et al., 2010; Mo et al., 2004). It is 
tempting to believe that PTMs on C/EBPβ might direct the differential interaction with 
its protein partners and that might restrict C/EBPβ activation in B lymphoid cells, 
however overexpression of C/EBPβ, like during experimental reprogramming, can 
overcome the repression by these B cell specific factors. 
 
 4.3 Reciprocal regulation of lymphoid and myeloid markers during the 
reprogramming and independence from endogenous C/EBPβ 
Others groups have shown that reprogramming of B cells to myeloid cells is a 
gradual process, passing through an unstable bi-phenotypic intermediate state 
(Bussmann et al., 2009; Xie et al., 2004) and that was also valid for C/EBPβ long 
isoforms and mutants that we tested (Fig. 3.1, 3.2 and 3.3). These intermediate cells 
indicate that the lymphoid to myeloid conversion by C/EBPs does not involve retro-
differentiation to hematopoietic progenitor and stem cells which then differentiate into 
the myeloid lineage, but rather takes a trans-differentiation ‘shortcut’ through bi-
phenotypic intermediates (Di Tullio et al., 2011; Fukuchi et al., 2006). In this regard, 
C/EBPβ itself is most probably not sufficient to transform cells to leukemic ones and 
stabilize the bi-phenotypic state described in bi-phenotypic leukemias (Matutes et al., 
1997; Zhao et al., 2009). We can speculate that a second mutation is needed to 
stabilize the intermediates induced by C/EBPβ in the process of reprogramming and 
this might then contribute to bi-phenotypic leukemic transformation. It is important to 
note that involvement of C/EBPβ mutations in human cancers is very rare and 
C/EBPβ tumorigenic function is connected mainly to deregulation of the isoform 
expression ratio or overexpression due to translocations to IgH locus (Akasaka et al., 
2007; Vegesna et al., 2002; Zahnow, 2009). Furthermore, trans-differentiation of 
follicular lymphoma to histiocytic/DC sarcoma has been associated with high C/EBPβ 
expression, however in this case it is not clear whether this is a cause for or a 
consequence from the reprogramming (Feldman et al., 2008). Nevertheless, the 
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contribution of C/EBPβ induced reprogramming to leukemogenesis warrants further 
investigation. 
It has been shown that B lymphoid to myeloid conversion by C/EBPs is dependent on 
synergy with endogenous PU.1, leading to the upregulation of CD11b, and 
repression of B lineage commitment factor Pax5 and downregulation of its target 
CD19 (Bussmann et al., 2009; Xie et al., 2004). None of the C/EBPβ mutant 
constructs differentially either upregulated CD11b or downregulated CD19, 
respectively Pax5. We also did not observe reprogramming through a CD19/CD11b 
double-negative state instead of a double-positive state (Fig. 3.2). This is in 
agreement with the published data that higher levels of C/EBPs are needed to inhibit 
Pax5 function than to activate the myeloid program in B cells (Bussmann et al., 
2009). However, the kinetics of differential regulation of both CD19 and CD11b were 
delayed by C/EBPβ ΔCR1,2 and ΔCR4, as compared to LAP* (Fig. 3.1 and 3.2). This 
suggests that the C/EBPβ functions to antagonize Pax5 and to synergize with PU.1 
both reside in TAD and might rely on SWI/SNF and Mediator recruitment (Kowenz-
Leutz and Leutz, 1999; Kowenz-Leutz et al., 2010; Mo et al., 2004). Along these 
lines, the efficiency of LAP to downregulate CD19 as compared to LAP* was lower in 
trans-differentiating C/EBPβ deficient B cells (Fig. 3.5A, C). This suggests that both 
C/EBPβ functions to antagonize Pax5 and synergize with PU.1 in the activation of the 
myeloid program reside into TAD CR2,3,4, however, CR1 might further contribute to 
Pax5 repression. The LIP isoform, which acts as an inhibitor, not only failed to 
reprogram but also failed to downregulate CD19 expression, whereas it has been 
shown that lack of PU.1 disrupts CD11b upregulation by C/EBPs but not 
downregulation of CD19 (Bussmann et al., 2009; Xie et al., 2004). Accordingly, loss 
of B cell identity and activation of the myeloid program both require the C/EBP TAD 
but represent PU.1 independent and PU.1 dependent functions, respectively 
(Bussmann et al., 2009; Xie et al., 2004). 
Since it has been shown that C/EBPs can reprogram B cell progenitors towards 
myeloid cell fate, the question about the dependence of C/EBPα and C/EBPβ 
reprogramming on the endogenous C/EBPs has been raised (Xie et al., 2004). In the 
process of reprogramming of a murine fetal pre B cell line to macrophages by 
C/EBPα, the family members C/EBPβ and C/EBPδ are upregulated and the 
dominant negative inhibitor C/EBPγ is faintly downregulated. Endogenous C/EBPα, 
which initially remains silent, becomes upregulated when reprogramming is already 
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completed (Bussmann et al., 2009). Our experiments with C/EBPβ-/- primary B cell 
progenitors showed that endogenous C/EBPβ was dispensable during the 
reprogramming process by ectopic expression of C/EBPβ and C/EBPα (Fig. 3.5) 
supporting the idea that reprogramming by C/EBPβ is not a simple transactivation of 
its own endogenous promoter but a more complex process. 
 
 4.4 C/EBPβ and cell proliferation control 
Although uncoupling of CD19 downregulation from CD11b upregulation was not 
observed with any of the mutants examined, we achieved uncoupling of cell 
proliferation and trans-differentiation functions with some of the constructs. It has 
been observed that during B cell reprogramming the percentage of cells infected with 
C/EBPβ expands significantly over time compared to the control virus infected cells, 
whereas the percentage of C/EBPα infected cells decreases (Xie et al., 2004). 
Furthermore, C/EBPβ reprogrammed pre B cells exit the cell cycle with a delay 
compared to C/EBPα reprogrammed cells (Di Tullio and Graf, 2012). The current 
study confirms the proliferation stimulatory effect of C/EBPβ long isoforms as well as 
of C/EBPβ mutants during reprogramming. Interestingly, the deletion mutants 
ΔCR3,4 did not support reprogramming, yet still induced cell proliferation. PTM 
mutants with strong reprogramming potential (R60A, R43/48A; Fig. 3.6 and data not 
shown) did not support increased proliferation, suggesting that reprogramming 
function and proliferation control could be uncoupled. In this respect it is important to 
note that previously fat cell differentiation and proliferation arrest, induced by C/EBPα 
could be uncoupled, suggesting related underlying mechanisms of the C/EBP TADs 
in proliferation control (Muller et al., 1999). The observation that LIP did not support 
proliferation was surprising taking into account its proliferation enhancing function in 
mammary epithelial, breast cancer, and anaplastic large cell lymphoma cells (Gomis 
et al., 2006; Jundt et al., 2005; Zahnow, 2009). Furthermore, after partial 
hepatectomy C/EBPβΔuORF hepatocytes (lacking only LIP expression) display 
reduced proliferation, later cell cycle entry and persistent repression of E2F target 
genes (Wethmar et al., 2010). However, the effect of C/EBPβ and its isoforms on the 
cell proliferation is highly context specific, because in some cases C/EBPβ displays 
growth-promoting activity and in others growth arrest (Johnson, 2005; Nerlov, 2007; 
Sebastian and Johnson, 2006). C/EBPβ deficiency leads to a reduced number of BM 
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B lymphocytes which have also decreased expansion in long-term culture (Chen et 
al., 1997). Under adipogenic differentiation conditions C/EBPβ deficient mouse 
embryonic fibroblasts (MEFs) do not undergo mitotic clonal expansion but can be 
rescued by ectopic expression of C/EBPβ LAP but not by LIP (Tang et al., 2003). 
Overexpression of a dominant negative C/EBP that antagonizes all C/EBP family 
members leads to a dramatic inhibition of proliferation of myeloid cell lines, whereas 
it does not have an effect on the proliferation of T cell and erythroid cell lines, 
suggesting cell type specific effects of C/EBPs on proliferation (Iwama et al., 2002). 
C/EBPβ functions in concert with RB/E2F pathway to inhibit proliferation of MEFs 
(Sebastian et al., 2005). Recently it has been shown that overexpression of LAP* in a 
monocytic cell line leads to a proliferation inhibition through RB/E2F pathway, as 
reduced phosphorylation of RB protein and reduced expression of c-Myc, E2F1 and 
cyclin D1 has been found (Gutsch et al., 2011). We can speculate that the 
reprogrammed cells, originating from B cells, still keep the hallmarks of B cell 
proliferation stimulation by C/EBPβ, whereas at later time points C/EBPβ myeloid 
growth inhibitory effects might become predominant (Fig. 3.6 and data not shown). 
 
 4.5 C/EBPβ structure and PTMs determine the myeloid cell type 
differentiation decisions 
It has been suggested that C/EBPβ regulates the development of a variety of 
hematopoietic cell types in the myeloid compartment, including 
monocytes/macrophages, granulocytes and DCs (Akagi et al., 2008; Hirai et al., 
2006; Iwama et al., 2002; Tanaka et al., 1995). C/EBPα and C/EBPβ may reprogram 
B cell progenitors to CD11b+ F4/80+ Gr-1+ CD62L+ inflammatory macrophages (Xie 
et al., 2004). Similarly, C/EBPα and C/EBPβ reprogram T cell progenitors to CD11b+ 
Gr-1+ CD62L+ CD11c– MHC-II– F4/80– inflammatory macrophages, whereas PU.1 
reprograms the same cells to CD11b+ Gr-1– CD62L– CD11c+ MHC-II+ F4/80lo myeloid 
DCs (Laiosa et al., 2006b). Ectopical expression of C/EBPβ or α in myb-ets 
transformed hematopoietic progenitors induces eosinophil differentiation, and 
C/EBPβ induces additionally myeloblast differentiation (Nerlov et al., 1998). C/EBPα 
expression in CLPs reprograms them into neutrophils and monocytes/macrophages 
(Iwasaki et al., 2006). However, C/EBPs inhibit DC differentiation, as it has been 
shown that C/EBPα and β promote granulocytic and monocyte/macrophage 
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differentiation at the expense of Langerhans DC differentiation (Iwama et al., 2002). 
However, that C/EBPβ may induce trans-differentiation of primary B cell progenitors 
into myeloid cell types other than macrophages has not been reported, even when 
the culture medium was supplied with G-CSF and GM-CSF, instead of M-CSF, 
although these reprogrammed macrophages expressed G-CSFR mRNA (Xie et al., 
2004). The discrepancy with our results might be explained by the previous use of 
the C/EBPβ LAP isoform (which basically omits granulocytic trans-differentiation) (Xie 
et al., 2004) or differences in culturing conditions, such as prevention of cell contact 
between B cells and feeder cells in our system. Moreover, even though we 
supplemented the cultures only with M-CSF, the stromal cells might also have 
provided cytokines supporting granulocytic and DC differentiation. Furthermore, Flt-
3L supplied to the cell culture can drive the differentiation of mouse hematopoietic 
BM progenitors into DCs in vitro. Interestingly, we observed typical DC clustering 
(Bakri et al., 2005; Manz et al., 2001) only in the cultures trans-differentiated by LAP 
and CR2,3,4 (data not shown). However, no differences in the cell differentiation 
outcome were seen when Flt-3L was omitted from the cultures (data not shown). 
Interestingly, studies have shown that M-CSF also has the capacity to support cDC 
and pDC differentiation in vitro in the absence of Flt-3L and in vivo in Flt-3L deficient 
mice, although M-CSF might not be as potent DC inducer as Flt-3L (Fancke et al., 
2008). 
Flt-3 and its ligand Flt-3L are key regulators of DC development and it has been 
shown that mTOR can act as a mediator of Flt-3L signaling in DCs. Adding mTOR 
inhibitor rapamycin into Flt-3L supplemented BMC cultures significantly reduces the 
number of all DC subsets, whereas rapamycin does not affected GM-CSF induced 
DC development in liquid culture (Sathaliyawala et al., 2010). In contrast, deletion of 
phosphatidylinositol 3-kinase (PI3K) - mTOR negative regulator Pten enhances Flt-
3L induced DC development (Sathaliyawala et al., 2010). Other studies have shown 
that mTOR signaling is important for the survival and proper differentiation of the 
monocyte-derived DCs and short-time inhibition of mTOR reduces their immune-
stimulatory features, whereas inhibition of mTOR does not negatively affect the cDCs 
differentiation (Haidinger et al., 2010). The inhibition of DC development by 
rapamycin treatment is in agreement with the published data that mTOR pathway 
inhibition influences C/EBPβ isoform ratio increasing the production of the long 
isoforms (Smink et al., 2009; Smink et al., 2012) and that C/EBPβ promotes 
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granulocytic and monocyte/macrophage differentiation from human CD34+ cells and 
disrupts Langerhans DC differentiation (Iwama et al., 2002). Similarly, it has been 
shown that C/EBPβ direct target gene, the bZip transcription factor MafB (Smink et 
al., 2009), favors macrophage fate over DC differentiation (Bakri et al., 2005). 
Therefore, all current data support the idea that C/EBPβ long isoforms are acting as 
inhibitors of DC differentiation, whereas neutralization of the long isoforms through 
dominant negative C/EBP induces DC differentiation. Hence, the observed DC 
stimulatory function by C/EBPβ might be due to overcome DC repressive function 
through a counteracting protein, like for example the short isoform LIP or the 
negative regulator C/EBPγ, or due to a cell type specific effect, as all of the above 
mentioned experiments were performed in hematopoietic progenitor cells or myeloid 
precursors (Bakri et al., 2005; Iwama et al., 2002) but not in the context of the B cell 
specific transcription factor network. 
Our data show that C/EBPβ isoforms and mutants may reprogram B cells to different 
myeloid cell lineages including granulocytes (Ly-6C+ Ly-6G+ M-CSFR–), inflammatory 
monocytes/macrophages (Ly-6C+ M-CSFR+), resident monocytes/macrophages (Ly-
6C– M-CSFR+) and cDCs (Ly-6C– M-CSFR– CD11c+ MHC-II+/++ CD86+/med) (Fig. 3.10 
and 3.11). C/EBPβ has been shown to directly bind to CD11c gene regulatory 
elements (Lopez-Rodriguez et al., 1997), however the CD11c+ DC phenotype does 
not seem a single marker activation, as those reprogrammed CD11c+ cells also 
expressed very high amounts of MHC-II and CD86, which are typical features of 
DCs. However, within the myeloid cell pool, DCs and macrophages might share 
common markers, as they share a common precursor, which might make it difficult to 
assign them to one of these cell types (Geissmann et al., 2010). In accordance to 
that we detected high surface expression of CD11c and MHC-II and medium 
expression of CD86 on the population assigned as resident monocytes/macrophages 
(Ly-6C– M-CSFR+), as well as low expression of CD11c, MHC-II and CD86 on the 
Ly-6C+ M-CSFR+ cells. Recently it has been shown that under sterile inflammatory 
conditions, both Ly-6C+ and Ly-6C– spleen monocytes can acquire a DC surface 
phenotype with high expression of CD11c, MHC-II and co-stimulatory molecules, 
while simultaneously keeping monocytic lineage characteristics like M-CSFR 
expression, phagocytic function and poor antigen presentation, raising the possibility 
that activated monocytes might express DC surface markers without conversion into 
DCs (Drutman et al., 2012). Furthermore, under inflammatory conditions monocytes 
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can differentiate into monocyte-derived DCs, which similarly to cDCs express CD11c 
and MHC-II, however lose the expression of M‑CSFR and Ly-6C (Belz and Nutt, 
2012) suggesting that the reprogrammed resident monocyte/macrophage population 
could have undergone initial steps towards monocyte-derived DCs differentiation. 
Although the phagocytosis assay confirmed the presence of functional heterogeneity 
among the reprogrammed cells, other functional analyses (e.g. mixed lymphocyte 
reaction) will be required to prove the functionality of these CD11c+ cells. 
Interestingly, lineage plasticity, shared lineage marker features and capacity of inter-
conversion are observed not only between monocytes/macrophages and DCs but 
there is evidence that it might be a common characteristic of the cells from the 
myeloid lineage to gain properties of the other myeloid cell types. For example, Ly-
6G+ granulocytes can be trans-differentiated into F4/80+ macrophage-like cells upon 
M-CSF stimulation (Sasmono et al., 2007). Furthermore, it has been shown that after 
incubation with T cells, mouse neutrophils can upregulate the expression of MHC-II 
and co-stimulatory molecules CD80 and CD86 and can present antigens to trigger T 
cell activation, suggesting that granulocytes can also acquire DC properties under 
certain conditions (Abi Abdallah et al., 2011). 
It has been shown that Ly-6C/Gr-1+ and Ly-6C/Gr-1– monocytes/macrophages differ 
in additional surface marker expression, gene expression profiles, biological 
functions and differentiation plasticity (Arnold et al., 2007; Auffray et al., 2007; 
Geissmann et al., 2003; Geissmann et al., 2010; Nahrendorf et al., 2007). For 
example, during skeletal muscle regeneration two monocyte/macrophage subsets 
sequentially emerge. Initially, Ly-6C+ cells, which express higher levels of Il1b and 
Tnf mRNA and therefore exhibit pro-inflammatory properties, are recruited and they 
convert later on into anti-inflammatory Ly-6C– monocytes/macrophages, which 
express higher levels of Tgfb1, Il10 and Pparg (Arnold et al., 2007). Furthermore, 
analysis of differentiation markers have shown that Ly-6C– anti-inflammatory 
monocytes/macrophages express CD11c and higher levels of F4/80 but are negative 
for the DC marker DEC-205, suggesting that Ly-6C– cells display high levels of 
macrophage differentiation markers compared to Ly-6C+ cells (Arnold et al., 2007). In 
another study, it has been shown that Gr-1– monocytes might acquire M2 anti-
inflammatory macrophage phenotype, whereas Gr-1+ monocytes differentiate into 
DCs (Auffray et al., 2007). Furthermore, the healing myocardium sequentially 
mobilizes two monocyte subsets, Ly-6Chi monocytes with inflammatory properties, 
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exhibiting higher MMP-2, -3, -9, and -13 proteinase activities and higher production of 
the pro-inflammatory cytokine TNF-α, whereas Ly-6Clo monocytes promote healing 
and angiogenesis and express higher levels of vascular endothelial growth factor 
(VEGF) (Nahrendorf et al., 2007). Under inflammatory and noninflammatory 
conditions, both Gr-1hi and Gr-1low blood monocytes can give rise to lung DCs, 
however only Gr-1low monocytes can differentiate into lung macrophages whereas 
Gr-1hi monocytes gain this capability after conversion into Gr-1low monocytes 
(Landsman et al., 2007). An additional layer of complexity is added by the finding that 
Listeria monocytogenes infection induces the recruitment of Ly-6C+ monocytes to the 
spleen where they differentiate into TNF-α and iNOS (Nos2)-producing Tip-DCs, 
providing further evidence for the relationship between monocyte/macrophages and 
DCs (Serbina et al., 2003). 
As mentioned before, Ly-6C+ monocytes can convert into Ly-6C– monocytes (Arnold 
et al., 2007; Drutman et al., 2012; Sunderkotter et al., 2004) and in our experiments 
comparison between 6 and 9 days reprogramming suggested a similar scenario (Fig. 
3.10). The observed decrease in the percentage of Ly-6C+ M-CSFR+ cells was not 
due to a higher apoptosis of the Ly-6C/Gr-1+ cells (Fig. 3.9). Furthermore, our data 
also suggested that at least some of the DC outcome might have resulted through 
differentiation from inflammatory or resident monocytes/macrophages, as DC 
representation also increased from day 6 to day 9. This is supported also by the 
observation that DC markers are expressed on the reprogrammed Ly-6C– M-CSFR+ 
resident monocytes/macrophages (Fig. 3.12). Another possibility is that the DC 
reprogramming had a delayed kinetics compared to monocyte/macrophage one, as 
on day 6 only a minority of the reprogrammed CD11b+ cells had DC characteristics, 
whereas on day 9 about quarter to half of the reprogrammed cells were CD11b+ Ly-
6C– M-CSFR– CD11c+ which might have emerged from cells that were GFP+ CD11b– 
on day 6. One can also not exclude expansion of the DC population from day 6 to 
day 9 due to higher proliferation of these cells as compared to the other myeloid 
populations. 
Comparison between surface marker expression, cell morphology and gene 
expression revealed that phenotypic differences seen between the cells 
reprogrammed by C/EBPβ WT or mutants correlated with differences in gene 
expression profiles (Fig. 3.7, 3.10, 3.11 and 3.13). For example, LAP* and ΔCR3 
showed similar surface marker expression and morphology, additionally they had 
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similar macrophage gene expression pattern (Fig. 3.7 and Table S2). On the other 
hand, Δ CR4 and Δ CR1,2 failed to upregulate certain M1 and M2 genes, as 
compared to LAP* and ΔCR3, suggesting a more immature phenotype, impaired 
macrophage gene activation or alternative reprogramming into DCs. Comparison 
between the genes activated by LAP*, LAP and ΔCR1,2 nevertheless revealed that 
several macrophage polarization genes might depend on SWI/SNF recruitment. 
Notably, LAP and ΔCR1,2 were the constructs which, compared to LAP*, showed 
significantly lower induction of Gr-1/Ly-6C+ cells (Table 3.1 and data not shown), 
suggesting that the differences seen in the surface marker expression reflected 
differences in macrophage gene activation. Interestingly, the granulocytic 
differentiation during B cell reprogramming was also dependent on the presence of 
CR1, as no neutrophil granulocytic differentiation was induced by LAP, CR2,3,4 and 
ΔCR1,2 (Fig. 3.10 and 3.13). This is in agreement with our previous results showing 
that activation of the neutrophil elastase gene in fibroblasts by C/EBPβ depends on 
its ability to recruit SWI/SNF which is, in turn, dependent on signal induced alteration 
in phosphorylation and arginine methylation (Kowenz-Leutz et al., 2010). Hence, our 
data support the notion that distinct CRs in C/EBPβ might be responsible for cell fate 
decisions by differential regulation of distinct genes. 
As it was already emphasized, macrophages can exhibit a high level of plasticity and 
in response to environmental signals could be polarized into classically activated M1 
and alternatively activated M2 macrophage phenotypes which have distinct biological 
functions and different gene expression profiles (Biswas and Mantovani, 2010; 
Mantovani et al., 2002; Solinas et al., 2009). Deregulation of many pro-inflammatory 
M1 genes upon LPS/IFNγ stimulation has been found in C/EBPβ deficient 
macrophages (Il6, Tnf, Nos2 and Il1b are downregulated, whereas Il12b is 
upregulated) (Akagi et al., 2008; Gorgoni et al., 2002). Furthermore, it has been 
shown that inflammatory stimuli lead to upregulation of M1 and M2 genes in WT BM 
derived macrophages, however, prevention of CREB-mediated C/EBPβ upregulation 
affects activation of M2 genes (Msr1, Il10, Il13ra and Arg1), but not M1 genes (Il1b, 
Il6, Il12b and Tnf) (Ruffell et al., 2009). However, it is widely accepted that the 
concept of M1 and M2 polarized macrophage phenotypes might reflect the extremes 
of a spectrum of functional macrophage states and an operational oversimplification 
of various intermediate phenotypes (Biswas and Mantovani, 2010; Mantovani, 2008; 
Mosser and Edwards, 2008). Furthermore, macrophages can exhibit a remarkable 
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plasticity in response to environmental signals and change their functional state and 
macrophage plasticity is considered as a complication when investigating 
macrophage polarization (Biswas and Mantovani, 2010; Cassetta et al., 2011). For 
example, LPS stimulation of IFNγ treated BM derived macrophages enhances the 
expression of the M1 gene Nos2 without inducing detectable expression of the M2 
gene Arg1, whereas LPS stimulation of IL-4 treated BM derived macrophages 
induces simultaneously Nos2 and Arg1 expression, suggesting that the pattern of 
macrophage polarization gene expression might shift upon changes in the cytokine 
environment and that M1 and M2 macrophage polarization genes can be 
simultaneously activated upon treatment with a type 2 cytokine and LPS (Stout et al., 
2005). Our mRNA expression analyses showed that C/EBPβ reprogrammed cells 
have upregulated simultaneously M1 and M2 genes and did not show M1 or M2 bias 
(Fig. 3.7 and Table S2). For example the already mentioned Nos2 and Arg1 were 
both upregulated by LAP*, ΔCR3 and ΔCR6, whereas ΔCR1,2 and ΔCR4 did not 
upregulate either of them. Interestingly, concomitant expression of Nos2 and Arg1 is 
a feature of regulatory macrophages, which are further characterized by high Il10 
expression and low Il12 expression, however the lack of Il10 expression on C/EBPβ 
reprogrammed cells argues against differentiation into regulatory macrophages in our 
experimental system (Cassetta et al., 2011; Mosser and Edwards, 2008). 
Furthermore, the phenotype of the reprogrammed cells might resemble those of 
LPS/IFNγ stimulated macrophages, as it has been shown that inflammatory stimuli 
lead to upregulation of C/EBPβ and sequential activation of M1 and M2 genes in WT 
BM derived macrophages (Ruffell et al., 2009). This is in agreement with C/EBPβ 
protein expression data showing that C/EBPβ is overexpressed in the reprogrammed 
cells to levels higher than in M-CSF derived macrophages (Fig. 3.4B). However, we 
do not exclude the possibility that the reason we did not see a clear M1/M2 
macrophage polarization might be due to the fact that our sorted CD11b+ 
reprogrammed cells gave rise to mixed cell populations consisting not only of 
monocytes/macrophages, however also of DC-like cells and granulocytes, which can 
also produce pro- and anti-inflammatory cytokines (Mantovani et al., 2011; Shey et 
al., 2012). Furthermore, it has been shown that monocytes can differentiate under 
certain conditions in vivo and in vitro to a subtype of inflammatory DCs, the so-called 
Tip-DCs characterized by high TNF-α and NOS2 production (Serbina et al., 2003). 
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Interestingly, the genes coding for the two subunits of the IL-12 cytokine - Il12b (p40) 
and Il12a (p35) are shown to be both C/EBPβ target genes, however they have 
opposite regulation - Il12a is C/EBPβ activated gene, whereas Il12b is repressed by 
C/EBPβ (Gorgoni et al., 2002). Our gene expression data showed that Il12b M1 gene 
was consistently upregulated only by LAP* but not by the other constructs (LAP 
reprogrammed cells showed inconsistent Il12b expression levels). Experiments using 
macrophages from C/EBPβM20A/M20A knock-in mice (lacking the expression of LAP) 
have shown that, similarly to C/EBPβ-/- genotype, these macrophages overexpress 
Il12b, suggesting that Il12b is a gene repressed by C/EBPβ LAP (Uematsu et al., 
2007). However our gene expression data showed that Il12b was activated by 
C/EBPβ LAP* supporting the idea of the existence of non-overlapping and even 
opposite functions of the two C/EBPβ long isoforms. 
Epigenetic studies have shown a relation between cytokine induced monocyte 
polarization, MAPK activation and H4 acetylation, proposing one potential 
mechanism for acquisition and maintenance of the macrophage polarization (Zhang 
et al., 2011). Other studies have shown the existence of a molecular pathway 
responsible for epigenetic regulation of murine key M2 polarization genes including 
Chitinase 3-like 3 (Chi3l3, also known as Ym1), Retnla, and Arg1. IL-4 stimulation 
leads to up-regulation of the lysine-specific demethylase 6B Kdm6b (Jmjd3), resulting 
in decreased H3K27 methylation (a modification correlated with transcriptional 
repression) at the promoters of M2 genes (Ishii et al., 2009). Furthermore, it has 
been found that Kdm6b is a gene essential for M2 but not M1 macrophage 
polarization in response to helminth infections (Satoh et al., 2010). Our data showed 
that Kdm6b was expressed by all C/EBPβ reprogrammed myeloid cells, although the 
highest expression levels were detected in LAP* reprogrammed cells (Table S2). 
Furthermore, M2 genes whose expression is dependent on Kdm6b, like Arg1 and 
Chi3l3, were expressed by LAP*, ΔCR3, ΔCR4 and ΔCR6. Interestingly, LAP and 
ΔCR1,2 which showed lower activation of Kdm6b gene, as compared to LAP*,  both 
failed to up-regulate Chi3l3, and Arg1 was not expressed in ΔCR1,2 reprogrammed 
cells (Fig. 3.7 and Table S2). Chi3l3 and Arg1 are key M2 genes involved in 
extracellular matrix remodeling. Arg1 codes for the enzyme Arginase1, which 
redirects the arginine metabolism towards polyamine synthesis and promotion of 
tissue regeneration (Biswas and Mantovani, 2012; Mosser and Edwards, 2008). 
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CHI3L3 is chitinase-like molecule, which lacks chitin-degrading activity, however it 
has carbohydrate and matrix-binding activity suggesting its role in matrix 
reorganization and tissue repair (Mosser and Edwards, 2008). Thus, our results 
support published data showing the dependence of certain M2 genes on Kdm6b 
chromatin modifying activity. 
Interestingly, except the strong activation of Maf by LAP, all constructs upregulated 
Mafb and Maf to a lesser extend as seen in WT and C/EBPβ-/- macrophages. This is 
in agreement with the published data showing that M2 polarized macrophages (which 
are similar to M-CSF differentiated macrophages) have much higher expression of 
Maf, as compared to M1 macrophages (Martinez et al., 2006). Furthermore, high 
Mafb and Maf expression has been associated with M2 macrophage differentiation 
from Gr-1– monocytes, whereas low Mafb and Maf expression and high PU.1 
expression has been associated with inflammatory DC differentiation from Gr-1+ 
monocytes (Auffray et al., 2007). The low Mafb and Maf expression might explain the 
fact that we still observed cell proliferation between 6 and 9 days reprogramming 
(Fig. 3.6). However, our data do not support the idea that C/EBPβ reprogrammed 
cells are identical with unrestrictedly proliferating Mafb/Maf double-knock out 
macrophages (Aziz et al., 2009), as we failed to detect cell proliferation after 2 weeks 
of reprogramming in M-CSF supplemented medium (data not shown). Furthermore, 
during B cells to macrophage reprogramming by C/EBPα the expression of Mafb and 
Maf is also not upregulated (Bussmann et al., 2009), however, cell proliferation is 
inhibited, as compared to the controls and C/EBPβ reprogrammed cells (Xie et al., 
2004). Furthermore, overexpression of LAP* in monocytic cells inhibits cell 
proliferation (Gutsch et al., 2011) probably through other, Maf-independent routes 
(Nerlov, 2007; Zaragoza et al., 2010). 
It is widely accepted that the interplay including collaboration and antagonism 
between C/EBPs and other key myeloid transcription factors, in particular PU.1, is 
crucial for the cell fate decisions in the myeloid lineage and this might also determine 
the differential outcome from B cell to myeloid reprogramming by C/EBPβ (Bakri et 
al., 2005; Bussmann et al., 2009; Iwama et al., 2002; Laiosa et al., 2006b; Xie et al., 
2004; Yeamans et al., 2007). In our reprogramming system those cells that 
accomplished high ectopical C/EBPβ expression, but medium/low PU.1 activation, 
might have become granulocytes. Interestingly, C/EBPβ-/- hematopoietic progenitor 
cells have impaired response to G-CSF and GM-CSF and C/EBPβ deficient 
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neutrophils exhibit increased apoptosis ((Akagi et al., 2008; Hirai et al., 2006) and 
Fig. 3.16). Additionally, SWI/SNF recruitment might be necessary for efficient 
granulocytic gene activation, as shown for the neutrophil elastase gene (Kowenz-
Leutz et al., 2010). Other cells that achieved intermediate PU.1 activation, high 
ectopical C/EBPβ expression and high expression of the C/EBPβ target gene Mafb 
might have differentiated into macrophages (Bakri et al., 2005). Among the 
macrophage genes, M2 genes need higher C/EBPβ expression than M1 genes 
(Ruffell et al., 2009). In consensus with that it has been shown that Mafb and Maf are 
higher expressed in Gr-1– monocytes differentiating into M2 macrophages than in Gr-
1+ monocytes giving rice to DCs (Auffray et al., 2007). Finally, the cells that achieved 
relatively lower C/EBPβ expression and hence lower MafB expression, however 
expressed high levels of PU.1 might have differentiated into DCs (Bakri et al., 2005; 
Iwama et al., 2002). The low C/EBPβ/MafB expression levels might be accomplished 
physiologically during DC differentiation through the Flt-3 signaling for which it has 
been shown that it leads to mTOR activation (Sathaliyawala et al., 2010), resulting in 
a decrease of the translation of the long C/EBPβ isoforms whose directly activated 
target gene is Mafb (Smink et al., 2009). Furthermore, other factors, like IRF8 should 
be also considered as potential key players in the myeloid cell fate decisions 
(Rosenbauer and Tenen, 2007). The fact that we have obtained relatively few trans-
differentiated cells however precluded a more detailed gene profiling study, which will 
also require separation of the different myeloid subpopulations by flow cytometric 
sorting. Nevertheless, it may be possible to generate sufficient cells with some of the 
C/EBPβ constructs that will enable us in the future to examine prevalence of key 
lineage determining factors, such as PU.1 and IRF8 or specific miRNA profiles 
(Baltimore et al., 2008). 
Our data showed that Irf8 deficiency affected the early steps of the reprogramming 
and M-CSFR+ cells were a minority (Fig. 3.15) in accordance to published data 
(Kallies et al., 2002). Later on, however, ectopical C/EBPβ expression overruled Irf8 
deficiency and little differences in the macrophage reprogramming outcome were 
observed. Of note, some differences in the trans-differentiation to Ly-6C+ M-CSFR+ 
monocytes/macrophages appeared, as previously shown (Becker et al., 2012) (Fig. 
3.15A). It is important to mention that we were able to obtain BM derived 
macrophages from Irf8-/- BM cells and these macrophages showed no difference in 
the expression of M-CSFR compared to WT (data not shown). Although this is not a 
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quantitative result, as the macrophage differentiation might be due to an overgrowth 
of a small fraction of cells having the capacity to produce macrophages, this anyway 
suggests that Irf8-/- BM can give rise to M-CSFR+ macrophages. This is supported by 
recent finding that Irf8 deficient mice still contain M-CSFR+ monocytes in BM, blood 
and spleen, although their numbers might be reduced, as compared to WT mice 
(Becker et al., 2012). 
 
 
 
Fig. 4.1 The structure of C/EBPβ defines the outcome from B cell to myeloid lineage 
reprogramming 
A. Simplified scheme of physiological hematopoietic lineage development (black arrows). Ectopical 
expression of C/EBPβ LAP* transcription factor in B cell progenitors leads to their reprogramming to 
monocytes/macrophages, DC and granulocytes (red arrows). B. Lack of CR1 in C/EBPβ (as in LAP, 
CR2,3,4 and	   ΔCR1,2) leads to abrogation of the granulocytic differentiation at the expense of an 
increase of the differentiation of the other myeloid cell types during B cell reprogramming. HSC – 
hematopoietic stem cells, CLP – common lymphoid progenitors, CMP – common myeloid progenitors, 
B – B lymphoid lineage, MPh – macrophages, DC – dendritic cells, Gr – neutrophil granulocytes. 
 
Our current data showed that ectopic expression of LAP* led to the trans-
differentiation of the primary B cell progenitors into granulocytes, inflammatory and 
resident monocytes/macrophages and DCs (Fig. 4.1). The other C/EBPβ long 
isoform LAP and the mutants CR2,3,4 and Δ CR1,2 lacking CR1 of TAD did not 
induce granulocytic differentiation, which suggests requirement for SWI/SNF 
recruitment for granulocyte cell differentiation program activation (Kowenz-Leutz et 
al., 2010). Other mutants like ΔCR6 showed increased granulocytic differentiation at 
the expense of the other populations (Fig. 3.11 and 3.13). However, not only certain 
protein regions (CRs) in C/EBPβ transcription factor were responsible for the 
instruction of distinct cell fates but we linked this observation to point mutations that 
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have been shown to reflect distinct signaling functions, such as modification by G9a 
(the K38/168A mutant), SUMOylation/methylation (as with the Δ CR6 mutant and 
previously with the methylation defective/mimicking R3A/R3L mutants involved in 
differential SWI/SNF recruitment (Kowenz-Leutz et al., 2010)) (Fig. 3.11, 3.13 and 
3.14). These conclusions are supported by the observation that SUMOylation on 
C/EBPα is responsible for erythroid versus granulocytic lineage decisions during 
primitive hematopoiesis in zebrafish and C/EBPα in hypoSUMOylated state exhibits 
enhanced inhibition of GATA1 transcriptional activity and skews progenitor cell 
differentiation towards granulopoiesis (Yuan et al., 2011). Similarly, it has been 
shown that phosphorylation or phosphomimetic mutation in CR2 in C/EBPα inhibits 
granulocytic differentiation from retinoic acid treated bi-potential myeloid cell line, 
however the monocytic differentiation is not blocked, suggesting that phosphorylation 
on C/EBPα does not generally restrain differentiation but rather diverts cell fate 
decisions (Ross et al., 2004). Knockdown of SUMO conjugating enzyme UBC9 leads 
to impairment of adipocyte differentiation (Cignarelli et al., 2010). Therefore, PTMs 
could be a potential mechanism how C/EBPβ accomplishes differentiation to 
alternative myeloid cell types like monocyte/macrophage, granulocyte or DCs. 
 
 4.6	  C/EBPβ, cytokine signaling and granulocytic differentiation 
The exact role of C/EBPβ in G-CSF and GM-CSF signaling is not completely 
clarified, however, current evidence suggests involvement of C/EBPβ in the cytokine 
signaling leading to granulocytic differentiation. On one hand, C/EBPβ binding sites 
are found in the regulatory regions of genes coding for G-CSF and the receptors G-
CSFR, GM-CSFR and M-CSFR (Tsukada et al., 2011). It has been shown that lack 
of all C/EBPβ isoforms or LAP deficiency leads to decreased G-CSF production from 
LPS-stimulated C/EBPβ-/- and C/EBPβM20A/M20A (lacking LAP isoform) macrophages 
compared to WT macrophages (Tanaka et al., 1995; Uematsu et al., 2007). 
However, M-CSF and GM-CSF mRNA expression is not affected in C/EBPβ deficient 
macrophages upon inflammatory stimuli (Gorgoni et al., 2002; Tanaka et al., 1995). 
On the other hand, C/EBPβ deficiency in BM hematopoietic cells leads to impaired 
G-CSF and GM-CSF responses (Akagi et al., 2008; Hirai et al., 2006). However no 
difference in G-CSFR and GM-CSFR mRNA in C/EBPβ-/- and WT total BMC has 
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been seen (Hirai et al., 2006). Furthermore, C/EBPβ-/- neutrophils display an 
increased apoptosis compared to WT neutrophils (Akagi et al., 2008).  
G-CSF is an essential cytokine for the growth and production of neutrophil 
granulocytes and their precursors and it signals through a homodimeric cytokine 
receptor G-CSFR, which leads to activation of Jak2 and/or Jak3 and subsequent 
phosphorylation and activation of STAT3. G-CSF signaling might also lead to 
activation of other pathways, like PI3K - AKT (also known as Protein Kinase B, PKB), 
or Ras-MAPK (Baker et al., 2007). However, despite the impaired G-CSF responses, 
no difference in STAT3 phosphorylation has been seen between C/EBPβ+/- and 
C/EBPβ-/- BMC stimulated with G-CSF (Akagi et al., 2008). 
C/EBPβ is an auto-repressed transcription factor whose N- and C-terminus physically 
interact. Signaling through Ras-MAPK pathway leads to phosphorylation of C/EBPβ 
on an evolutionary conserved MAPK consensus site in RD CR7 and this 
phosphorylation results in protein activation (Kowenz-Leutz et al., 1994). Glycogen 
synthase kinase-3β (GSK-3β) has also been shown to phosphorylate C/EBPβ and to 
modify its functionality (Tsukada et al., 2011; Zahnow, 2009). One can hypothesize 
that G-CSF and/or GM-CSF signaling might, through Ras-MAPK pathway, or 
regulation of GSK-3β activity, or other signaling pathway, lead to acquirement of 
PTMs on C/EBPβ which might change its activity on target genes. These PTMs on 
C/EBPβ might include not only phosphorylation but also protein methylation, a PTM 
associated with a negative impact on C/EBPβ target gene activation (Kowenz-Leutz 
et al., 2010; Leutz et al., 2011; Pless et al., 2008). For example methylation-
mimicking mutant of LAP* – R3L - shows inability to activate neutrophil elastase gene 
in fibroblasts and to induce adipocyte differentiation (Kowenz-Leutz et al., 2010). 
Furthermore, a crosstalk between C/EBPβ PTMs has been shown, as Ras/MAPK 
phosphorylation of C/EBPβ CR7 abrogates the interaction with PRMT4, the 
methyltransferase which methylates R3 (Kowenz-Leutz et al., 2010). 
It has been shown that fetal and adult definitive hematopoiesis share common 
characteristics, however they also differ. For example fetal and adult HSC have 
phenotypical and functional differences: fetal HSCs are largely cycling, they undergo 
symmetric cell divisions and have an increased long-term repopulation compared to 
adult BM HSCs when transplanted into irradiated recipients (Harrison et al., 1997; 
Lessard et al., 2004). Fetal and adult HSC have a distinct transcriptional regulation 
and different surface marker profiles and FL hematopoiesis, in contrast to adult 
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hematopoiesis, involves mainly erythropoiesis and myelopoiesis, while lymphopoiesis 
is reduced (He et al., 2011; Lessard et al., 2004; Mikkola and Orkin, 2006). 
Furthermore, Il7ra-/- fetal HSCs but not adult BM HSC are capable of differentiation 
into B cells, suggesting that IL-7 is dispensable for FL B cell development (Kikuchi 
and Kondo, 2006). These altogether underline the necessity of a detailed 
characterization of the fetal hematopoiesis regulation and comparison between FL 
and BM definitive hematopoiesis. 
Comparison between G-CSF and GM-CSF responses of FL and adult BM 
hematopoietic progenitor cells showed a developmentally conserved function of 
C/EBPβ in cytokine induced granulocytic differentiation. FL cells, similarly to their BM 
counterparts, showed impaired G-CSF and GM-CSF responses (Fig. 3.16). Although 
we did not go into any further details to analyze the molecular basis of the 
dependence of G-CSF and GM-CSF responses of FL cells on the presence of 
C/EBPβ, our current data and data from other labs point out that C/EBPβ is a crucial 
factor in granulocyte differentiation and possibly a key molecule in G-CSF and GM-
CSF signaling (Akagi et al., 2008; Hirai et al., 2006; Jones et al., 2002). Similar 
function has been proposed for PU.1 in TNF-α and GM-CSF-induced DC 
differentiation in liquid culture (Bakri et al., 2005; Iwama et al., 2002). Interestingly, it 
has already been shown that C/EBPβ is a crucial intracellular mediator of IL-7 
signaling and its deficiency leads to impaired proliferative responses of BM B 
lymphocyte progenitors to IL-7 (Chen et al., 1997). 
Results presented here also show that the C/EBPβ structure and PTMs determined 
the outcome of B cell to myeloid cell reprogramming, revealing that some C/EBPβ 
mutants completely abrogated neutrophil granulocytic differentiation, while others 
increased the granulocytic outcome of the reprogramming. Interestingly, our data 
related the granulocytic differentiation to C/EBPβ CR1 (Fig. 4.1), suggesting 
dependence of the granulocytic differentiation on SWI/SNF recruitment (Kowenz-
Leutz and Leutz, 1999) and potentially linking G-CSF and GM-CSF signaling to 
chromatin remodeling. One can speculate that in myeloid progenitor cells, 
granulocytes, macrophages and DCs C/EBPβ might have a different PTM pattern 
which determines the cell fate decisions through changing the activation state, 
interactome or cellular localization of C/EBPβ. This hypothesis should be examined 
through obtaining C/EBPβ protein from highly purified by FACS sorting GMP, 
granulocytic, monocytic, macrophage and DC populations and subsequent mass 
Discussion 
100 
spectrometric analyses. These data will complement the current data obtained 
through the reprogramming system and will shed light on the variety of mechanisms 
involved in regulation of C/EBPβ functions. 
 
 4.7 Concluding remarks and future directions 
Cell fate decisions are defined by synergistic and/or antagonistic action of 
transcription factors, as well as their dosage and temporal sequence of expression 
(DeKoter and Singh, 2000; Hsu et al., 2006; Iwasaki et al., 2006; Laiosa et al., 
2006a). Studies have also shown distinct roles of different protein isoforms of 
C/EBPs (Bedi et al., 2009; Smink et al., 2009; Uematsu et al., 2007; Wethmar et al., 
2010). Using B cell lineage to myeloid lineage trans-differentiation approach, we 
were able to show that TAD CR2,3,4 is the essential protein module for C/EBPβ 
reprogramming function, responsible for both its B cell extinguishing and myeloid fate 
activating function. Interestingly, C/EBPβ structural and PTM site mutations led to 
different reprogramming outcomes, suggesting a potential mechanism for 
accomplishment of alternative myeloid cell fates by C/EBPβ. 
C/EBPβ function in the macrophage differentiation, polarization and functionality is 
well known (Gorgoni et al., 2002; Gutsch et al., 2011; Ruffell et al., 2009; Tanaka et 
al., 1995). Our data also bring the attention to an often underestimated, however 
important function of C/EBPβ during granulopoiesis. Despite the fact that C/EBPα is 
considered to be the master regulator of granulopoiesis, the importance of C/EBPβ 
during granulocytic differentiation should not be neglected (Hirai et al., 2006; Jones 
et al., 2002; Zhang et al., 1997) and this is also supported by our data (Fig. 3.11, 
3.13 and 3.16). Furthermore, in contrast to previous studies (Bakri et al., 2005; 
Iwama et al., 2002), our data suggest that C/EBPβ can act as a positive regulator of 
DC differentiation. One possible reason for these discrepancies might be that 
different set of transcription factors are expressed in B cells versus BM progenitors 
and that C/EBPβ might take advantage of the lymphoid branch to generate DCs. 
Nevertheless, a detailed understanding of the regulation of DC differentiation will 
provide novel tools for manipulation of DCs in new cancer immune-therapies and 
vaccination strategies. 
Our data point out interesting questions about the potential differences between the 
myeloid cell subtypes in mice lacking or expressing a single C/EBPβ isoform, like 
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C/EBPβLIP and C/EBPβΔuORF genotypes, and their comparison to C/EBPβ-/- and WT 
mice. Analyses of the expression of macrophage polarization genes in these C/EBPβ 
knock-in and C/EBPβ deficient macrophages are also planned. Another important 
question is the one concerning C/EBPβ interacting partners during the 
reprogramming. Mass spectrometry analyses of CR2,3,4 binding partners might help 
selecting for candidate proteins whose knock-down could be investigated in order to 
see whether reprogramming depends on them. Another important question is 
whether we will be able to find PTMs and their enzymes that might abrogate C/EBPβ 
reprogramming potential. Analysis of C/EBPα PTM site mutants in the B-to-myeloid 
cell reprogramming system is also of a current interest. Last but not least, uncovering 
differential C/EBPβ PTM profile in distinct hematopoietic cell types in vivo might help 
to deepen our knowledge of the regulation of cell fate decision by C/EBPβ.  
Many lines of evidence suggest that C/EBPs may be involved in multivalent binding 
or assembly of regulatory complexes and link signaling to epigenetic regulation. 
Similarly to the “histone code”, the extensive PTM pattern seen on C/EBPβ suggests 
that multiple modifications of a transcription factors might be pivotal for integration of 
extracellular signals, gene expression and determination of diverse cell fate decisions 
(Leutz et al., 2011; Nerlov, 2008). Therefore, acquisition of signal dependent PTMs 
might explain how C/EBPβ accomplishes differentiation to alternative myeloid cell 
types. 
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Supplement 
 
Table S1 
Selected genes whose expression was analyzed in the reprogrammed cells and BM derived 
macrophages by NanoString technology. 
 
 Gene symbol Target ID Full name 
Tnf (Tnfa) NM_013693.1 tumor necrosis factor 
Il1b NM_008361.3 interleukin 1 beta 
Il6 NM_031168.1 interleukin 6 
Il12b NM_008352.1 interleukin 12b 
Il12rb1 NM_008353.2 interleukin 12 receptor, beta 1 
Ccr7 NM_007719.2 chemokine (C-C motif) receptor 7 
Cxcl9 NM_008599.2 chemokine (C-X-C motif) ligand 9 
Cxcl10 NM_021274.1 chemokine (C-X-C motif) ligand 10 
Ccl2 (Mcp-1) NM_011333.3 chemokine (C-C motif) ligand 2 
Mmp8 NM_008611.4 matrix metallopeptidase 8 
Mmp9 NM_013599.2 matrix metallopeptidase 9 
M
1 
ge
ne
s 
Nos2 NM_010927.3 nitric oxide synthase 2, inducible 
Il10 NM_010548.1 interleukin 10 
Arg1 NM_007482.3 arginase, liver 
Il13ra1 NM_133990.4 interleukin 13 receptor, alpha 1 
Msr1 NM_031195.2 macrophage scavenger receptor 1 
Tgfb1 NM_011577.1 transforming growth factor, beta 1 
Il4ra NM_001008700.3 interleukin 4 receptor, alpha 
Alox15 NM_009660.3 arachidonate 15-lipoxygenase 
Mmp12 NM_008605.3 matrix metallopeptidase 12 
Pparg NM_011146.1 peroxisome proliferator activated receptor gamma 
Ccl22 NM_009137.2 chemokine (C-C motif) ligand 22 
Kdm6b (Jmjd3) NM_001017426.1 lysine (K)-specific demethylase 6B 
Chi3l3 (Ym1) NM_009892.1 chitinase 3-like 3 
M
2 
ge
ne
s 
Fcgr3 NM_010188.5 Fc receptor, IgG, low affinity III 
Mafb NM_010658.2 
v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein B (avian) 
Maf (c-maf) NM_001025577.2 
avian musculoaponeurotic fibrosarcoma (v-maf) 
AS42 oncogene homolog 
Myd88 NM_010851.2 myeloid differentiation primary response gene 88 
Kdm4a (Jmjd2a) NM_172382.2 lysine (K)-specific demethylase 4A 
O
th
er
s 
Ddr2 NM_022563.2 discoidin domain receptor family, member 2 
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Table S2 
Expression levels of selected macrophage genes in the reprogrammed cells and BM derived 
macrophages as evaluated by NanoString technology. For each construct values represent two to 
three independent experiments. Value “1” substitutes for expression below the background level. 
 
 Uninfected MSCV LAP LAP* 
Gene 
symbol #1 #2 #1 #2 #1 #2 #1 #2 #3 
Tnf 112.7 1 1 85.3 5453.3 1 2039.1 1937.8 1817.5 
Il1b 1 1 1 1 15567.5 11579.5 2244.8 1466.8 1628.5 
Il6 1 1 1 1 4334.7 1 75.3 13.9 1 
Il12b 1 1 1 1 93.2 1 643 135.1 87.2 
Il12rb1 1.6 1 1 1 466.1 1 550.3 554.2 445.9 
Ccr7 1600.8 2276.5 1 2671.6 11465.9 1 6346.2 2701.5 5113.3 
Cxcl9 1 1 1 1 1 1 1 1 1 
Cxcl10 9.4 1 1 1 3775.4 6616.8 2635.8 1499.7 1958.1 
Ccl2 1 1 1 1 179539.1 161285.7 7163 6019.5 6087.5 
Mmp8 1 1 1 1 35376.5 35979.1 96186.3 83282.7 84473.4 
Mmp9 1 1 1 1 512.7 1 640.1 2208 2278 
Nos2 1 1 1 1 2377.1 1 1184.7 763.7 644.6 
Il10 1 1 1 1 885.6 1 1 1 1 
Arg1 1 1 1 1 34537.5 28121.6 136.1 256.3 872.4 
Il13ra1 1 1 1 1 1817.8 1 15148.6 9964.4 11050.5 
Msr1 1 1 1 1 18317.5 8271.1 7742.3 5422.1 7231.3 
Tgfb1 18800 17493.4 31248.2 23816.6 20601.3 5789.7 21462.9 18126.1 23201.2 
Il4ra 1629 2516.2 1 3012.6 24236.8 26053.8 15137 9347.9 11462.5 
Alox15 1 1 1 1 1 1 1 1 1 
Mmp12 1 1 1 1 1 1 289.6 503.9 542.8 
Pparg 1 1 1 1 1 1 49.2 48.5 33.9 
Ccl22 1 1 1 1 14821.8 1240.7 19354.3 10321.2 21509.7 
Kdm6b 600.9 239.6 1 1193.7 512.7 1 3105 2675.5 3576.9 
Chi3l3 1 1557.6 1 1 1 1 81098.5 142875.3 70796 
Fcgr3 1 1 1 1 16639.5 21091.2 30876.5 23208.8 27960.7 
Mafb 1 1 1 1 1 1 674.9 445.1 930.6 
Maf 1 1 1 1 4334.7 3308.4 330.2 207.8 416.8 
Myd88 887.3 1677.4 1 1961 4241.4 1 5390.3 3960.5 4681.9 
Kdm4a 768.3 2156.7 1 2216.8 1 1 952.9 755 1274.7 
Ddr2 1 1 1 1 1 1 1 1 1 
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  ΔCR1,2 ΔCR3 ΔCR4 
Gene 
symbol #1 #2 #1 #2 #3 #1 #2 #3 
Tnf 1749 1467.1 2146.6 1153.2 1949.9 1982.7 3211.4 3420.2 
Il1b 347 1 847 288.3 580.4 1562.1 2768.4 1741.8 
Il6 1 1 1 1 1 15 1 1 
Il12b 1 1 1 1 1 1 1 1 
Il12rb1 922 427.9 690 557.4 618.4 1028.9 664.4 855.1 
Ccr7 266.2 1 2427.7 307.5 531.1 2838.9 442.9 1013.4 
Cxcl9 1 1 1 1 1 1 1 1 
Cxcl10 42.8 1 1296 384.4 481.8 706 1 63.3 
Ccl2 2257.6 4360.5 9729 7649.4 12333.1 8952.3 4872.4 5795.4 
Mmp8 10760.2 14202.1 165079.6 45281.5 85576.5 23154.4 43630.5 66092.7 
Mmp9 1 1 766.6 634.2 1464.3 405.6 1439.6 2216.8 
Nos2 1 1 500.1 115.3 318.7 1 1 1 
Il10 1 1 1 1 1 1 1 1 
Arg1 1 1 65.7 595.8 6179.8 195.3 1 1 
Il13ra1 5860.1 6112.8 9663.3 2383.2 5087.2 3815.2 6644.2 7030.5 
Msr1 5988.5 7539.1 11098 6803.8 11456.7 8103.7 14949.5 12825.8 
Tgfb1 18664 22352.5 21005.9 14799.1 18990.9 16875.7 22147.5 25556.7 
Il4ra 4833.5 5786.8 10897.2 4920.2 7340.7 5407.4 8637.5 6618.8 
Alox15 1 1 1 1 1 292.9 1 538.4 
Mmp12 1 1 773.9 1 273.1 90.1 332.2 253.3 
Pparg 1 1 21.9 115.3 3.8 1 1 1 
Ccl22 1596.9 1548.6 9623.2 3997.7 4419.6 7465.3 9191.2 5637 
Kdm6b 979.1 794.7 2372.9 961 2219.3 1126.6 775.2 2660.2 
Chi3l3 1 1 53077.1 77243.7 111058.3 42508.5 14063.6 45413 
Fcgr3 6492.2 9739.7 29716.4 10724.6 18220.8 11047.7 13288.5 14219.3 
Mafb 61.8 20.4 368.7 249.9 485.6 180.2 1 1 
Maf 1 1 441.7 1 239 1 110.7 1 
Myd88 2704.3 2404.4 4913.8 4939.4 4222.3 3852.8 8526.8 5003.7 
Kdm4a 608.4 529.8 938.2 1134 1153.3 480.7 1218.1 1235.1 
Ddr2 1 1 1 1 1 1 1 1 
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  ΔCR6 MPh WT MPh KO 
Gene 
symbol #1 #2 #3 #1 #2 #3 #1 #2 #3 
Tnf 1370.9 1220 1514.4 7761.4 1073.8 1219.5 7363.6 3312 2107.9 
Il1b 305.9 499.1 115.1 1193 256 1 69.5 1 35.8 
Il6 1 1 1 1 1 1 1 1 1 
Il12b 1 1 1 1 1 1 1 1 1 
Il12rb1 696 457.5 451.1 1 1 1 1 3.3 1 
Ccr7 678 464.4 220.9 1 1 1 2171.1 1 1 
Cxcl9 1 1 1 1 1 1 1 6.7 27.8 
Cxcl10 733.1 519.9 138.1 774.7 466.2 115.8 4636.3 813.8 942.6 
Ccl2 4580.2 2620.2 5224.5 9719.6 23794.7 15413.3 15556 10317.8 6108.9 
Mmp8 51888.4 42553.8 51550 6169.2 8036 13761.6 4000 5318 3758.4 
Mmp9 151.4 672.4 731.9 118.8 214 872.2 246 1142 1328.4 
Nos2 402.2 305 174.9 1 26.7 1 1 1 1 
Il10 1 1 1 2143.5 221.6 216.1 1 1 1 
Arg1 34.1 159.4 87.5 1 1 1 219.2 271.3 127.3 
Il13ra1 4876 4159 4483.4 884 1238.1 2415.8 3262 1306.1 1622.7 
Msr1 6344.3 4796.7 6959.9 26844 33512.1 50106.7 53069 49311.8 47193.2 
Tgfb1 15547.8 14646.7 18076.3 32110.2 37795.7 49921.5 31887.4 38843.3 36729.2 
Il4ra 5215 5178 5542.1 10893.5 7481.9 9616.9 7010.6 6041.3 5234 
Alox15 1 1 1 1 1 1 1 1 1 
Mmp12 97.3 1 23 337.5 1112 4036.6 2609.6 3713.9 4188 
Pparg 71.2 13.9 115.1 1031.4 2159 2477.6 1283.4 1419.9 1332.4 
Ccl22 3822 2467.7 2375.2 1 1 1 7171 67 103.4 
Kdm6b 1590.6 1774.5 2154.2 2029.5 554.1 532.6 1246 428.7 564.8 
Chi3l3 65761.4 79791 105373.9 1311.8 107 2570.2 5502.6 1624.2 71.6 
Fcgr3 14594 11562.1 14380 20750.9 44200 67727.5 25486.4 38679.2 36959.9 
Mafb 73.2 34.7 267 31815.5 38170.1 56945.1 22267.1 26871.2 27649.3 
Maf 55.2 1 78.3 6473.4 6969.9 7733.7 1513.4 4182.7 3161.9 
Myd88 2859.2 3958 3461.5 4116 4581.6 6244 3839.5 4547.7 4207.9 
Kdm4a 595.7 1150.7 980.5 779.5 871.2 1211.8 1112.3 1165.4 1113.6 
Ddr2 1 1 1 38 145.2 1 1 3.3 1 
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